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The aim of this post graduate thesis is to study novel disease severity factors in Systemic 
Lupus Erythematosus (SLE) relating to infections, and involvement of the kidney and 
brain. Although the pathogenesis of SLE is not fully understood, the management of SLE 
has dramatically improved over the last decade with use of various therapeutic agents. 
Lupus patients are now expected to live longer compared to those of earlier days. 
However, the number of hospitalizations of lupus patients is still significant. The 
predominant causes of hospitalizations were infections and major organ complications.  
 
It is reasonable to conclude that more lupus patients are seen with infections because of 
the use of immunosuppressive drugs in lupus management. In innate defense mechanisms, 
complement proteins are generally well regarded, as “important proteins” against 
pathogens. They also play a role in clearance of immune complexes and complement 
deficiencies are associated with SLE. Mannose Binding Lectin (MBL) is from the lectin 
pathway of complement system. Its deficiencies were associated with infections in both 
children and adults. It was also interesting to note that MBL plays an important role 
against infections in patients on immunosuppressive therapy. We therefore studied the 
different variants of genotypes and haplotypes of MBL, especially structural mutants and 
MBL low-producing haplotypes, to determine its predisposition to infection. Recurrent 
infections worsen disease severity in lupus patients on immunosuppressive therapy. 
 
Proper management of lupus patients on immunosuppressive drugs can reduce the disease 
severity and increase the survival rate of lupus patients. However organ damages are still 
significant morbidity and mortality issues facing lupus patients. Among many suggested 
 ix
mechanisms causing organ-system damages, autoantibodies against structural systems in 
the kidneys and brain are thought to play important roles. However it is not clear how 
these autoantibodies are involved in the pathogenesis of such organ involvement.  
 
The significant finding of renal involvement in lupus is proteinuria, which is widely been 
used as a diagnostic, prognostic and disease-monitoring tool in the management of lupus 
nephritis. Recently a monoclonal antibody (mAb 5-1-6), which caused immediate transient 
and massive proteinuria in animal models upon intravenous injection, was reported as 
targeting against nephrin, a structural protein of slit diaphragm.  We therefore studied 
nephrin autoantibodies in lupus patients to determine the role these autoantibodies play in 
disease severity in lupus nephritis patients. The role of brain reactive autoantibodies in 
lupus has been studied. However no significant autoantibodies that can be used in 
diagnosis and management of neuropsychiatric lupus are yet defined. We looked into 
autoantibodies against the neuronal membrane proteins in unselected lupus patients to 
determine their roles in neuropsychiatric lupus and disease severity.  
 
Together with those finding (genetic MBL variants with protein deficiencies, anti-nephrin 
antibodies and brain reactive autoantibodies), the damage index in SLE patients 
(SLICC/ACR score) were studied if these factors predispose to severity in Systemic Lupus 
Erythematosus. The structural MBL mutant alleles and MBL low-producing promoter 
haplotypes are found to be associated SLE and correlated with infections during 
immunosuppressive therapy. Anti-nephrin antibodies are highly associated with lupus 
disease, but their association with renal involvement was seen only in lupus mouse 
models. Brain Reactive Autoantibodies are highly associated with lupus patients and 
correlated with psychosis or seizure disorders.  
 x
 
The data suggests that the MBL variants play a role in SLE pathogenesis and the 
usefulness of anti-nephrin antibodies and BRAA need further exploration before their 
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1.1. Systemic Lupus Erythematosus 
 
Systemic Lupus Erythematosus (SLE) is a chronic and potentially fatal autoimmune 
disease, characterized by exacerbations and remissions with diverse clinical 
manifestations. SLE was first described with systemic manifestation in 1895 with the 
proposed pathophysiology based on the inflammation of blood vessels or vasculitis:- 
which previously was considered a destructive skin disease (Rothfield, 1989). SLE 
was later associated with other pathogenic lesions such as glomerulonephritis, heart 
valve vegetations, arthritis and pericarditis (Baehr et al., 1935). The first diagnostic 
test for SLE, the lupus erythematosus cell preparation (LE cell prep), was described 
by Hargraves et al., in 1948 and it was followed by an increase in the frequency of 
detection of SLE. The discovery of the LE cell prep opens up the understanding of 
immunological basis for SLE. With better immunologic and molecular biologic tools, 
the understanding of the pathogenesis of SLE has further improved and has resulted in 
better management of SLE. However the actual etiology of SLE still remains a 
mystery.    
 
Clinical manifestations range from minor skin lesions to severe internal organ system 
derangement. Many organ-systems such as joint, skin, kidney, brain, lung, heart and 
gastrointestinal tract are involved during the disease course. Therefore treatment of 
patients with SLE is related to the severity of the disease and may be straightforward 
for mild disease such as skin lesions, or highly complex for severe, life-threatening 
complications such as nephritis or cerebritis. 
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1.1.1. Prevalence of Systemic Lupus Erythematosus 
 
SLE is most common in women of reproductive age, although it has been reported in 
both extremes of life (i.e. it can occur in childhood or later in life). Females are 
predominantly affected during their reproductive age (female: male = 9:1), and the 
basis of this unequal sex ratio is not clear. According to the Lupus Foundation of 
America, more than 16,000 Americans develop lupus each year and it is estimated 
that 500,000 to 1.5 million Americans had been diagnosed with lupus. It was 
documented that the worldwide incidence is 50 per million population, the incidence 
varies hugely depending on ethnicity, geographical variation and socioeconomic 
status. For example, SLE is three times more common in African Americans than 
American Caucasians. The ethnic group at greatest risk is African Caribbeans. SLE is 
also more common in Asian Chinese.  
 
1.1.2. Pathogenesis of Systemic Lupus Erythematosus 
 
The pathogenesis of SLE is complex and a unifying mechanism has yet to be 
confirmed (Boumpas et al., 1995). Although the disease is homogenous and has 
predictable incidence and course in many lupus mouse models, the autoimmune 
response in human lupus patients is diverse. Furthermore, other factors such as genes, 
sex hormones, environment and microbes may contribute to SLE pathogenesis. 
 
Evidence for genetic predisposition includes increased concordance for disease in 
monozygotic compared with dizygotic twins, a higher susceptible risk for persons 
with more than one affected family members, and correlation of certain genes 
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(especially MHC class II and III) with disease and autoantibodies. C4AQ0, a 
defective class III allele that fails to encode a functional C4A protein, is the most 
common genetic marker associated with SLE in many ethnic groups. Certain extended 
haplotypes, such as B8.DR3.DQw2.C4AQ0, predispose to SLE in some populations. 
The strongest single gene associations occur between HLA class II, especially DQB, 
and autoantibodies, which define clinical subsets of lupus. For example, high titers of 
IgG anti-dsDNA antibodies are associated with lupus nephritis and with DQB1*0201, 
*0602, and *0302 associated with either DR2 or DR3. Antibodies to Ro/La (SS-
A/SS-B) are associated with the dermatitis of subacute cutaneous lupus and with 
certain DQA and DRB genes associated with DR3. The lupus anticoagulant, 
correlated with clotting, is associated with DQB*0301, *0302, *0303, and *0602 
associated with DR4 or DR7. Family studies suggest that genes not linked to HLA 
antigens also participate in susceptibility and that females are more likely than males 
to express the autoimmune manifestations of their genotypes. The more susceptibility 
genes one has, the higher is the relative risk for development of SLE.   
 
Females are more prone to develop SLE compared to males. However it seems 
unlikely that the X chromosome is involved because SLE does not follow a sex-linked 
pattern. Sex distribution are almost equal in those developing SLE in children or when 
older than 50 years. It is generally accepted that female sex hormones, not sex 
chromosome, are permissive for development of SLE. Sanchez-Guerrero et al.(1995), 
reported that menopausal women treated with hormone replacement therapy had 
increased risk for development of SLE compared to those without hormone 
replacement therapy. He further reported in 1997 that women using estrogen-
containing oral contraceptives also had increased risks for SLE. Similarly, the 
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increased frequency of SLE in patients with Klinefelter’s syndrome suggests that 
androgens may serve a protective function. Klinefelter’s syndrome patients have low 
testosterone but higher estrogen levels. Femaleness is thought to be a susceptible 
factor in pathogenesis of SLE.  
 
The environmental factors that induce or cause flares in SLE are largely unknown, 
with the exception of ultraviolet (UV) light, drugs and dietary modulation. Exposure 
to UV light can exacerbate SLE disease. It is postulated that UV light alters the 
normally non-antigenic dsDNA to become antigenic. UV light may also cause local 
skin damage that allows immune complex formation or deposition. Certain drugs, 
such as hydralazine and procainamide, induce lupus-like disease by possibly altering 
nuclear antigens, especially histones. Drug induced lupus has notable clinical and 
autoantibody differences compared to spontaneous lupus. Preliminary data have been 
suggested that diet may modulate the expression of SLE. For example, Hurd and 
Gilliam demonstrated in 1981 that NZB/NZW F1 mice fed a diet deficient in essential 
free fatty acids had a prolonged survival together with a decreased severity of their 
glomerulonephritis and inhibition of their anti-native DNA antibody response when 
compared to controls. And the lupus disease process in primates fed alfalfa sprouts is 
characterized by the development of anti-Sm and dsDNA antibodies, cutaneous and 
glomerular lesions (Bardana et al., 1982). 
 
Microbial factors might also play roles in the pathogenesis of SLE. Bacterial 
liposaccharides (potent polyclonal B-cell activator) administered to animals induce 
the formation of circulating immune complexes and, subsequently antibodies to both 
single- and double-stranded DNA. Viruses are postulated to play major roles in both 
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murine and canine models of SLE. Theoretically, the chronic infection of 
lymphocytes with a virus might account for many of the immunologic aberrations 
present in SLE. Indirect evidence for a persistent viral infection in SLE includes 
increase in antibodies to multiple DNA and RNA viruses; the presence of electron-
dense paramyxovirus-like cytoplasmic inclusions; and reports of type C virus 
oncornaviruses in involved renal and skin tissue. However attempts to isolate viruses 
from SLE tissue by hybridization and co-cultivation techniques have been largely 
unsuccessful. Thus the hypothesis, of viral infection as disease inducer, is 
inconclusive.  
 
An association of the SLE with apoptosis was proposed. Apoptosis is regulated by 
several genes, comprising genes that inhibit (i.e. Bcl-2 gene) or promote (i.e. 
apoptosis-1/Fas gene) (Rose et al., 1994). The abnormal expression of apoptosis-
related genes (e.g. the over-expression of Bcl-2 or defect in the Fas gene) is 
associated with the development of lupus –like systemic autoimmune diseases in 
animals. A soluble form of the Fas protein, an apoptosis-signaling receptor molecule 
on the surface of lymphocytes, was found on the sera of some lupus patients (Singh., 
1995). Normal mice injected with this soluble form of the Fas protein resulted in the 
inhibition of apoptosis and the appearance of autoimmune features. Accumulation of 
nucleosomes formed during apoptosis by cleavage of chromatin has to be cleared. 
Failure of clearance by mutant DNAse I has been proposed as a factor in the 
pathogenesis of SLE (Napirei et al., 2000).  
 
A healthy immune system produces antibodies, which help to fight and destroy 
viruses, bacteria, and other foreign substances. In lupus, the immune system fails to 
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recognize “self” from “non-self” and “mistakenly” produces antibodies against self-
tissues. This leads to counterproductive inflammation and damage to various organs 
and tissues. In addition, some autoantibodies react with substances from the body's 
own cells or tissues to form immune complexes. Clinical manifestations are mainly 
due to the effects of this impaired immune system. Impaired immune responses 
include sustained production of pathogenic subset of autoantibodies and immune 
complexes.  
 
The antibodies to host antigen (self-antigen), particularly nucleic acid-protein 
complexes such as the nucleosome made up of DNA and histones, are the 
predominant antibodies produced. These antibodies combine with their corresponding 
antigens to form antigen-antibody complexes. The immune complexes are eliminated 
by the reticuloendothelial system (RES). Defect in the clearance of antibody-coated 
erythrocytes, removed through Fc receptor-mediated phagocytosis in the liver and 
spleen, have been demonstrated in SLE patients. Conceivably, the uncontrolled 
formation of immune complexes leads to a saturation of receptor-binding sites, 
resulting in a functional blockade of the RES and an accumulation of circulating 
immune complexes. 
 
When the circulating immune complexes are not cleared adequately, the circulating 
immune complexes are deposited in the subendothelial layers of vascular basement 
membranes of multiple organs. The sites of deposition and pathologic potential of 
immune complexes in skin, kidney, choroid plexus, or serosal surfaces are dictated in 
part by physiochemical properties of antigen or antibody such as size, charge, 
molecular configuration, immunoglobulin class and complement-fixing properties. 
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Once deposited, the immune complexes initiate a localized inflammatory response 
involving activation of complements, emigration of neutrophils, release of kinins and 
prostaglandins and antigen-antibody cell mediated tissue injury. 
 
1.1.3. Clinical manifestations and diagnosis of Systemic Lupus Erythematosus 
 
Genetic susceptibility, environmental triggers, hormonal influences and defective 
immune system are generally considered as major contributing factors in pathogenesis 
of SLE. SLE patients can present with different clinical presentations and many sub-
sets have been observed. Furthermore there is no single diagnostic test or 
investigation method for diagnosis of SLE. The diversity and heterogenicity of the 
disease, require a set of clinical manifestations and investigations to establish a 
diagnosis of SLE.  
 
At onset, SLE may involve only one organ system, which can progress on to 
multisystemic manifestations. Sometimes patients may have multisystemic 
involvement at onset. Clinical features in SLE patients can be divided into two broad 
categories; namely generalized and specific presentations. While generalized signs 
and symptoms, such as fatigue, malaise, fever, anorexia and weight loss, are common 
in SLE, specific presentations are based on the organ systems involved. The two most 
frequently involved organs/organ-systems in SLE causing major morbidity and 
mortality are the kidneys and brain.  However, signs and symptoms presented by 
other systems are not uncommon. There can be vasculitic rashes in the skin, arthritis, 
pericarditis, pleuritis, pneumonitis, etc.  The diagnosis has to be established using a 
set of clinical presentations and laboratory investigations. The most useful 
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investigations are hematological and immunological investigations. Decreased red 
blood cells, white blood cells and platelets are common findings in hematological 
tests and a phletora of autoantibodies are the hallmark of SLE. Among them, 
immunological tests, such as antinuclear antibodies, anti-dsDNA antibodies, anti-Sm 
antibodies provide strong supportive evidence for the classification of SLE. 
 
The American College of Rheumatology (ACR) has presented criteria for 
classification of SLE in 1982 (Tan EM et al., 1982) (Table 1.1). According to 
advanced diagnostic technology and discovery of clinical association of 
antiphospholipid antibodies in SLE patients, ACR updated them in 1997 (Hochberg 
MC, 1997) (Table 1.2). The diagnosis of SLE can be established if a patient fulfils 4 
or more of the 11 criteria according to the 1997 updated ACR criteria. 
 
1.1.4. Prognosis of Systemic Lupus Erythematosus 
 
SLE was considered a fatal disease in the past, however 5- and 10- year survival rates, 
especially in the western countries, have been increased dramatically since the 
introduction of steroids in disease management. It was noted that a 5-yr survival rate 
of only 50% in the 1950s (Merrell and Shulman., 1955) changed to a 10-yr survival 
rate of nearly 90% in the 1990s (Gripenberg and Helve., 1991; Pistiner et al., 1991). 
However, poor survival rate of SLE is still reported in certain ethnic groups such as 
Indians (Kumar et al., 1992), African Caribbeans (Nossent., 1993) and Hispanics 
(Lopez-Acuna et al., 1982). Developing countries reported 10-year survival rates as 
between 50 to 80%. (Kumar et al. 1992 and Massardo et al. 1994) The difference in 
these studies might be related to socio-economic conditions of these countries. 
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Table 1.1. The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus (Tan et al. 1982) 
Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older 
lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician  
5. Arthritis Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion 
6. Serositis a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion (OR)  
b) Pericarditis--documented by ECG or rub or evidence of pericardial effusion 
7. Renal disorder a) Persistent proteinuria greater than 0.5 grams per day or grater than 3+ if quantitation not performed (OR)  
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic derangements; e.g., uremia, ketoacidosis, or electrolyte 
imbalance (OR)  
b) Psychosis—in the absence of offending drugs or known metabolic derangements, e.g., uremia, ketoacidosis, or electrolyte 
imbalance   
9. Hematologic 
disorder 
a) Hemolytic anemia--with reticulocytosis (OR)  
b) Leukopenia--less than 4,000/mm3 total on 2 or more occasions (OR)  
c) Lyphopenia--less than 1,500/mm3 on 2 or more occasions (OR)  
d) Thrombocytopenia--less than 100,000/mm3 in the absence of offending drugs   
10. Immunologic 
disorder 
a) Positive LE cell preparation (OR)  
b) Anti-DNA: antibody to native DNA in abnormal titer (OR)  
c) Anti-Sm: presence of antibody to Sm nuclear antigen (OR)  
d) False positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum 
immobilization or fluorescent treponemal antibody absorption test   
11. Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the 
absence of drugs known to be associated with "drug-induced lupus" syndrome   
The proposed classification is based on 11 criteria. For the purpose of identifying patients in clinical studies, a person shall be said to have systemic 




Table 1.2. The 1997 updated Criteria for Classification of Systemic Lupus Erythematosus (Hochberg. 1997) 
Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older 
lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician  
5. Arthritis Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion 
6. Serositis a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion (OR)  
b) Pericarditis--documented by ECG or rub or evidence of pericardial effusion 
7. Renal disorder a) Persistent proteinuria greater than 0.5 grams per day or grater than 3+ if quantitation not performed (OR)  
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic derangements; e.g., uremia, ketoacidosis, or electrolyte 
imbalance (OR)  
b) Psychosis--in the absence of offending drugs or known metabolic derangements, e.g., uremia, ketoacidosis, or electrolyte 
imbalance   
9. Hematologic 
disorder 
a) Hemolytic anemia--with reticulocytosis (OR)  
b) Leukopenia--less than 4,000/mm3 total on 2 or more occasions (OR)  
c) Lyphopenia--less than 1,500/mm3 on 2 or more occasions (OR)  
d) Thrombocytopenia--less than 100,000/mm3 in the absence of offending drugs   
10. Immunologic 
disorder 
a) Anti-DNA: antibody to native DNA in abnormal titer (OR)  
b) Anti-Sm: presence of antibody to Sm nuclear antigen (OR)  
c) Positive finding of antiphospholipid antibodies based on  
1. an abnormal serum level of IgG or IgM anticardiolipin antibodies,  
2. a positive test result for lupus anticoagulant using a standard method, or  
3. a false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema 
pallidum immobilization or fluorescent treponemal antibody absorption test.   
11. Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the 
absence of drugs known to be associated with "drug-induced lupus" syndrome   
The proposed classification is based on 11 criteria. For the purpose of identifying patients in clinical studies, a person shall be said to have systemic 
lupus erythematosus if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.  
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Appropriate care of patients with SLE will lead to fewer hospitalizations due to 
uncontrolled disease exacerbations, less severe renal disease with fewer patients 
developing end-stage renal disease requiring chronic dialysis, fewer episodes of 
avascular necrosis requiring total joint replacements, and less severe osteoporosis and 
fractures.  
 
On the other hand, the longer SLE patients live, the morbidity and/or disability due to 
SLE-related illnesses will rise. All morbidity and complications of SLE are probably 
due to the consequences of disease itself or drugs used in disease management. At the 
same time, low socioeconomic status or inadequate psychological support (Ward et 
al., 1999) will aggravate morbidity.  
 
The American College of Rheumatology developed and validated the damage index 
to estimate morbidity in SLE in 2000 (Gladman et al., 2000). The Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology Damage 
Index (SLICC/ACR damage index) is issued to estimate the irreversible damage, 
regardless of cause, in 12 organ-systems related to SLE, its treatment or intercurrent 
illness. It was validated to identify the changes in damage seen in the patients with 
both active and inactive diseases.  
 
Lupus patients present with different types of nephritis on biopsy. The exact 
pathogenesis for renal involvement is not clear in SLE; it is widely accepted that 
circulating autoantibodies and immune complexes are the main causes for lupus 
nephritis. Improved management of SLE over the years has helped to reduce the 
complications of renal involvement in SLE.   
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A positive relationship has been demonstrated, in a longitudinal study, to exist 
between persistently raised anticardiolipin antibody levels and neuropsychological 
performance in patients with systemic lupus erythematosus (Menon et al., 1999). 
Lupus patients were evaluated by neuropsychological assessments and cognitive 
deficits, like impaired attention, memory, deficits in language understanding and 
psychomotor speed were noted. They found that neurocognitive deficits are more 
frequent in SLE patients than in controls and these deficits appear in lupus patients 
without overt CNS manifestations and independent of disease activity. 
 
Cardiovascular diseases and cerebrovascular diseases have also been recognised as a 
significant cause of morbidity in SLE. The risk of hospitalization for acute myocardial 
infarctions, congestive heart failures or cerebrovascular accidents is increased in 
young women with lupus compared to those without SLE. The authors suggested the 
importance of preventive measures to reduce risk factors for cardiovascular and 
cerebrovascular diseases in the management of SLE patients (Petri et al., 1992)    
 
Mortality in SLE is an issue in many countries, especially developing countries with 
less funding for health care management. The factors contributing to mortality in SLE 
are divided into two categories; the social and demographic factors and disease-
related factors (Drenkard and Alarcon-Segovia, 2000). However, factors such as age 
at onset, race, gender, socioeconomic status are controversial and the use of these 
factors as predictors of mortality is difficult to interpret. It is better to predict 
mortality in SLE using disease-related factors such as renal involvement, CNS 
involvement, antiphospholipid syndrome and persistent active disease process. 
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Almost all SLE patients have multiple organ-systems involvement during their 
disease course. The commonest major organ-systems involved in SLE are the kidneys 
(lupus nephritis) and brain (neuropsychiatric lupus). Proper management can 
reasonably control SLE disease activity and morbidity. The commonest causes of 
death are infectious complications, renal failure, or severe central nervous system 
disease. Early mortality of SLE is often due to complications related to active disease 
process while vascular events and end organ failures contribute to late mortality (Abu-
Shakra et al., 1995.). 
 
1.1.5. Management concerns in SLE 
 
Several studies have documented substantial improvements in the survival of patients 
with SLE. Two factors possibly contribute to this improvement; ANA testing which is 
widely available now, had helped in early diagnosis, and the use of corticosteroids in 
control of disease activity.  Despite advances in diagnosis and management, 
complications attributable to SLE or its therapy continue to cause substantial 
morbidity. In a prospective university-based study, the incidence of hospital 
admissions for patients with lupus was found to be 0.69 admission per patient-year. 
(Petri and Genovese, 1992). Complications such as lupus nephritis, nervous system 
involvement and infections are still major concerns in all societies.    
 
Infections are common cause of death or first to second cause of hospitalization in 
lupus patients. Susceptibility of lupus patients to infection is considered because of 
altered immune system, which is affected by the disease itself or immunosuppressive 
drugs used in lupus management. Immunosuppressive drugs used in lupus 
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management may alter the immune system function of lupus patients. Innate 
immunity might play an important role in functional asplenic state. 
   
The most serious organ systems involved in SLE are the kidneys (lupus nephritis) and 
the nervous system (neuropsychiatric lupus) (Cameron JS. 1999, West SG et al 1995). 
A significant number of all lupus patients presented with nephritis, which was 
confirmed with renal histology.  Approximately 75% of renal biopsy results are 
reported with at least one abnormality in lupus patients. Cytoxic drugs are more 
effective than corticosteroids in controlling the clinical signs of nephritis. The use of 
these drugs, whether intermittent pulse therapy or long term therapy, can lead to 
different outcomes. Currently, significant renal involvements in lupus patients are 
started on immunosuppressive therapy. 
  
It was estimated that between 31%-70% of SLE patients have significant neuro-
psychiatric (NP) manifestations, in both retrospective and prospective studies (West  
et al., 1995; Kaell et al., 1986; Futrell et al., 1992; Sibley et al., 1992; Rood et al. 
1999). The spectrum of NP manifestations in SLE includes both neurologic and 
psychiatric features, many of which are subjective to both patients and clinicians. 
They vary from overt neurologic dysfunctions due to psychoses and seizures, to subtle 
abnormalities in neurocognitive functions such as impaired memory, reduced 
intellectual capacity (Hanly and Hong 1993). They cannot be easily identifiable 
because lupus itself or drugs used in lupus management or other associated 
pathological condition may contribute to the cognitive deficits. Early diagnosis that 
can lead to earlier intervention has been hampered by the lack of an accurate marker 
for NP involvement.  
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1.2. Complement system and its role in SLE 
 
The complement system, an important part of the innate immune system, plays a 
critical role in the defense against invading microorganisms. Initially the complement 
system comprised of two pathways, namely the classical and alternative pathways. 
Over the decade, Mannose Binding Lectin (MBL) has been accepted as the third 
complement pathway. Three separate pathways can now activate the complement 
cascade. The pathways are as follow:  
 
• the classic pathway (C1q, C1r, C1s, C2, C4),  
• the alternative pathway (C3, factor B, properdin) and  
• the lectin pathway (MBL)  
 
These 3 pathways converge centrally at component protein C3 and the terminal 
complement pathway consists of all proteins activated after C3; the most notable 
protein is the C5-C9 group of proteins known collectively as the membrane attack 
complex (MAC). The MAC exerts powerful “killing” activity by causing perforations 
in cellular membranes.  
 
When the complement system is activated without the presence of specific antibodies, 
the invading microorganisms will be removed by opsonization, phagocytosis and the 
action of MAC. Deficiencies in complement proteins predispose patients to infection, 
leading to recurrent infectious episodes and severe sepsis.  
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In addition to playing an important role in host defense against infections, the 
complement system is a mediator in the clearance of immune complexes. In 
autoimmune disorders with high production of autoantibodies, the complement 
system aids clearing these autoimmune complexes. Failure to do so could result in 
accumulation and deposition of these complexes in organ tissues leading to organ and 
tissue damage. Specific complement deficiencies such as C2 and C4 are also 
associated with an increased risk of developing autoimmune diseases, such as SLE 
(Walport., 1993) (Table 1.3).  
 
There is an important clinical association of hypocomplementaemia in SLE. Patients 
with chronic hypocomplementaemia are at particular risk of developing serious 
infections with encapsulated organisms such as Streptococcus pneumoniae and 
Neisseria meningitidis.  These patients can be considered to be  “functionally 
asplenic” because the hypocomplementaemia, in addition to causing defective 
opsonization and local phagocytosis, also results in reduced splenic clearance of these 
organisms (Davies, 1995).  There is a case that such patients, analogous to a post-
splenectomy state, receive prophylactic penicillin therapy and be considered for both 
pneumococcal and meningococcal vaccination. 
 
Therefore the complement system plays important roles in both innate immunity 
protecting against different microorganisms and aiding in the clearance of immune 
complexes. Since the lectin pathway is part of the complement system, it is important 
to review if MBL deficiencies contribute to infectious episodes in SLE. 
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Table 1.3. The common complement deficiencies, their associated diseases, detection methods and genetic basis 
Component Disease condition Detection methods Genetic basis 
C1q, s collagen vascular disease,  
SLE, bacterial infections 
CH50, RID  
 
Point mutations 
acquired form due to C1q autoantibodies 
C2 Neisserial infections,  
Respiratory infections,  
SLE (often symptomless) 
CH50, RID, 
electrophoresis 
type I: 28-bp deletion at exon/ intron junction 6 leading to splicing 
error; linked to HLA -A25 -B18 -C2Q0 -C4A4,B2 -DR2;  
type II: impaired C2 secretion 
C4A / B Collagen vascular disease,  
SSPE, Autoimmune diseases 
(SLE, PBC, autoimmune 
hepatitis, scleroderma) 
CH50, RID, SDS-PAGE 1. Complete gene deletion;  
2. Gene conversion (isotype change)  
3. Nonexpression due to 2-bp insertion >> stop codon 
 
CH50 - complement haemolytic activity; AP50 - alternative pathway haemolytic activity; RID - radial immunodiffusion 
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1.2.1. Complement deficiencies in systemic lupus erythematosus. 
 
A variety of genetic factors have been linked to SLE and, among these, the 
deficiencies in components of the classical pathway of complement carry stronger 
association (Pisetsky, 1991). SLE develops in most individuals with genetic 
deficiencies in C1q, C1r, C1s, C2 and C4 (Hauptmann et al., 1988; Morgan and 
Walport, 1991; Walport et al., 1997). Hereditary deficiencies of C1s and C1r are rarer 
than that of C1q (Loos and Heinz, 1986; Chevailler et al. 1994). The majority of C1q 
deficient individuals are strongly associated with SLE (Bowness et al., 1994) and 
selective C1s deficient individuals have been reported in association with SLE 
(Suzuki et al. 1992).    
 
The role of C1q in suppressing autoimmunity in mice was demonstrated by Botto et 
al. in 1998. C1q-deficient (C1qa-/-) mice on a mixed B6/129 genetic background 
spontaneously produced high titers of ANA, whereas wildtype controls generated low 
levels of autoantibodies. Furthermore, C1q-deficient mice had increased mortality and 
25% of them also showed glomerulonephritis with immune complexes. This is 
consistent with the hypothesis that C1q deficiency causes autoimmunity by 
impairment of the clearance of apoptotic cells.  
 
While almost all patients with C4 deficiency are associated with severe SLE, only 
33% of those with C2 deficiency are associated with a milder form of SLE (Walport, 
1993). Two tandemly duplicated genes, C4A and C4B, encode C4 and they are highly 
polymorphic with variants including non-expressed gene or null alleles for which no 
protein product is identifiable. There is a strong association between C4AQ*0 null 
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alleles and SLE in all different ethnic groups of SLE patients (Christiansen et al., 
1983; Dunckley et al., 1987 Kumar et al. 1991).  Although C2 null alleles were 
reported to be associated with SLE in 1976 (Glass et al., 1996), later studies did not 
demonstrate similar strong associations with SLE. Instead the C2 null alleles are 
linked with other HLA class I and C4 gene haplotype (Awdeh et al., 1981; 
Hauptmann et al. 1982). The C2 component of complement is probably a minor 
susceptible factor in the development of SLE (Pickering and Walport, 2000). 
 
Chen et al. reported the role of C4 in autoimmunity in 2000. In their study, high titers 
of ANA were observed in all female and almost all male C4-/- mice (deficient of C4) 
in B6/129 genetic background after 10 months of age. However the titers of ANA of 
CR2-/- mice (deficient of CR1 and CR2) never rose above those of normal controls.  
Therefore C4 deficiency causes spontaneous lupus through a mechanism which is 
independent of CR1/CR2. 
 
Acquired deficiencies in complement components are common in SLE patients 
(Walport et al., 1997). The measurement of complement protein levels and functional 
activity in serum is widely used as markers of disease activity in SLE. During periods 
of active disease, serum complement activity is usually reduced. Typically levels of 
the classical pathway of complement component (C1q, C2, C4) are low in patients 
with severe disease, may be accompanied by reduction in C3 levels. However, the 
levels of complement components usually correlate with disease activity, except C4 
may remain low when the patient is clinically inactive (Lloyd and Schur, 1981).  
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Determinants of protein level are not well understood yet. Decrease in synthesis of 
complement components may lead to reduced concentrations in SLE (Sliwinski and 
Zvaifler, 1972). These acquired deficiencies are also thought to result from over-
consumption of complement proteins by circulating immune complexes (De Bracco 
and Manni, 1974, Sturfelt et al. 1983). Low concentrations of complement 
components may also be due to a series of autoantibodies to complement components. 
They include anti-C1q autoantibodies (Antes et al., 1988), anti-C1 autoantibodies 
(Ordi-Ros et al., 1997), classical pathway nephritic factors autoantibodies (an 
autoantibody to the classical pathway C3 convertase, C4b2a) (Daha et al., 1983) and 
C3 nephritic factor autoantibodies (Daha et al., 1976). 
 
1.2.2. The Third Complement pathway: Mannose Binding Lectin (MBL)  
 
Mannose Binding Lectin (MBL) is a calcium-dependent serum lectin secreted by the 
liver as an acute phase protein (Wild et al., 1983; Thiel et al., 1992). Normal MBL is 
structurally analogous to C1q and is a multimeric molecule, comprising up to 6 of 96 
kD subunits, each consisting of identical 32-kD polypeptide chains (Taylor et al., 
1989). The MBL is now considered a member of the complement protein family.  
 
MBL contributes to immune defense in two ways. Firstly it can directly bind the 
pathogens’ membranes containing carbohydrate, opsonise the pathogens and finally 
enhance the phagocytosis of invading pathogens (Sheriff et al., 1994). Secondly, it 
can also activate the complement system via lectin complement pathway using two 
serine proteases, MBL-associated serine proteases (MASP)-1 and –2 (Matsushita and 
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Fujita, 1992; Thiel et al., 1997). The MASP complex shares many conserved features 
with C1r2s2. It can cleave complement protein C2 to initiate the complement cascade.  
 
The association of hereditary deficient alleles of early complement components have 
been described earlier, the hierarchy of susceptibility and severity of lupus, according 
to missing classical pathway proteins (C1q>C4>>C2) suggest that the early part of 
classical pathway plays a key protective role against SLE (Pickering and Walport, 
2000). Since one of the major roles of the classical pathway is that of host defense 
against infectious diseases, deficiency of classical pathway components may 
predispose to SLE because of impaired resistance to infectious trigger (Pickering and 
Walport, 2000). MBL is analogous to C1q, one of the early components of classical 
pathway, hence dysfunctional plasma MBL due to mutant structural alleles may 
impair defense mechanism against invading microorganisms such as viruses, bacteria, 
fungi etc. Thus deficiency in MBL is possibly a predisposing factor to SLE.  
 
Complement proteins concentrations are low not only in hereditary causes, but also in 
acquired conditions in SLE patients. Decreased synthesis of complement components 
(Sliwinski and Zvaifler, 1972), consumption of complement by accumulated 
circulating immune complexes (De Bracco and Manni, 1974, Sturfelt etal. 1983) and 
autoantibodies to complement components (Ordi-Ros et al., 1997; Daha et al., 1983; 
Daha et al., 1976) have been reported in SLE patients. C1 inhibitor deficiency is also 
an important factor resulting in decreased complement components (Cicardi et al., 
1998). In normal circumstances, this inhibitor, a serine proteinase inhibitor (sepin), 
binds and inactivates enzymatically active C1r and C1s. Deficiency results in 
uncontrolled fluid phase classical pathway activation and consequently reduced levels 
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of both C2 and C4. Therefore, the complement component may be decreased due to 
many acquired factors. SLE patients can be in a chronic hypocomplementaemia state 
as disease progresses. MBL might play a role in innate immunity against infectious 
pathogens by enhancing phagocytosis through binding to C1qR (C1q Receptor) 
(Nepomuceno et al., 1997). Thus MBL can help prevent infections in SLE disease. 
 
1.2.3 Mannose Binding Lectin (MBL) in SLE 
 
Three point mutations, encoding 3 different structural variants of MBL, have been 
found in the human MBL gene (Sumiya et al., 1991; Madsen et al., 1994; Lipscombe 
et al., 1992), located at codons 52, 54 and 57 of exon 1 and are associated with low 
serum levels of MBL (Lipscombe et al., 1995; Garred et al., 1992a and 1992b). 
Additional polymorphisms also exist at position –550 (H/L variants) and –221 (X/L 
variants) in the promoter region of the gene (Madsen et al., 1995). Like structural 
mutations in exon 1, the variants at promoter region of MBL influence serum MBL 
levels. Madsen et al., reported that HY haplotype is associated with the highest 
plasma levels of MBL, LY haplotype with intermediate levels and LX haplotype with 
lowest circulating serum level of MBL (Madsen et al., 1995). 
 
The LX haplotype, associated with lowest-producing serum MBL, was significantly 
associated with Chinese SLE patients and reported as risk factor for SLE (Ip et al., 
1998; Huang et al., 2003). This haplotype association was not found in Danish SLE 
patients, instead homozygous structural mutations in exon 1 of MBL gene were 
strongly associated with complicating infections. (Garred et al., 1999; Garred et al., 
2001). However, studies from Hong Kong, UK and Spain did not report significant 
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findings. (Davies et al.,1997; Davies et al., 1995; Lau et al., 1996; Garcia-Laorden et 
al., 2003). Interestingly, there are two conflicting reports, with one stating no 
significant findings on mutations of structural MBL gene related to development of 
SLE, and another with significant linkages with SLE. (Horiuchi et al., 2000; Tsutsumi 
et al., 2001). 
 
The issue of MBL as a predisposing factor to SLE development is controversial. 
There are no reported studies on whether MBL haplotypes confer risk to susceptibility 
of infectious agents in SLE patients, resulting in more severe disease and worse 
outcome. MBL is thus studied to clarify its role in severe lupus disease.    
 
1.2.4 Therapeutic uses of MBL in clinical trials 
 
MBL has been reported as playing an important role in innate immunity and recurrent 
severe infections are associated with its mutant alleles. The MBL protein, purified 
from pooled human sera and recombinant technology, was used in clinical trials for 
subjects with frequent infections. The results were promising, with good control of 
infections in patients and more trials are planned. Affinity purified MBL from pooled 
fresh human plasma (pMBL) has been used to treat patients with frequent and chronic 
infections with promising initial results. A 2-year old girl with recurrent infections 
since the age of 4 months remains free of abnormal infections for eight years since 
she received pMBL infusions. No adverse clinical or immunological reaction was 
observed in both patient and healthy volunteers (Valdimarsson et al., 1998; 
Valdimarsson, 2003). Recent production of recombinant MBL (rMBL) was reported 
and clinical trials were expected to start using rMBL (Jensenius et al., 2003). 
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Summerfield suggested that MBL infusion may potentially be a therapeutic option for 
patients with uncontrolled sepsis (Summerfield, 2003).  
 
1.3. Autoantibodies and their roles in SLE  
 
The production of antibodies against one's own tissue has been known for years and 
medical textbooks had documented that 10% of the normal population have at least 
one autoantibody. The production of autoantibodies could be considered a normal 
phenomenon, assisting in the removal of “damaged” tissues. It was documented that 
the levels of ANA dramatically increased immediately after an ischemic event which 
however normalizes over a few days. This showed that antibody producing cells (B 
cells) produce ANAs upon stimulation by nuclear materials released after an ischemic 
event. 
 
Physiologically, detectable autoantibodies indicate the presence of tissue or cellular 
damages. However, the persistent presence of excess autoantibodies may be an 
indicator of abnormal tissue damage (acute or chronic inflammations) or over-
expression of these autoantibodies without tissue damages. When these accumulated 
autoantibodies become pathogenic factors that target specific organs, tissues or cells, 
they manifest clinically by two possible mechanisms. Firstly, autoantibodies mediate 
the tissue injury by an immune-complex-mediated inflammatory response, as can be 
seen in glomerulonephritis caused by deposition of antigen-antibody complexes. 
Secondly, autoantibodies can also mediate cellular dysfunction or destruction by 
binding to specific autoantigens. Autoimmune hemolytic anemia is mediated through 
this mechanism. Cellular destruction (haemolysis) of red blood cells is due to 
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antibodies formed to components on the surface of the red blood cells. These 
mechanisms are not mutually exclusive, but can explain the actions of pathogenic 
autoantibodies. For example, pathogenic anti-dsDNA antibodies usually result in 
immune-complex-mediated renal disease, but a subset of these antibodies may also 
penetrate renal cells, bind to nuclei and induce glomerular disease. 
 
It is important to note that more than one self-antigen may drive an autoantibody 
response and that an autoantibody nominally directed to one self-antigen may arise 
from stimulation of another. Anti-dsDNA antibodies appear to be the product of an 
antigen-driven, T-helper-cell-dependent immune response. Although DNA is the 
target antigen, recent studies have suggested that anti-dsDNA antibodies may result 
from autoimmunization with chromatin (the complex of DNA, histones, and other 
proteins found in the nucleus) or nucleosome (the basic structural subunit of 
chromatin) rather than naked DNA. Likewise, anti-dsDNA antibodies may bind both 
DNA and components of the small nuclear ribonucleoprotein, a characteristic 
attributed to anti-Smith antibodies.  
 
Generally, SLE has a profile of multiple autoantibodies during their disease course. 
However their pathogenicity and specific relationships with organs or tissues are still 
largely unknown. Circulating pathogenic autoantibodies directed against different 
tissues are present in several autoimmune states. The pathogenic roles of many 
autoantibodies are not clear in autoimmune disorders. In acquired myasthenia gravis, 
specific acetylcholine receptor autoantibodies alter the physiological state of 
neuromuscular end-plate by reducing impulse transmission to the post-synaptic 
membrane of neuromuscular end-plate. Similarly, calcium channel autoantibodies 
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play a role in altering the physiological state of synaptic gap junction in Lambert-
Eaton myasthenic syndrome. They reduce release of neurotransmitter acetylcholine 
from the nerve terminals into the synaptic gaps.  
 
Anti-phospholipid syndrome (APS), now accepted as a systemic autoimmune disease, 
was reported in the setting of SLE as associated with recurrent thrombotic episodes 
and fetal losses, together with pre-eclampsia (Wilson et al., 1999). The autoantibodies 
detected in APS are anti-phospholipid antibodies, which are detectable by tests for β-
2 glycoprotein or anti-cardiolipin antibodies or lupus anticoagulant. Anti-
phospholipid antibodies play a pathogenic role in addition to being a diagnostic 
marker for APS (Meroni and Riboldi, 2001). These antibodies have pathogenic roles 
against the normal physiological functions of soluble coagulation factors and 
coagulation cells (De Groot and Derksen., 2000). Although the pathogenic roles on 
the obstetric manifestations are not definitively clear, they do interfere in the 
physiological function of trophroblast cells via reduction in proliferation and 
differentiation, and impairment of gonadotrophin secretion. These may promote a 
defective placenta, which results in pre-embryonic loss and utero-placental 
insufficiency (Di Simone et al., 2000).  
 
Antibodies to the Ro/SS-A were first reported in 1962, as antibodies from sera of 
patients with Sjogren’s syndrome were reactive with RNA protein particles (Anderson 
et al., 1962). There are two molecular types of the protein, 52-kD and 60-kD iso-
forms. Anti-Ro antibodies are also detected in SLE (40-50%), however their 
significant association with Sjogren’s syndrome (60-75%) was well demonstrated 
(Reichlin, 1994) and used as criteria for the latter condition. The pathogenic roles of 
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anti-SS-A antibodies in neonatal congenital heart blocks have been shown by 
detection of these antibodies on affected fetal heart, induction of AV block in rabbit’s 
heart after perfusion with anti-SS-A antibodies and development of congenital heart 
block in BALB/c mice after immunization of purified SS-A protein. (Reichlin et al., 
1994; Garcia et al., 1994; Miranda-Carus et al., 1998). Therefore pregnant women 
with anti-SS-A autoantibodies are at risk of having infants with congenital heart 
block. In this autoimmune-mediated congenital heart block, it can be concluded that 
the autoantibodies that cross the placenta, have altered the normal function of the 
conduction system of fetal heart by injuring the cardiac conductive tissue.   
 
In SLE, heterogeneous autoantibodies are detectable against different cellular 
components and most of these autoantibodies’ functions are still unknown with only 
some of them having diagnostic values. This is mainly due to heterogenicity of the 
disease itself. There is a need to clarify the roles and practical importance of these 
autoantibodies in SLE. 
 
1.3.1. Prevalence of autoantibodies in SLE  
 
Sherer et al. (2004) reported that more than 100 different autoantibodies (116 in total) 
have been found in both human and animal lupus studies. Antibodies are directed 
against nuclear components, cytoplasmic proteins, cell membranes and lipid-related 
proteins. Most SLE patients have more than one autoantibody, however the vast 
majority of the listed autoantibodies are not found in lupus patients. In addition to the 
different autoantibody frequencies, there are great variability regarding the correlation 
with disease activity and clinical associations. Some autoantibodies correlate with 
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disease severity and clinical manifestations.  For example, increased anti-dsDNA 
antibodies level preceding disease exacerbations, anti-Ro antibodies associated with 
congenital heart blocks and anti-ribosomal P proteins antibodies associated with 
nephritis and central nervous system involvement. However it is not clear how many 
of these autoantibodies contribute to pathogenesis of SLE.  
 
1.3.2. Usefulness of detection of autoantibodies in SLE    
 
Since autoantibodies in SLE are abundant in nature and can be detected easily by 
improved methodology, this unique feature of autoantibodies was used in diagnosis, 
disease activity and disease severity assessments in SLE (Table 1.4).  
 
In the 1997 updated ACR criteria for classification of SLE, two criteria based on the 
detection of autoantibodies are included for the purpose of SLE classification. They 
are  
 
i) Immunologic disorder: -   
  a) Anti-DNA: antibody to native DNA in abnormal titer (OR)  
  b) Anti-Sm: presence of antibody to Sm nuclear antigen (OR)    
  c) Positive finding of antiphospholipid antibodies based on  
• an abnormal serum level of IgG or IgM anticardiolipin antibodies,  
• a positive test result for lupus anticoagulant using a standard method, or  
• a false-positive serologic test for syphilis known to be positive for at least 
6 months and confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test. 
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ii) Antinuclear antibody  
  An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known to be 
associated with "drug-induced lupus" syndrome. 
 
Apart from their use in establishing the diagnosis of SLE, prospective serum level of 
autoantibodies are also useful in management and disease activity monitoring in lupus 
clinics. Anti-dsDNA antibodies are used as disease activity markers in SLE and useful 
in assessing lupus nephritis. Anti-histone antibodies are found mainly in drug-induced 
lupus. Recently reports on the association of ribosomal P protein antibodies with NP 
lupus have been published. 
  
We decided to explore further the roles of specific autoantibodies in two areas, 
namely autoantibodies to the kidneys and brain, since their involvement can lead to 
serious adverse outcomes.  
 
1.3.3. Renal involvement in SLE   
 
Renal involvement in systemic lupus erythematosus (SLE) is one of the commonest 
disease manifestations and a strong predictor of poor outcome. Most patients with 
SLE have immunoglobulins deposited in their glomeruli, but only about half have 
clinical nephritis as defined by proteinuria. According to ACR criteria for the 
classification of SLE, “Persistent proteinuria greater than 0.5 grams per day or greater 
than 3+ if quantitation not performed” is considered as one of the criteria for lupus 
nephritis. However, the clinical spectrum of lupus nephritis ranges from  
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Table 1.4. Some of the autoantibodies present in SLE with practical value in diagnosis and monitoring SLE patients. 
ANTIBODY ANTIGEN DISEASE ASSOCIATION 
Anti-nuclear antibodies Nuclear materials SLE (>95%) 
Anti-DNA Double stranded DNA (native DNA) SLE (50-70%); Especially with glomerulonephritis 
Anti-Histone Basic proteins bound to DNA SLE (30%); Drug induced lupus (95-100%)  
Anti-Sm Acidic nucleoprotein SLE (25-30%) 
Anti-SSA (Ro) Acidic protein SLE (10-20%);  
ANA Negative-SLE and other forms of Lupus (30-40%) 
Anti-SSB (La) Acidic protein SLE (10-20%). 
Anti-Cardiolipin  Cardiolipin SLE (60%) 
Lupus Anticoagulant Phospholipid coagulation activator complex SLE (5-10%) 
Anti-Nucleolar Nucleolar antigens SLE 
Anti-PCNA Proliferating Cell Nuclear Antigen SLE (5-10%) 
Anti-RNP  Acidic protein SLE: (25-40%) 
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asymptomatic, low-grade proteinuria to a rapidly progressive course with 
hypertension, edema, leading to severe renal failure within days.  
 
Immune complexes are present at the sites of injury in glomeruli and in tubules. 
Whether these are derived from circulating immune complexes or from in situ 
combination of antigen with antibody, is still unclear. The incidence of renal disease 
in lupus varies with the criteria used to define renal involvement and the selection of 
patients. In early stages of lupus, renal abnormalities can be detected in 25-50% of 
patients. It has been shown that up to 2/3 of patients with lupus will develop some 
renal abnormalities in the course of their disease. However, if kidney tissue from 
lupus patients (obtained by biopsy) is analyzed using refined histology techniques 
such as immunofluorescence or electron microscopy, abnormalities can be found in 
almost all cases, regardless of the presence of clinical signs and symptoms. 
 
Lupus patients develop nephritis early in their disease and it is uncommon to have 
renal disease onset more than ten years after the appearance of SLE. Studies have 
suggested a mild increase in the proportion of male lupus patients compared to 
women with renal disease. Asians, African-Caribbeans and African-Americans may 
have more nephritis than other ethnic groups (Lee and Spargo., 1985). HLA antigens 
have been associated with an increased risk of developing nephritis and the HLA-DR2 
and HLA-B8 are associated with the development of lupus renal disease (Pistiner et 
al., 1991; Freedman et al., 1993 ; Klippel, 1995). Polymorphisms of Fc receptors for 
IgG (FcgammaR) were recently identified as a risk factor, implicating defective 
handling of circulating immune complexes in the development of renal disease 
(Salmon et al., 1996). The prevalence of renal disease in eight large cohort studies 
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consisting of 2649 SLE patients varied from 31% to 65% (Wallace, 1996). A recent 
study analyzed the annual incidence of nephritis in 384 lupus patients followed at the 
Johns Hopkins Medical Center between 1992 and 94. The one year incidence of acute 
renal disease was 10% (Skovron and Petri, 1997).  
 
i. Pathogenesis of renal involvement in SLE   
 
Up to 50% of lupus patients develop clinically relevant nephritis at some time in the 
course of their illness. The pathogenetic mechanisms involved in lupus nephritis are 
still unclear. However at least three potentially overlapping, immuno-pathogenic 
mechanisms are supported by experimental data. Firstly, circulating immune 
complexes consisting chiefly of DNA and anti-DNA are deposited in the kidney. This 
results in complement activation and chemotaxis of neutrophils, leading to a local 
inflammatory process. Secondly, in-situ formation of antigen and antibody complexes 
may similarly lead to complement activation and leucocyte mediated injury. Thirdly, 
antibodies against specific cellular targets may produce renal injury. For example, 
antibodies against kidney tissue such as glomerular basement membrane, may bind to 
specific antigens, and this antigen-antibody reaction could cause disruption of cellular 
function.  
 
ii. Autoantibodies in lupus nephritis 
 
The majority of patients with lupus nephritis are positive for anti-dsDNA antibody 
and rising anti-DNA titers accompanied by hypocomplementemia, especially a low 
C3 level, are often harbingers of active and deteriorating lupus glomerulonephritis. 
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Since different substrates are used (i.e. bacterial DNA in Farr assay, mammalian 
DNA, such as calf thymus, in ELISA, and protozoan DNA within the kinetoplast 
organelle in Crithidia lucilae assay) patients may be negative in one but have a 
positive test in another assay. Occasionally lupus patients who are genuinely anti-
DNA test-negative develop clinically significant nephritis. This may occur because of 
antigen excess and inability to detect circulating anti-DNA, which is deposited in the 
kidney. Alternatively, antibodies such as anti-ribosomal P, anti-Ro, or antibodies to 
C1q may mediate renal disease. However, the antibodies directly reacting with or 
specifically targeting against renal tissue, have not been demonstrated in lupus 
nephritis patients. 
 
iii. Diagnosis and management of lupus nephritis 
 
Testing the urine for abnormalities is important in detecting renal involvement in 
lupus. Various degrees of proteinuria, red blood cells in the urine and abnormalities of 
urine sediments are seen. Patients with lupus nephritis have significant proteinuria. 
Active lupus renal disease can be categorized clinically or histologically. Clinical 
disease is evaluated by urinalysis, 24 hour urine protein assay and creatinine 
excretion, serum creatinine, anti-DNA titers, and serum complements. Additionally, 
serum albumin and cholesterol can be used to help characterize the nature of lupus 
renal disease.  
 
Lupus nephritis is highly variable in its histological manifestations and presentation. 
The only way to define the histological type of lupus nephritis is by performing renal 
biopsies. Renal biopsies are necessary in all patients with lupus who have abnormal 
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urine and/or reduced renal function. It provides information for prognostication and 
management. The World Health Organization (WHO) has defined six histological 
types of lupus nephritis (Table 1.5). Exacerbation of lupus nephritis is often preceded 
by a rise in the titre of serum anti-dsDNA antibodies, a fall in the serum 
concentrations of complement components, C3 and C4, an increase in the serum 
concentration of immune complexes and a markedly elevated erythrocyte 
sedimentation rate.  
 
The five-year survival rate of treated patients with lupus nephritis from 1990 to 1995 
was 82%. About 10-15% of patients with lupus nephritis progressed to end-stage 
renal failure. Renal failure supervenes usually within the first decade of follow-up. A 
proportion of lupus nephritis patients in endstage renal failure still requires 
immunosuppression. Recurrence of lupus nephritis is not uncommon, but renal 
transplant cases are rare. 
 
 
In some lupus patients in remission, the phenomenon of fixed proteinuria is present. 
These are patients who do not have active immunologic injury, but who have 
persistent proteinuria. It is hypothesized that the prior immunologic injury and 
inflammatory process caused dysfunctional glomeruli incapable of preventing protein 
leakage. Patients may excrete 1-3 grams per day of proteins even during periods of 
disease remission. The postulated mechanism is the reaction of an autoantibody 
against a structural protein, causing proteinuria without damaging the structural 
protein. From extensive literature search, we found a monoclonal antibody, which 
causes transient proteinuria in animal models.  
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Table 1.5. World Health Organization Classification of Lupus Nephritis 
 
 
Class Description by light microscopy Clinical presentation 
I Normal Normal Urine 
II a Normal Asymptomatic hematuria & proteinuria 
II b Mild mesangial hypercellular          -do- 
III Focal & segmental proliferative GN  
Necrosis and proliferation < 50% glomerul 
Proteinuria, Hypertension,Hematuria 
III a Focal & segmental proliferative GN 
with active necrotizing lesions 
         -do- 
III b Focal & segmental proliferative GN 
with active necrotizing and sclerosing lesions 
         -do- 
III c Focal & segmental proliferative GN 
with sclerosing lesions 
         -do- 
IV Diffuse proliferative GN;  
> 50% glomeruli; ±crescents; focal necrosis 
Acute nephritis ±nephrotic syndrome 
V Membranous GN Nephrotic syndrome 
VI Chronic sclerosing GN          -do- 
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iv. Significance of mAb 5-1-6 in proteinuria 
 
In 1988, Orikasa et al. generated a monoclonal antibody (mAb 5-1-6) which was 
produced in BALB/c mice immunized with collagenase-treated Winstar rat glomeruli. 
This monoclonal antibody reacts with the slit diaphragm in immunoelectron 
microscopy. (Kawachi et al.  1995). Single intravenous injection of mAb 5-1-6 into 
the rat causes transient but massive proteinuria. Protein excretion started immediately 
following mAb injection and sustained an average value of 138.5 mg/24 hours on day 
5, This was followed by a gradual decline, so that normalization was virtually 
resumed by day 15. No histological abnormalities could be detected by light 
microscopy on day 5 when the proteinuria was most severe. Deposition of host (rat) 
IgG and complement proteins, and the infiltration of inflammatory cells were not 
detected during the proteinuria phase.  Thus it was concluded that mAb 5-1-6 induced 
the proteinuria in a complement- and inflammatory cells- independent manner and it 
was postulated that its antigen is important for the filtration function of the slit 
diaphragm. It was proposed that mAb 5-1-6 affects glomerular permeability by 
altering the molecular composition of the slit diaphragm.  
 
The characteristics of the protein that mAb 5-1-6 binds remained unknown until 2000 
when Topham et al. reported that mAb 5-1-6 was directed against the extracellular 
domain of nephrin by protein mass spectrometry. The extracellular domain of nephrin 
is a member of the podocyte proteins, which can alter the configuration of slit 
diaphragm, thus regulating the glomerular permeable-selectivity. Massive proteinuria 
is thus observed immediately after intravenous injection of mAb 5-1-6 to normal rats. 
It is possible that these antibodies are gradually being removed by the host immune 
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system, normalizing glomerular filtration function in about two weeks (Kawachi et al.  
1995). We postulate that anti-nephrin antibodies are associated with proteinuria in 
SLE patients. 
 
1.3.4.  NP involvement in SLE 
 
People with lupus can experience headaches, dizziness, difficulties with 
concentration, and may be confused, have seizures, strokes, or other signs of central 
nervous system involvement. The variety of NP manifestations in lupus has been well 
described in prospective and retrospective studies. (Kaell et al., 1986; Sibley et al., 
1995; Futrell et al., 1992; West et al., 1995; Rood et al., 1999).  However, it is often 
difficult to differentiate if these manifestations are disease-related or the result of 
therapy (Jennekens and Kater., 2002). 
 
Three classifications for neurological and psychiatric disorders of SLE have been 
published; the first consists of 12 diagnostic criteria proposed by The Ad Hoc NP 
Lupus Workshop Group (Singer and Denburg., 1990) (Table 1.6), the second consists 
of a list of 29 lupus related CNS descriptors ranked according to diagnostic 
weightage, (Rood et al., 1999) (Table 1.7) and the last is the nomenclature system 
comprising 19 lupus related CNS syndromes with detailed definitions.(ACR Ad Hoc 
Committee, 1999) (Table 1.8). However all reports indicated that the classification, 
nomenclature and definitions are designed to facilitate clinical research and 
multicenter trials in order to generate unique diagnostic criteria for NP lupus. They 
suggested these classifications and definitions to be used critically. Currently there are 
no single diagnostic tests or investigations to establish NP lupus. Many investigations 
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(a series of hematological, biochemical, radiological and psychological tests) must be 
performed to establish NP lupus.  
 
i. Pathogenesis of NP Lupus 
 
Postulated mechanisms to explain the pathogenesis of NP lupus are many, but no concrete 
pathogenesis was reported. Inflammatory processes are no longer considered to be the main 
cause of cerebral damage. Complex processes due to a variety of factors including 
immunological and vascular factors, are acknowledged to cause cerebral damage 
(Jennekens and Kater., 2002). Autoantibodies against cerebral components are considered 
as one of the possible mechanisms for CNS involvement in SLE. SLE is a disease that 
presents diverse autoantibodies against its own cells and tissues, autoantibodies targeting 
neuronal cells or vascular tissue in central nervous system, are not rare. Nerve tissues may 
be damaged when antibodies target nerve cells or blood vessels, resulting in neuronal cell 
dysfunction. In addition, autoantibodies may bind to neuronal cells or tissues without 
causing physical damage, but may alter their physiological function. Clinically these 
altered processes manifest as NP-lupus. 
 
ii. Autoantibodies in NP lupus 
 
Many reports of autoantibodies detected in SLE patients with NP manifestations have 
been published (Bonfa and Elkon., 1986; Robbins et al., 1988;  
Denburg and Behmann., 1994; Hanly et al., 1988; Hanson et al., 1992, Hirano et al., 
1980). However their diagnostic value remains unclear. There have been a few reports 
on profiles of autoantibodies used in diagnostic evaluation of NP lupus (Conti et al.,  
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Table 1.6. The Diagnosis criteria for NP SLE (Singer and Denburg., 1990) 
 Criterion 
1 Aseptic meningitis 
2 Cerebrovascular disease 
3 Demyelinating syndrome 
4 Headache (including migraine and benign intracranial hypertension) 
5 Movement disorder (chorea) 
6 Myelopathy 
7 Seizure disorders 
8 Acute confusional state 
9 Anxiety disorder 
10 Cognitive dysfunction 
11 Mood disorder 
12 Psychosis 
 
Table 1.7. The Descriptors of CNS manifestation of SLE  (Ranked according to 
decreasing importance)  (Rood et al., 1999) 
 Descriptors 
1 Seizures, primary generalized 
2 Psychosis(brief reactive or atypical) 
3 Transverse myelitis 
4 Global cognitive dysfunction (dememtia) 
5 Seizures focal (motor or sensory) 
6 Seizures, complex partial 
7 Stroke syndrome 
8 Limited cognitive dysfunction (objective) 
9 Status epilepticus 
10 Optic neuropathy 
11 Meningitis, aspetic 
12 Movement disorders 
13 Attentional cognitive dysfunction 
14 EEG abnormality 
15 CSF abnormality 
16 Schizophreniform disorder 
17 Cerebral angiographic abnormality 
18 Brain scan abnormality 
19 Major affective disorder 
20 Absence attacks 
21 Transient ischaemic attacks 
22 Headache, vascular 
23 Headache, intractable 
24 Schizophrenia 
25 Benign intracranial hypertension 
26 Limited cognitive dysfunction (subjective) 
27 Other psychiatric syndrome/symptoms 
28 Generalized anxiety/pain disorder 
29 Headache tension 
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Table 1.8. Case Definitions for NP Syndromes in Systemic Lupus Erythematosus  




1 Acute Confusional State 
2 Cognitive Dysfunction 
3 Myasthenia Gravis 
4 Acute Inflammatory Demyelinating Polyradiculoneuropathy 
(Guillain-Barré Syndrome) 
5 Demyelinating Syndrome 
6 Myelopathy 
7 Anxiety Disorder 
8 Headache 
9 Neuropathy, Cranial 
10 Aseptic Meningitis 
11 Mononeuropathy (single/multiplex) 
12 Plexopathy 
13 Autonomic Disorder 
14 Mood Disorders 
15 Polyneuropathy  
16 Cerebrovascular Disease 
17 Movement Disorder (Chorea) 
18 Psychosis 
19 Seizures and Seizure Disorders 
 
 
NB. For detail definitions of NP syndromes, basic laboratory evaluation and 
diagnostic imaging in NP-SLE and suggested proposed One-Hour neuropsychological 
Battery for SLE, refer to “ACR Ad Hoc Committee on NP lupus nomenclature. The 
American College of Rheumatology nomenclature and case definitions for NP lupus 
syndromes”. Arthritis Rheum. 1999; 42: 599-608” 
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2004; Nakamura., 1997). Autoantibodies associated with NP lupus can be grouped 
into five categories. They are (1) anti-neuronal antibodies, (2) brain-lymphocyte 
cross-reactive antibodies, (3) anti-ribosomal P proteins, (4) anti-phospholipid 
antibodies and (5) anti-gangliosides antibodies (Greenwood et al., 2002). 
 
Bluestein and Zvaifler reported an association of brain-lymphocyte cross-reactive 
antibodies with NP lupus (Bluestein and Zvaifler 1976). These antibodies were 
identified with reactive lymphocytes antigen of 32, 52, 56 and 98 kD and significant 
associations with cognitive impairment in patients is observed with the 52 kD proteins 
(Denburg et al., 1994). However, brain-lymphocyte cross-reactive antibodies react 
with 52kD autoantigen from both lymphocytes (CD4+ HUT-78) and neuroblastoma 
cells (SK-N-SH and IMR-6) (Denburg and Behmann., 1994). Thus it is not clear that 
if these antibodies should be classified as anti-neuronal antibodies.  
An association between anti-ribosomal P protein antibodies and SLE psychosis was 
reported by western blot analysis. (Bonfa and Elkon., 1986). It was confirmed by 
some, but also refuted by others. Anti-ribosomal P protein antibodies are reported 
frequently in patients with lupus psychosis, lupus nephritis and also increased during 
the active phase of SLE (Teh and Isenberg., 1994), and associated with liver 
dysfunction in SLE patients (Yoshio et al., 1998). Thus anti-ribosomal P antibodies 
are not solely associated with NP lupus.  
 
Anti-cardiolipin antibodies, associated with antiphospholipid syndrome, are also 
found in a variety of disorders, such as SLE, syphilis, Q fever, Acquired Immune 
Deficiency Syndrome (AIDS) (Mouritsen et al., 1989; Harris et al., 1988; Ordi-Ros et 
al., 1994; Canoso et al., 1987). However, their association with NP lupus is debatable. 
 43
Although anti-cardiolipin antibodies are found, not exclusively, to be in high titers in 
NP lupus, Alarcon-Segovia et al (1997) did not observe an association of serum 
anticardiolipin antibodies and NP lupus.  
 
Anti-gangliosides antibodies are antibodies against gangliosides located on neuronal 
and myelin membranes in the central and peripheral nervous system. An association 
of anti-gangliosides antibodies in NP lupus was reported by Hirano et al. in 1980. 
However the incidence of these antibodies in NP lupus is yet to be confirmed. 
Currently it provides little assistance in the management of NP lupus. Many anti-
neuronal antibodies have been described in relationship with NP lupus. However the 
identification of antigens that these antibodies binds to is still unclear except for 
neurofilament proteins (Robbins et al., 1988). Currently, many of the autoantibodies 
detected in NP lupus do not show any diagnostic value because of poor specificity and 
sensitivity. Greenwood et al., (2002) suggested (1) to standardize the methods to 
prevent discrepancies in antibody detection and (2) to use the ACR definitions and 
classification for NP lupus to prevent the subjective definitions of CNS 
syndromes/symptoms.  
 
Anti-neuronal antibodies were first reported in NP SLE using radioimmunoassay and 
SK-N-SH, a human neuroblastoma cell line (Bluestei., 1978). Subsequently, a variety 
of human and animal neuronal substrates have been used to detect autoantibodies in 
NP lupus using a range of methods, such as immunofluorescence, immunoblotting 
and ELISA. However the identity of most brain-specific proteins remains unknown 
except for their associations in NP lupus. Whether the presence of these 
autoantibodies contributes to the development of NP-lupus is not known. 
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The neuronal proteins used as antigens in detection of autoantibodies can be divided 
into following categories; (1) neuronal protein from normals, such as human, rat, 
mouse or cow, and (2) neuronal protein from tumor cell lines such as human 
neuroblastoma and mouse neuroblastoma. Using tumor cell line as antigens to detect 
autoantibodies in NP lupus will pose a question of whether these proteins are 
expressed under normal conditions in neuronal cells and tissues.  However a variety 
of autoantibodies reacting against tumor cell lines was reported to be associated with 
human and mouse NP-lupus. (Isshi and Hirohata., 1998; Hanly and Hong., 1993; 
Hoffman et al., 1988; Danon and Garty., 1986; How et al., 1985).  
 
The autoantibodies from human and mouse NP-lupus sera bind to different proteins 
from human and other animals. (Hanly and Hong., 1993; Klein et al., 1991; Hanson et 
al., 1992; Moore et al., 1994). Besides the presence of these anti-neuronal antibodies 
in lupus sera from both human and murine models, attempts to show the presence of 
antibodies in murine model of NP lupus was also done. Using laser confocal 
microscopy, the presence of immunoglobulin in brain section of murine model mice 
(MRL/lpr and BXSB) was reported by Zameer and Hoffman in 2001. Antibodies 
eluted from brain parenchyma of NZBxW (F1) mice were shown to react with brain 
tissue of BALB/c mice. (Moore 1992). Furthermore, Narendran and Hoffman (1989) 
and Moore (1990) demonstrated that multiple autoantibodies are identified against 
normal mouse brain tissue in sera of different murine lupus models. Among these 
anti-neuronal antibodies that have shown associations with NP-lupus, none of them 
has been identified except for one that is partially cloned. (Moore et al., 1998).  
 
 45
Recently, 2 other autoantibodies have been described as associated with NP lupus. 
Antibodies to triosephosphate isomerase (TPI) was reported to be associated with NP 
lupus (Watanabe et al, 2004).  TPI is a highly conserved 29 kD glycolytic enzyme that 
catalyses the interconversion of dihydroxyacetone phosphate and D-glyceraldehyde 3-
phosphate. Deficiency of TPI causes hemolytic anemia and neurological disorders 
(Schneider, 2000). TPI, though quite similar in molecular weight to one of the 2 novel 
BRAAs identified by us, has recently been found to be associated with osteoarthritis 
and advocated as a diagnostic marker for OA (Xiang et al, 2004). N-methyl-D-
aspartate (NMDA) receptors are responsible for the majority of excitatory synaptic 
transmission in the central nervous system. Antibodies to NMDA receptor types 
NR2a or NR2b, have been reported as being associated with NP lupus, specifically to 
depressed mood, decreased short-time memory and learning (Omdal et al, 2005). 
They are about 180 kD in molecular weight (Stephenson, 2001). 
 
iii. Diagnosis and management of NP lupus 
 
During the course of SLE, a variety of NP disturbances are reported (Kaell et al., 
1986; Sibley et al., 1995; Futrell et al., 1992; West et al., 1995; Rood et al., 1999). 
The reported prevalence of these disorders varies widely, raging from 17% to 75%. 
The diagnosis of NP-lupus is difficult and depends on the exclusion of other causes of 
CNS manifestations such as metabolic, cardiovascular or infectious causes (Jennekens 
and Kater., 2002). Many CNS manifestations are subjective and difficult to interpret, 
requiring a careful and complete psychological evaluation. Thus diagnosis depends on 
a series of tests (series of hematological, biochemical, radiological and psychological 
tests).  
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1.4. Aims of the study  
 
Effective management of lupus with immunosuppressive drugs, which lead to 
increased survival rate of lupus patients, are also associated with higher risk of 
recurrent infections. Presence of certain MBL variants favoring MBL deficiencies, 
can aggregate the infectious risks. The presence of autoantibodies, which target 
specific organ system, may pose additional severity factors in lupus patient 
undergoing current aggressive lupus management. We therefore aim to study 
following: 
 
• The role of polymorphic MBL gene in lupus patients and infections 
• The role of anti-nephrin antibodies in lupus patients and renal involvement 
• The role of BRAA in lupus patients and NP manifestations 
 
We will also determine if specific MBL variant, anti-nephrin antibodies and brain 














MATERIALS AND METHODS 
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2.1 Patient selection and sample collection  
 
One hundred and two healthy volunteer controls were recruited into the study. One 
hundred unselected lupus patients, fulfilling the 1997-updated ACR criteria for 
classification of SLE (Hochberg, 1997), were recruited into this study. One hundred 
and thirty non-lupus rheumatic patients (20 Rheumatoid Arthritis patients, 20 
Ankylosing Spondylitis patients, 20 Psoriatic Arthritis patients, 20 Osteoarthritis 
patients, 50 patients with Primary Anti-phospholipid syndrome) were also recruited 
into the study. All non-lupus patients were diagnosed by attending rheumatologists 
using established disease criteria. All lupus patients and non-lupus rheumatic patients 
were attending the rheumatology clinics at the Singapore General Hospital. 
 
After informed consent, 5 ml each of peripheral venous blood from controls and lupus 
patients, were taken in both plain tube and Na2EDTA tube for DNA extraction and 
sera preparation. 5 ml of the peripheral venous blood from non-lupus patients was 
collected in plain tubes for sera preparation. The sera were separated from clotted 
blood using standard protocol and genomic DNA extraction was done using modified 
salting-out method (Miller et al., 1998).  All aliquoted sera and DNA samples were 
kept in -80°C freezer until further experiments.  
 
A standard protocol was used to collect demographic and clinical data of lupus 
patients. Briefly the drugs used in lupus treatment (especially steroid and cytotoxic 
drugs), renal and NP involvements as defined by the 1997-updated ACR criteria for 
classification of SLE (Hochberg, 1997) and ACR-defined NP lupus nomenclature, 
detailed renal presentation, and infections (bacterial, viral and fungal) were recorded 
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together with patients’ demographic data. SLE Damage Index of lupus patients was 
defined for twelve organ systems using SLICC/SCR DI during this study (Appendix 
1). 
 
2.2  Mannose Binding Lectin 
 
Currently the available methods used in genotyping and haplotyping of MBL gene 
were PCR-based methods, such as PCR-SSP, PCR-SSO, realtime PCR, UHG-PCR. 
PCR-RFLP methods were also available to genotype codons 54 and 57 of exon 1 and 
–221 bp site (X/Y alleles) of promoter region. The lack of readily available restriction 
endonucleases for codon 52 and –550 bp site (H/L alleles) made PCR-RFLP a partial 
method to genotype and haplotype the MBL gene. We therefore decided to design 
mismatched primers where restriction endonucleases sites are incorporated so that 
genotyping and haplotyping of MBL gene can be completely determined by PCR-
RFLP method. 
 
2.2.1. A novel PCR-RFLP for genotyping and haplotyping of MBL gene. 
 
We introduced a restriction endonuclease recognition sites at codon 52 of exon 1 and 
–550 bp site (H/L alleles) of promoter region of MBL gene, by altering some 
nucleotides at mismatched primers and validated a novel PCR-RFLP method for 
complete genotyping and haplotyping of the MBL gene polymorphisms. 
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i. Design and synthesis of primers 
 
All primers were synthesized locally (Research Biolabs and BST Scientific, 
Singapore).  
 
Two mismatched primers were manually designed for use in this study. The forward 
mismatched primer for MBL exon 1 (MBL-E1-FOR; 5'-
CATCAACGGCTTCCCAGGgcAAGATGGG-3') containing Mwo I recognition site 
was designed at the 5’ end of Codon 52. The reversed primer for exon 1 (MBL-E1-
REV; 5'-GTCTCCTCATATCCCCAGGC-3') was also synthesized for PCR 
amplification (Figure. 2.1). The forward mismatched primer for promoter region 
(MBL-PRO-FOR; 5'-GAAAATGCTTACCCAGaCAAGCCTGT-3') was also 
designed manually at the 5’ end of the polymorphic site H/L and Drd I enzyme 
cleavage site was added. The reversed primer for promoter PCR (MBL-PRO-REV; 5'-
TCATCTGTGCCTAGACACCTGGC-3') was designed away from the X/Y mutation 
site to allow for differentiable fragments and easy interpretations after RFLP (Figure. 
2.2). 
 
Sequence specific primers for exon 1 and promoter gene polymorphism were 
synthesized according to Steffensen et al. (2000). (Table 2.1) 
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ii. Polymerase Chain Reactions  
 
MBL-E1-FOR and MBL-E1-REV primers were used to amplify the polymorphic sites 
at exon 1 while MBL-PRO-FOR and MBL-PRO-REV were used for polymorphic 
sites at the promoter gene region. 
 
PCR conditions, using BioMetra T3 thermocycler, were as follows: 1 cycle of 95°C 
for 5 minutes followed by 35 cycles of denaturing at 94°C for 10 seconds, annealing 
at 62°C for 30 seconds and extension at 72°C for 30 seconds. The final extension step 
was done at 72°C for 10 minutes. 30 μl of PCR reaction contained 50ng of genomic 
DNA, 0.2 μM each of forward and reverse primers; 0.1 mM of dNTPs, 1x reaction 
buffer (10 mM Tris-HCl pH 8.8 at 25 °C, 1.5 mM MgCl2,, 50 mM KCl and 0.1% 
Triton X-100) and 0.2 units of DyNAzyme TM II DNA polymerase (FinnZymes).  
 
4 μl of PCR products were visualized on Ethidium Bromide stained 2% agarose gel in 
0.5xTBE buffer before cleavage by different restriction endonucleases.  
 
iii. Restriction Fragment Length Polymorphisms 
 
All restriction endonucleases used in this study were purchased from New England 
Biolabs. 
 
4 μl each of MBL exon 1 PCR products were incubated with Mbo II (1 unit), Ban 
I (0.13 unit) at 37°C, and Mwo I (0.13 unit) at 60°C for one hour according to 
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Figure. 2.1 Design of forward mis-matched and reversed primers for Exon 1 
MBL ; Mwo I (I) will cut wild type allele, Ban I (II) will cut wild type allele and Mbo 
II (III) will cut mutant allele.  r = a or g; y = c or t ; n = a or c or t or g: 
Figure. 2.2 Design of forward mis-matched and reversed primers for promoter 
region of MBL; Drd I (IV) will cut L allele and Btg I (V) will cut Y allele:  
r =a or g ; y =c or t ; n = a or c or t or g. 
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Table 2.1. List of primers (for PCR-RFLP and PCR-SSP) to genotype the exon 1 and promoter region of MBL. 
 
 
No Primers Sequence Methods Remark 
1 MBP-E1-FOR (mismatched) 5’-CATCAACGGCTTCCCAGGGCAAGATGGG-3’ PCR-RFLP # 
2 MBP-E1-REV 5’-GTCTCCTCATATCCCCAGGC-3’ PCR-RFLP # 
3 MBP-PRO-FOR (mismatched) 5’-GAAAATGCTTACCCAGACAAGCCTGT-3’ PCR-RFLP # 
4 MBP-PRO-REV 5’-GCCAGGTGTCTAGGCACAGATGA-3’ PCR-RFLP # 
5 MBLSSP 5’-CTGCACCCAGATTGTAGGACAGAG-3’ PCR-SSP * 
6 52DR 5’-TCTCCCTTGGTGCCATCACA-3’ PCR-SSP * 
7 52AR 5’-TCTCCCTTGGTGCCATCACG-3’ PCR-SSP * 
8 54BR 5’-CCCCCTTTTCTCCCTTGGTGT-3’ PCR-SSP * 
9 54AR 5’-CCCCCTTTTCTCCCTTGGTGC-3’ PCR-SSP * 
10 57CR 5’-ACGTACCTGGTTCCCCCTTTTCTT-3’ PCR-SSP * 
11 57AR 5’-ACGTACCTGGTTCCCCCTTTTCTC-3’ PCR-SSP * 
12 H-s 5’-GCTTACCCAGGCAAGCCTGTG-3’        76-96 PCR-SSP * 
13 Y-as 5’-CTGGAAGACTATAAACATGCTTTCC-3’ PCR-SSP * 
14 L-s 5’-GCTTACCCAGGCAAGCCTGTC-3’ PCR-SSP * 
15 X-as 5’-GGAAGACTATAAACATGCTTTCG-3’ PCR-SSP * 
 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 (NB: # newly designed primer, *  R. Steffensen et al.)
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manufacturer’s instructions. The cleaved DNA fragments were visualized on 
Ethidium bromide stained 2 % agarose gel (SeaKem LE agarose) in 0.5x TBE buffer.  
 
4 μl each of MBL promoter gene region PCR products were incubated with Drd  I 
(0.13 unit) and  Btg I (0.5 unit) overnight at 37°C. The cleaved DNA fragments were 
visualized on Ethidium-bromide-stained 3 % agarose gel ( 1% NuSieve GTG agarose 
and 2% SeaKem LE agarose) in 0.5x TBE buffer. 
 
iv. Validation of the PCR-RFLP results. 
 
We have tested the robustness and reproducibility of our novel PCR-RFLP method by 
i.) DNA sequencing, ii.) comparison with PCR-SSPs and iii) independent 
performance by volunteers.  
 
Samples with homozygous and heterozygous results at exon 1 and samples with 
different promoter gene haplotypes were randomly selected for sequencing. DNA 
sequencing reactions were performed with appropriate forward and reversed primers 
on purified PCR products (spin columns, QIAGEN) using ABI PRISM BigDye 
Terminator v3.0 Sequencing Kit and ABI 3100 Genetic Analyzer (Applied 
Biosystem). PCR-SSP typing method was performed using established method of 
PCR-SSP to genotype and haplotype the MBL gene in selective samples. PCR 
conditions and compositions are as described elsewhere (Steffensen et al., 2000). 
 
To test reproducibility and simplicity of use, DNA samples containing different 
genotypes of exon 1 and promoter gene region polymorphisms were distributed to 
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four different laboratory-personnel volunteers together with the detailed protocol. 
These volunteers performed the PCR-RFLP using this detailed protocol, the results of 
which were collected separately and compared. 
 
2.2.2. Genotyping of Exon 1 and Haplotyping of Promoter region of MBL gene. 
 
Upon successful optimization, healthy individuals and lupus patients were genotyped 
and haplotyped for exon 1 and promoter region of MBL gene using novel PCR-RFLP 
protocol. 
 
A total of 102 healthy Chinese individuals were used in genotyping and haplotyping 
of MBL exon 1 and promoter region using our novel PCR-RFLP method. 
 
The genotype of exon 1 and haplotypes of promoters region of MBL gene of 100 
lupus patients were also analyzed using PCR-RFLP method. 
 
2.2.3. Prevalence of MBL gene variants in lupus patients 
 
The frequencies of different variants were analyzed in lupus patients compared to 
control individuals. All significant MBL variants were further correlated with 
infections among lupus patients. Chi-square test was used to determine the 
significance of these findings and Fisher’s exact test was used when necessary.  
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2.3  Nephrin 
 
The nephrin gene was responsible for Finish-type of familial nephrotic syndrome. It 
was well established that mutations in the nephrin gene is associated with proteinuria. 
Recently it was reported that the monoclonal antibodies (mAb 5-1-6), which caused 
transient proteinuria in rat when injected intravenously, was targeted against the 
extracellular domain of nephrin. We decided to express the fragment of extracellular 
portion of mouse nephrin protein, which has similar amino acid sequence among the 
mouse, rat and human nephrin genes (Figure. 2.3).  
 
2.3.1.  Expression of nephrin protein fragment 
 
All animals were purchased from the Animals Holding Unit, National University of 
Singapore. All procedures and protocols used in this study are in concordance with 
standard practice. The flowchart for cloning of nephrin protein is presented in Figure 
2.4. 
 
i. Animal selection and RNA extraction 
 
Two 8 week-old female BALB/c mice were sacrificed by using Chloroform 
intoxication. Abdominal cavities were opened under standard sterile conditions and 
the kidneys were removed, weight measured and then snap-frozen in liquid nitrogen. 






Figure. 2.5. pGEM®-T Easy vector and its multiple cloning site 
Figure. 2.3. The fragment of murine nephrin protein for expression and its 





Selected and cleaved by Nde I
PCR            NEP-FOR 
           T-7
Discarded 
Ligated into pGEM-T Easy
Selected, expressed and purified  
 
     NEPHRIN PROTEIN 
total RNA 
RT-PCR  NEP-FOR 
          NEP-REV
Discarded pGEM-T Easy 
PCR            NEP-FOR 
          T-7Ligated into pGEM-T Easy
Fig. 2.4. Molecular cloning flowchart for mouse nephrin;  
Murine nephrin of BALB/c origin was cloned into pET-16b (His-tagged expression system), with brief construction of expression vector 
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Frozen kidneys were homogenized by means of mortar and pestle in the presence of 
continuous flow of liquid nitrogen. Using syringes and needles (from 19G to 25 G 
sizes) the tissue lysates were further homogenized. Homogenized tissues were 
transferred to Trizol reagent (Gibco BRL) according to manufacturer’s instructions (1 
ml of Trizol reagent per 100 mg tissue). The amount of extracted total RNA was 
measured by spectrophotometer.  Reverse transcriptions and polymerase chain 
reactions (RT-PCR) were then performed. 
 
ii. Design and Synthesis of primers 
 
The primers used in RT-PCR are manually designed and vector construction and 
selection of correctly orientated clone were available from manufacturer’s instruction 
manuals. All of them were synthesized locally (Research Biolabs and BST Scientific, 
Singapore) (Table 2.2).  
 
iii. Reverse transcription and polymerase chain reaction  
 
The first strand cDNA from murine kidney RNA was synthesized with random 
primers using RNase H Reverse transcriptase (SuperScriptTM II, Gibco-BRL) 
according to manufacturer’s instructions. RNase inhibitors were used when handling 
RNA samples in the experiments. 
 
The cDNA containing gene segment of interest was amplified in PCR using forward 
and reversed primers flanking the region of interest by means of standard PCR 
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Table 2.2. List of primers for RT-PCR, construction of expression vector in cloning of nephrin protein fragment. 
 
 
No Primers Sequence Used in Remark 
1 NEP-FOR  5’- GGCCCATATGGACAACGGGGTGGCTCCC -3’ RT-PCR # 
2 NEP-REV 5’-GGCCCATATGTCACCTCGGGGGTCCCGGAGG -3’ RT-PCR # 
3 T7- promoter 5’- TAATACGACTCACTATAGGG -3’ pGEM-T easy vector * 
4 SP6- primer 5’- ATTTAGGTGACACTATAG-3’ pGEM-T easy vector * 
5 T7-primer 5’- TAATACGACTCACTATAGGG -3’ pET-16 expression vector @ 
6 T7-terminator 5’- GCTAGTTATTGCTCAGCGG -3’ pET-16 expression vector @ 
 
      (NB: # manually designed primer, * Promega; @ invitrogen.)
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procedure, utilizing DyNAzyme DNA polymerase kit in Thermocycler (MJ 
Research). 
 
iv. Sub-cloning for PCR product and selection of correct orientation 
 
The PCR product was transferred into the pGEM-T easy vector (Figure 2.5) using 
Promega TA-cloning kit. Briefly, the PCR product was ligated into pGEM-T easy 
vector using DNA ligase, transformed into chemically competent JM 109 cells using 
heat-shock method. The E. Coli (JM 109) cells grown in LB media without antibiotics 
for one hour were then transferred to LB+ampicillin agar-plate and incubated 
overnight at 37°C.  
 
The single colonies were picked and grown in 1 ml LB media for three hours and the 
clone containing the corrected orientation were selected by using PCR method. The 
clones with correct orientation were further grown in 10 ml LB liquid media 
containing Ampicillin as selection agent. Upon obtaining reasonable culture, the 
plasmid DNA was extracted using standard alkaline miniprep. The plasmid DNA, 
containing correct orientation of PCR product, was cleaned by phenol method and 
measured the amount of plasmid DNA measured by spectrophotometer.  
 
v. Construction and selection of expression vector 
 
The His-tagged protein expression system was used to express the gene of interest in 
this study.  
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The E. Coli (JM109) containing the expression vector pET-16b (Figure 2.6) was 
grown in LB media without antibiotics, the plasmid DNA was then extracted and 
cleaned by phenol method. The amount and purity of plasmid DNA was measured.  
 
The expression vector (pET-16b) and pGEM-T easy vector, containing gene of 
interest were subjected to cleavage by restriction endonuclease Nde I (New England 
Biolabs) according to recommended conditions. The cleaved plasmids (pET-16b) 
were separated on 0.8% normal agarose gel electrophoresis while the cleaved  
plasmids (pGEM-T easy) were separated on 1.5% gel electrophoresis. The cleaved 
fragments were confirmed by enzyme map, then the cleaved expression vector (pET-
16b) and the fragments containing gene of interest were excised from the gel. The 
cleaved expression vector and fragment were spun in glass-wool columns and purified 
using phenol method. The linearised pET-16b was dephosphorylated, prior to ligation 
with DNA insert, to prevent self-ligation. 
 
The dephosphorylated expression vector (pET-16b) and DNA insert (fragment of 
nephrin gene) were ligated using Promega DNA T4 ligase according to 
manufacturer’s instructions. The ligated plasmids were transformed into the 
chemically competent JM109 cell using heat-shock method. The transformed JM109 
cell grown after one hour in LB media without antibiotics were plated onto 
LB+Ampicillin agar plate and incubated at 37°C overnight. The single colonies were 
selected and grown in LB media with ampicillin as selection agent for three hours 
with shaking. The E.Coli clones, containing the pET-16b expression vector with 
correct orientation, were selected using PCR technique with cell lysate as templates. 
The pET-16b with correct orientation were further grown in 10 ml of LB media 
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containing ampicillin at 37°C with constant shaking. Upon reasonable growth of 
bacterial cells, the plasmid DNA was extracted using standard mini-prep. The plasmid 
DNA was cleaned by using phenol method and quantity of plasmid DNA was 
measured by spectrophotometer. 
 
vi. Expression of nephrin protein fragment 
 
The plasmid DNA (Expression pET-16b vector containing gene of interest) was 
transformed into chemically competent E. Coli BL21 (expression strain) by using 
heat-shock method. The transformed BL21 cell grown after one hour in LB media 
without antibiotics were plated onto LB+Ampicillin agar plate and incubated at 37°C 
overnight. The single colonies were selected and grown on LB media containing 
ampicillin as selection marker, separated into two eppendorfs tubes after three hours 
and grown further. One of the eppendorf tubes was induced using 0.1mM IPTG for 
one more hour while the other eppendorf tube acted as control without IPTG 
induction.  After an hour’s induction, E.coli pallet was collected and SDS-PAGE was 
done using both cell lysates (both induced and uninduced) to determine if the 
expected protein was seen.  
 
An expression experiment was done to find out if the protein was expressed as soluble 
protein or insoluble protein (inclusion bodies) after confirming the expression of 
nephrin protein. Briefly, the IPTG-induced E Coli were lysed using different 
approaches (sonication, homogenization by syringe and needle, proteolytic lysis, free-
thaw cycles, combination of these methods). Insoluble fraction was separated by 
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Figure. 2.6. pET-16b expression vector and its multiple cloning site 
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using centrifugation and solubilised using 8M Urea. Both soluble and insoluble 
fractions were visualized on SDS-PAGE to find out the nature of expressed protein.       
 
2.3.2.Purification of expressed nephrin protein 
 
Small scale of purification was carried out in 5 ml of LB-media of the expressed 
protein. E.coli were collected and lysed by means of mechanical and proteolytic 
approaches (combination of free-thaw cyles and proteolytic approaches). The 
insoluble fractions (inclusion bodies) was washed completely and solubilised in 8M 
Urea. The expressed nephrin protein was purified from the mixture of urea-solubilised 
proteins using Ni-NTA agarose (Qiagen) (Figure 2.7). Briefly, the urea-soluble 
protein was incubated with Ni-NTA agarose and washed completely to remove any 
unbound proteins. Then the 6xHis-tagged expressed protein was eluted using acidic 
elution buffer. All proteins from the different fractions (binding step, washing steps 
and elution steps) were eletcrophoresed on SDS-PAGE.  
 
Large scale expression and purification was carried out using 1 liter LB medium after 
the confirmation of the small-scale purification result. Briefly, the columns were 
made using 10 ml syringe with 2 ml of Ni-NTA agarose bed volume. Glass wool 
plugs were used to prevent agarose leaking from the syringes during all steps of 
purification. The concentration of protein purified from Ni-NTA was measured using 
BIORAD protein assay. All proteins were aliquoted and kept in -80°C freezer. 
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Fig. 2.7. His-tag fusion protein purification system 
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2.3.3.Production of polyclonal antibodies against expressed protein 
 
All animals were purchased from the Animals Holding Unit, National University of 
Singapore and maintained in Animals Room, Department of Physiology, National  
University of Singapore with standard accommodation and food provided during the 
period of production of polyclonal antibodies. All procedures and protocols used in 
this study are recognized internationally.  
 
i. Animal selection, bleeding and culling 
 
Two New Zealand white (NZW) female rabbits (about 2.5 kilograms) each obtained 
from the Animal Holding Unit, National University of Singapore were allowed to get 
accustomed to their new environment (Animals Room, Department of Physiology, 
National University of Singapore) for one week before the first pre-bleed and first 
immunization.  
 
Before the immunization, the pre-bleed (5 ml of whole blood per rabbit) was taken 
from both rabbits. The subsequent bleedings (25 ml of whole blood per rabbit) were 
done every two weeks after booster doses. Immunizations and bleedings were done 
under anesthesia at the Animals Holding Unit, NUS, under standard sterile condition. 
The rabbits were kept for four months after which they were sent to Animal Holding 
Unit for culling according to standard procedures. 
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ii. Rabbit immunization. 
 
500 µg of purified protein per rabbit was used. The antigens were prepared in 
Complete Freund's adjuvant (containing 0.5 mg/ml microbacterium cell wall 
components) and the total volume of 1 ml consisted of 500 μl CFA and 500 μl of 
1xPBS containing 500 μg of antigen for one rabbit. Upon complete suspension by 
vigorous mixing, the antigen were injected into four sites, two on the thighs and two 
on lower back. All sub-cutaneous immunizations were done under sterile conditions. 
Booster doses with antigen prepared only with incomplete Freund's adjuvant were 
done every 4 weeks, with 25 ml-bleed per rabbits 14 days after each injection. 
  
The quantity of the antibodies in rabbit’s serum is monitored using indirect ELISA. 
The cut-off point for anti-nephrin antibodies was set at 3 S.D (Standard Deviation) 
above the mean value (OD) of anti-nephrin antibodies from BALB/c mice sera. The 
indirect ELISA is used primarily to determine the strength and/or amount of antibody 
response in a sample, whether it is from the serum of an immunized animal or the cell 
supernatant from growing hybridoma clones. 
 
iii. Purification of polyclonal antibodies. 
 
A standard ELISA method for the assaying of anti-nephrin antibodies with pre-bleed 
sera as controls, were used to determine the titers of anti-nephrin antibodies. When 
significantly high titers of anti-nephrin antibodies were present in the rabbit serum, 
the polyclonal antibodies were purified by ammonium sulfate precipitation. Two-
thirds volume of saturated ammonium sulfate solution was added to pooled rabbit’s 
sera and the pallet was separated by centrifugation. The precipitation was repeated 
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and precipitated polyclonal antibodies were suspended in 1xPBS. After dialysis 
against 1xPBS thrice, the protein concentration was determined by BioRad protein 
assay.  
 
2.3.4.Production of monoclonal antibodies against expressed protein 
 
All animals were purchased from the Animal Holding Unit, National University of 
Singapore and maintained in Animals Room, Department of Physiology, National 
University of Singapore with standard accommodation and food provided until 
scarified. All procedures and protocols used in this study are recognized 
internationally.  
 
i. Animal selection and bleeding 
 
Two 8-week old female BALB/c mice were used for production of monoclonal 
antibodies.  These mice were allowed to get accustomed to their new environment for 
one week before the first pre-bleed and first immunization. All standard 
accommodation and food were provided during the period of production of 
monoclonal antibodies. Before the immunization, the pre-bleed (50μl) was taken from 
all mice from tail vein.  
 
ii. Mouse immunization. 
 
100 µg of purified protein per mouse was used. The antigens were prepared in 
complete Freund's adjuvant (containing 0.5 mg/ml microbacterium cell wall 
components) and total volume of 200 μl of consisted 100 μl CFA and 100 μl of 
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1xPBS containing 100 μg of antigen for one mouse. Upon complete suspension by 
vigorous mixing, antigens were injected into mouse intraperitoneally using standard 
sterile method. Booster dose with antigen prepared only with incomplete Freund's 
adjuvant was repeated every 2 weeks, with 50μl-bleed per mouse. 
 
Indirect ELISA monitors the quantity of the antibodies in serum (humoral immune 
response) of the bleeds. The cut-off point was defined as described. 
 
 
iii. Preparation of myeloma cells and splenic cells 
 
The myeloma cell line of murine BALB/c origin (P3X63Ag8.653) was used as 
immortal cell line in fusion because they do not secrete any antibodies. The cell line 
was maintained for about two weeks at 4x105cells/ml in ClonalCellTM-HY pre-fusion 
Medium (Medium A of ClonaCellTM complete kit) using standard sterile cell culture 
procedure. This is to ensure that they are well adapted to this medium before fusion 
Since the recommended cell density for fusion is 2x105 cells/ml, double density of 
myeloma cells are kept to make sure sufficient numbers are available on fusion day. 
Cells harvested on the fusion day were washed three times with serum-free 
ClonalCellTM-HY fusion Medium (Medium B of ClonaCellTM complete kit). The 
viable cells were counted after the third wash, the cell suspension containing 2x107 
cells was prepared and kept on ice until the fusion step.  
  
The BALB/c mouse immunized with expressed nephrin protein and had shown high 
titer of antibodies against immunized protein was sacrificed. The spleen was removed 
aseptically and splenic cells were prepared for fusion. Briefly, the splenic cells were 
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collected through smashing against a metal sieve, collected cells washed thrice with 
serum-free ClonalCellTM-HY fusion Medium (Medium B of ClonaCellTM complete 
kit). After the last wash, the viable splenic cells were counted using 3% acetic acid 
where red cells will be lysed. The cell suspension containing 2x108 cells was prepared 
and kept on ice until fusion step.  
 
iv. Fusion using ClonaCellTM complete kit. 
 
The fusion of the myeloma cells and splenic cell was done using PEG solution 
according to manufacturer’s instructions. After the fusion step, the cell pallet was 
resuspended in Medium C of ClonaCellTM complete kit and incubated at 37°C in 5% 
CO2 atmosphere for one day. On the following day, ClonalCellTM-HY Hybridoma 
selection Medium (Medium D of ClonaCellTM complete kit) was used to resuspend 
the fused cells and this resuspended fused cells were plated on ten petri plates which 
were incubated at 37°C in 5% CO2 atmosphere for two weeks without any 
disturbances.  
 
v. Selection of the correct clone from fused myeloma. 
 
After a 2-week incubation, the plates were examined for the presence of colonies 
visible to the naked eye. Each visible clone was transferred to an individual well of 
96-wells tissue culture plates containing 200 μl of ClonalCellTM-HY Growth Medium 
(Medium E of ClonaCellTM complete kit) and incubated at 37°C in 5% CO2 
atmosphere for 4 days without feeding. The supernatant of each hybridoma was 
collected for screening to detect anti-nephrin antibodies using ELISA method. The 
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positive clones were resuspended in 1 ml of ClonalCellTM-HY Growth Medium 
(Medium E of ClonaCellTM complete kit) and incubated at 37°C in 5% CO2 
atmosphere to grow further so as to reach a suitable density.    
 
2.3.5.Confirmation of expressed protein and its polyclonal antibodies 
 
The expressed protein (fragment of mice nephrin protein) was checked by enzymes 
map during vector construction before protein expression and by molecular weight in 
SDS-PAGE gel after protein expression. Further more, the expression protein was 
confirmed by protein finger printing and its polyclonal antibodies were also 
confirmed by immunohistochemical methods. 
 
i. Peptide Mass Fingerprinting 
 
The expressed nephrin protein was electrophoresed on acrylamide gel at denatured 
condition. Upon completion of SDS-PAGE, Coomassie blue was used to detect 
presence of expressed nephrin protein. The protein was punched using a yellow 
pipette tip and the punched gel piece was sent for peptide mass fingerprinting using 
MALDI-TOF-MS (matrix-assisted laser desorption ionization- Time of Flight - Mass 
Spectrometry) at Agenica Research Pte Ltd, Singapore.  
 
ii. Immunohistochemistry  
 
Two female BALB/c mice were sacrificed, and the kidneys were removed and frozen 
using freezing media. The kidneys were cut into 5μm thick frozen sections using 
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cryostat, fixed using acetone for 2 minutes, then used for immunohistochemical 
staining. Briefly, endogenous peroxidase activity was blocked by incubating the 
frozen sections with 0.3% H2O2 for 10 minutes, followed by incubation with rabbit 
polyclonal antibodies against expressed and purified nephrin protein fragment. 
Second antibodies (goat anti-rabbit IgG) conjugated with Horse Raddish Peroxidase 
and chromogen 3,3'-diaminobenzidine (DAB) were used to visualize the location of 
antigen where antibodies bind.    
 
2.3.6.Detection of anti-nephrin antibodies (ELISA method) 
 
A standard ELISA was set up for detection of anti-nephrin antibodies in both mouse 
and human samples. The expressed nephrin protein was coated in standard ELISA 
plate using carbonate buffer. Samples diluted at 1:100 dilution in TBS-T were then 
incubated, followed by the second antibodies, which were either goat anti-human or 
goat anti-mouse immunoglobulins according to sera used. The OPD substrate was 
used to detect colourimetric changes in the final step as second antibodies were 
conjugated with horse raddish peroxidase enzymes (HRP).      
 
Using pre-bleed immunized sera of BALB/c mice as negative and positive controls 
respectively, the BALB/c (normal mice), MRL lpr/lpr mice (lupus model), the 
experimental lupus mouse model of  (PL/JxNZW) F1 x NZB mice were tested for 
anti-nephrin antibodies. All sera in duplicate were tested in two ELISA tests (one with 
coated expressed protein and one without any coated protein) and all ELISA tests 
were repeated twice to ensure validity of results.  
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The sera of healthy individuals (102 samples) and lupus patients (100 samples) were 
tested for presence of anti-nephrin antibodies using standard ELISA protocol. 
However, absorbance values (non-specific binding) were unexpectedly high in both 
control and lupus sera. Different blocking agents such as bovine serum albumin 
(BSA), scanned milk powder, fetal calf serum, gelatin, human albumin, were used in 
optimization of ELISA to reduce the non-specific binding. Among all different 
blocking agents, the ELISA result using human albumin was best among all blocking 
agents tried.  
 
2.3.7.Detection of anti-nephrin antibodies (Immunobloting method) 
 
The anti-nephrin antibodies were detected using immunoblotting technique. Briefly, 
the expressed nephrin protein, electrophoresed in 12% denatured polyacrylamide gel, 
was transferred onto nitrocellulose membrane. The membrane containing nephrin 
protein was cut into appropriate strips and incubated in samples sera diluted at 1:100 
dilution in TBS-T. Secondary antibody was goat anti-human immunoglobulin 
conjugated with alkaline phosphatase diluted at 1:10,000 dilution in TBS-T. 
NBT/BCIP was used to detect presence of antibodies in sample sera. 
 
Using pre-bleed immunized sera of BALB/c mice as negative and positive controls 
respectively, the BALB/c (normal mice), MRL lpr/lpr mice (lupus model), the 
experimental lupus mice model of  (PL/JxNZW) F1 x NZB mice was tested for anti-
nephrin antibodies by immunoblotting method.  
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The sera of healthy individuals (102 samples) and lupus patients (100 samples) were 
tested for presence of anti-nephrin antibodies using immunoblotting methods. A total 
of 100 non-lupus samples (20 Rheumatoid Arthritis patients, 20 Ankylosing 
Spondylitis patients, 20 Psoriatic Arthritis patients, 20 Osteoarthritis patients, 20 
patients with Primary Anti-phospholipid syndrome) were also tested for presence of 
anti-nephrin antibodies by using immunoblotting method.  
 
2.3.8.Prevalence of anti-nephrin antibodies in lupus patients 
 
The frequencies of anti-nephrin antibodies were analyzed in lupus mouse model 
(PL/JxNZW F1 x ZNB) compared to BALB/c mice and correlated with presence of 
proteinuria. Similarly the frequencies of anti-nephrin antibodies of lupus patient were 
analyzed and correlated with renal involvement as defined by the ACR criteria. Chi-
square test was used to determine the significance of these findings and Fisher’s exact 
test was used when necessary.  
 
2.4.Brain reactive autoantibodies 
 
Brain lysate from different species and different cell lines were studied. Since cell 
membrane is the structure that can readily react with pathogenic antibodies, we 




2.4.1.Selection of brain tissues for protein lysates 
 
Two 8 weeks-old female BALB/c mice purchased from the Animals Holding Unit, 
National University of Singapore, were sacrificed by chloroform intoxication method, 
then perfused with 50 ml of 1xPBS through cardiac ventricles. The brains and other 
tissues (liver, heart, kidney and spleen) were removed, immediately snap-frozen in 
liquid nitrogen, and kept in -80°C freezer until protein extraction.  
 
The female Wistar rat’s brain was a gift from Ms Irene Kee of Department of 
Experimental Surgery, Singapore General Hospital. The brains of pig, chicken, duck, 
quail, frog and fish (Indian Mackerel-Rastrelliger kanagurta ) were bought from local 
markets. 
 
Human neuronal membrane proteins (normal adult male) were purchased from 
BioChain, USA. 
 
2.4.2.Membrane protein preparations  
 
All chemicals were purchased from Sigma Aldrich, unless otherwise mentioned. 
 
The frozen mouse brain was thawed, cut into smaller pieces followed by 
homogenisation using mortar and pestle in 1xPBS containing a cocktail of proteinase 
inhibitors (5μg/ml leupeptin, 5μg/ml approtinin and 1mM PMSF). Brain lysates were 
further homogenised using syringe and needles method (started from 19G and 
gradually reduced in bore sizes to 27G). The water-insoluble pallet was separated by 
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centrifugation at 12,000xg for 10 minutes at 4°C. Repeated washings with 1x PBS 
containing cocktail of protein inhibitors were done until proteins were not detected in 
wash buffer using BioRad protein assay. The water-insoluble protein was dissolved in 
1xPBS containing 6M urea together with 1 mM PMSF and incubated on shaker for 15 
minutes at room temperature. The urea-soluble protein was separated using 
centrifugation at 12,000xg for 30 minutes at room temperature. The protein 
concentration was measured using BioRad protein assay and aliquoted proteins were 
kept in -80°C freezer for future use.     
 
Membrane proteins were also extracted from different mouse tissues (kidney, liver, 
heart and spleen) using the standard protocol described. Concentrations of extracted 
membrane proteins were determined using BioRad protein assay and aliquoted 
membrane proteins were kept in -80°C freezer until further experiment.  
 
The described protocol was used to extract brain membrane proteins from different 
species (rat, pig, duck, chicken, quail, frog and fish). The proteins were kept in –80°C 
freezer for further experiments after protein concentrations were determined by 
BioRad protein assay.  
 
2.4.3 Protocol for detection of Brain Reactive Autoantibodies 
 
The protocol for detection of brain reactive antibodies was set up using 
immunoblotting approach. Briefly brain membrane lysates were separated on 
denatured polyacrylamide gel electrophoresis, transferred to solid support and 
hybridized with controls and patients sera. 
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i. SDS-PAGE electrophoresis and gel staining 
 
The sodium dodecyl sulphate-polyacrylamide gel electrophoreses (SDS-PAGE) were 
done using analytical comb or preparative comb according to needs of experiments. 
The membrane proteins (20μg proteins per well for analytical comb or 200 μg 
proteins per well for preparative comb) were denatured and separated in 12 % or 20% 
denatured SDS-PAGE according to Laemmli. Upon completion of protein separation, 
the polyacrylamide gels were either visualized with Coommasie blue or Silver stain or 
transferred to nitrocellulose membrane (Hybond, Amshersham). Commassie blue 
stain was done according to established protocol and silver staining was done with 
SilverPlus (BioRad) which is compatible with MS analysis. 
 
The electrophoretic transfer of separated proteins to nitrocellulose membrane was 
performed at 100 constant Volts for one-hour using buffer transfer tank (BioRad) in 
cold room. All polyacrylamide gels after protein transfer were stained with Coomassie 
blue to confirm complete transfer of protein and for documentation.   
 
ii. Immunoblotting experiment  
 
The nitrocellulose membrane, on which the proteins were transferred, was incubated 
in blocking solution (1xTBS containing 3% scanned milk powder) on a shaker for one 
hour at room temperature to block non-specific reactions prior to sample incubation. 
Depending on the purpose of experiment, nitrocellulose membrane with proteins 
separated using analytical combs were used for sample incubation straight away, 
while those with proteins separated using preparative combs were cut into strips and 
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incubated with samples separately. The samples were diluted at 1:200 in blocking 
solution and incubated with membrane on shaker for overnight at 4°C. Membranes 
were washed by 1xTBS-T (1xTBS containing 0.1% Tween 20) thrice with 10 minutes 
soaking while shaking between washes. The membranes were further incubated with 
goat anti-human Ig conjugated with Alkaline Phosphatase (Chemicon) diluted in 
blocking buffer 1:10,000 on shaker for one hour at room temperature. The membranes 
were, after incubation, washed with 1xTBS-T thrice with 10 minutes shaking between 
washes. The 5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine/Nitro-Blue 
Tetrazolium Chloride (BCIP/NBT) substrate (Zymed Laboratories Inc) was used to 
visualise the positive protein bands on the membranes. When the optimal colour is 
visualized, the substrate was removed, membranes were dried and documented.  
 
2.4.4.Detection of BRAA in controls, non-lupus patients and lupus patients  
 
Standard immunoblotting protocol was used for detection of lupus antibodies in sera 
of lupus, non-lupus and healthy individuals. Western blot analyses were repeated at 
least twice for confirmation and both positive and negative lupus autoantibodies 
reacting with neuronal autoantigens were used in every Western blot analysis. The 
screening of immunoblotting was started with 12% SDS-PAGE and repeated using 
20% SDS-PAGE for higher resolution when necessary.  
 
The sera of healthy individuals (102 samples) were used to detect brain reactive 
autoantibodies against membrane protein lysate prepared from mouse brain. 12% 
SDS-PAGE was used in protein separation and sera prepared at 1:200 dilution with 
TBS-T were used. All tests were repeated twice to validate the results. One sample 
 80
was chosen to represent the negative control samples in subsequent immunoblotting 
experiment. 
 
A total of 100 unselected lupus patients were also tested for presence of Brain reactive 
antibodies in their sera against membrane protein lysate prepared from mouse brain. 
12% SDS-PAGE was used and 1:200 diluted samples were used in immnoblotting 
experiment. After repeating the experiment twice, one positive sample was selected to 
represent the positive lupus group in subsequent experiment. 
 
130 non-lupus rheumatic patients (20 Rheumatoid Arthritis patients, 20 Ankylosing 
Spondylitis patients, 20 Psoriatic Arthritis patients, 20 Osteoarthritis patients, 50 
patients with Primary Anti-phospholipid syndrome) were also tested for presence of 
Brain reactive autoantibodies in their sera using immunoblotting experiments. 20% 
SDS-PAGE was used to separate the membrane protein lysate prepared from mouse 
brain and sera were diluted at 1:200 in TBS-T. As standard practice, all tests were 
repeated to validate the result and a positive sample from the lupus group and a 
negative sample from control group were used as internal controls. 
 
2.4.5.Detection of BRAA in different tissues and different species 
 
The detected brain reactive autoantibodies against membrane protein lysate prepared 
from mouse brain were further tested for their tissue specificity and species specificity 
using different membrane lysates prepared from different tissues, different species 
and tumour cell lines too. In this experiment, a sample representing positive lupus 
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group and a sample from negative control group were used to detect autoantibodies 
against different membrane lysates preparations. 
 
i. Detection of cross reactive BRAA in different tissues 
 
The sera were immunoblotted against membrane protein lystae prepared from 
different mouse tissues; namely heart, liver, spleen and kidney. 12 % SDS-PAGE was 
used to separate protein lysate and 1:200 diluted sera were used in immunoblotting 
experiment. All tests were repeated to validate the results. 20% SDS-PAGE was also 
used to differentiate the same autoantigens binding to autoantibodies of positive 
samples. 
 
ii. Detection of cross-reactive brain autoantibodies in different species 
 
These two representative samples were again tested in immunoblotting experiment 
using brain membrane proteins extracted from different animal species (rat, pig, 
chicken, duck, quail, frog, and fish) together with human brain membrane proteins 
(BioChain). 12 % and 20% SDS-PAGE were used to separate the proteins well and 
samples were diluted at 1:200 with TBS-T.  
 
2.4.6. Two-dimensional gel electrophoresis  
 
The membrane proteins from mouse brain were used in two-dimensional gel 
electrophoresis. The same protocol described was used, except that the water-
insoluble pallet was resuspended in 2-DE sample solubilization buffer containing 6M 
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urea, 50mM DTT, 4% CHAPS, 0.2% carrier amphyolytes (1:2 Biolyte pH 7-9:Biolyte 
pH 8-10), 0.0002% Bromophenol Blue. Protein concentration was determined by 
BioRad RC DC protein assay.  
 
100 μg brain membrane proteins each were applied onto a pair of pH 7-10 7cm 
ReadyStrip IPTG strip (BioRad) during passive rehydration in Protean IEF cell 
(BioRad). The first dimension (Isoelectric Focusing) was done for 8000 V-hr at 15°C 
on the same machine. Upon completion of first dimensional gel electrophoresis, the 
strips were equilibrated in SDS-buffers prior to second dimensional gel 
electrophoresis. The second dimensional separation was done in 12%SDS-PAGE. The 
paper wick soaked with mouse brain membrane protein and another paper wick 
soaked with pre-stained markers were added next to IPG strips when the IPG strips 
were loaded onto SDS-PAGE gel. The second dimension was carried out at 45 mAmp 
constant. Upon completion of second dimensional gel electrophoresis, the gel was 
visualized with silver staining and a separate gel was used for immunoblotting using 
brain reactive autoantibodies positive serum. Immunoblotting was performed 
according to protocol described above.   
 
The gel spots from silver stained polyacrylamide gel matching with positive spots of 
immunoblotting were punched and sent for peptide mass finger-printing (PMF) using 
MALDI-TOF-MS (matrix-assisted laser desorption ionization- Time of Flight - Mass 
Spectrometry) at Agenica Research Pte Ltd, Singapore.  
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2.4.7. Peptide mass finger-printing  
 
Peptide mass finger-printing was done using the MALDI-TOF-MS analysis. Briefly, 
the silver-stained gel spots were destained with freshly prepared destaining buffer (5 
μl of 30mM potassium ferricyanide and 5μl of 100mM sodium thiosulfate). The gel 
spots were washed properly and incubated with trypsin (Promega) overnight. The 
trypsin-cleaved peptides released by sonication were desalted by ZipTip μ-C18 
(Millipore).  The peptides together with 1 μl of matrix mix containing 5mg/ml Alpha-
Cyano-4-Hydroxycinnamic Acid (CHCA) and 5mg/ml 2,5-dihydroxybenzoic acid 
(DHB) were loaded onto MALDI plate. The MS analysis was done by the curved 
field reflectron instrument Axima CFR-plus (Kratos, Shimadzu). The MALDI mass 
spectra were searched in Swissport and NCBI protein databases for matches with 
known proteins.  
 
2.4.8. Calculation of possible molecular weights of brain membrane proteins 
reactive with lupus autoantibodies 
 
The known molecular weights of prestained protein ladder (MBI, Fermentus) were 
plotted against corresponding distance from upper edge of the polyacrylamide gel in 
semi-log (log-linear) graph. Then the approximate expected molecular weights of 
brain membrane protein were calculated using linear regression. Similar observations 
were made in 10 available western-blot results. The mean theoretical molecular 
weights of two mammalian neuronal autoantigens were calculated. 
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2.4.9.Prevalence of BRAAs in lupus patients 
 
The prevalence of BRAAs was analyzed in lupus patients compared to control 
individuals and non-lupus patients, and correlated with Psychoses or Seizures as 
defined by 1997-ACR criteria or NP lupus syndromes as defined by ACR Ad Hoc 
Committee on NP lupus nomenclature. Chi-square test was used to determine the 
significance of these finding and Fisher’s exact test was used when necessary.  
 
2.5. Correlation of MBL genetic variants, anti-nephrin antibodies and brain 
reactive antibodies with clinical data and SLE damage index  
 
The SLE disease severity was analyzed in lupus patients using SLICC/ACR Damage 
Index. The MBL genetic variants were further analyzed in lupus patients with regards 
to infections and immunosuppressive drugs used in lupus management. The anti-
nephrin antibodies and brain reactive antibodies were correlated with renal 
involvement and NP involvement in unselected lupus patients. All of these findings 
were further evaluated against SLE Damage Index. 
. 
2.6. Statistical analysis  
 
The demographic data of controls, lupus and non-lupus patients together with clinical 
manifestations and SLICC/ACR disease damage index were analyzed using SPSS 
version 10.1 for Windows.  
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Genetic frequencies (haplotypes and haplotypes) were calculated from PCR-RFLP 
results and the significant difference between controls and lupus patients were 
determined by 2x2 Chi-square test with continuity correction or Fisher’s exact test. 
All controls and lupus patients were tested if they are in Hardy-Weinberg equilibrium 
with 5% significant level at 1 degree of freedom. 
 
In optimization of anti-nephrin ELISA, mean value of control mouse sera was 
calculated based on average of three runs and the cut-off OD for normal anti-nephrin 
antibodies was determined as mean with three standard deviations (mean + 3 SD). 
The ODs showed above the cut-off were considered as positive anti-nephrin 
antibodies. Significant presence of anti-nephrin antibodies in mouse sera and lupus 
sera were determined using 3x2 Chi-square test.  
 
Linear regression analysis was used to determine the approximate expected molecular 
weights of brain membrane proteins reacting with BRAA. BRAA positivity in 
controls, lupus and non-lupus patients was tested for determination of statistical 
significance using 3x2 Chi-square test. 
 
In analysis of clinical manifestation with genetic results or autoantibodies, appropriate 
Chi-square test was used to determine the statistical significance because these data 
were unpaired categorized data. Similar approach applies to determine the statistical 
significance between SLICC/ACR damage and genetic results or autoantibodies too. 
   
All given p value are two-sided. The p values of <0.05 were considered significant 

















3.1.Demographic data of controls, lupus patients and non-lupus patients 
 
There were 102 healthy control individuals, 100 lupus patients and 130 non-lupus 
patients (Table 3.1 and 3.2). There were 2 deaths within the cohort of lupus patients 
during the study period. One of the patients perished from severe lupus disease and 
multiple infections while the second patient died of hepatosplenic T cell lymphoma. 
The lupus patients, in this study, presented with abnormal titers of antinuclear 
antibodies (97%), immunological disorder (95%), hematological disorder (81%), 
arthritis (77%) and renal disorder (53%) followed by the remaining ACR criteria (8-
41%) (Table 3.3). 
 
NP involvement in SLE patients were found in 10 lupus patients as defined by 1997-
updated ACR criteria for classification of SLE and 27 lupus patients according to 
1999-proposed NP lupus syndromes by ACR Ad Hoc Committee on NP Lupus 
Nomenclature (Table 3.4). However the number of lupus patients with renal 
involvement did not change under both inclusion criteria; according to a.) 1997-
updated ACR criteria for classification of SLE, and b.) modified inclusion criteria 
made up of proteinuria, cellular casts, nephrotic syndrome, nephritic syndrome and 
renal histology. 53 lupus patients were found to have proteinuria or cellular cast as 
renal involvement according 1997-updated ACR criteria. The number of patients 
(where all were same patients) still maintained as 53 with modified inclusion criteria 
as well (Table 3.5). 
 
Fifty-three lupus patients (53%) did not have any damage recorded, as indicated by a 
total SLICC/ACR score of 0. The NP and renal damages were the commonest organ 
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system damage detected with SLICC/ACR score of 1 or more. The 26 lupus patients 
having NP and/or renal damage (patients with both NP and renal damages = 2; 
patients with NP damage = 4 and patients with renal damage = 20) as defined by 
SLICC/ACR Damage Index have a score of 1 or more (Table 3.6).  
 
There were 51 lupus patients treated with corticosteroids and cytotoxic drugs and 45 
patients with only corticosteroids. 2 patients were treated only with cytotoxic drugs 
alone and 2 did not require corticosteroid or cytotoxic drugs. Infections were grouped 
into bacterial, viral and fungal causes in this study. One case of systemic fungal 
infection was noted. Bacterial infections were more common than viral infections. A 
total of 66 lupus patients had infections. 22 patients had bacterial and viral infections, 
32 had bacterial infections only and 12 had viral infections only.   
 
3.2. Mannose Binding Lectin 
 
3.2.1. A novel PCR-RFLP protocol for genotyping and haplotyping of MBL 
 
 
The PCR-RFLP approach was limited in the genotyping of exon 1 and haplotyping of 
promoter region of MBL gene because restriction endonucleases are not available for 
codon 52 mutation site at exon 1 and –550 bp site of promoter region. To overcome 
this limitation, we designed mismatched primers where restriction enzyme recognition 
sites were carefully inserted. During the process of optimization, DNA samples with 
rare genotypes at codons 52 and 57 at exon 1 were provided as gifts from overseas 
researchers. We optimized our novel PCR-RFLP protocol for all possible genotypes
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Table 3.1 Demographic data of controls, lupus and non-lupus patient cohort. 
---------------------------------------------------------------------------------------------------- 
Lupus (n=100)  
  Female: Male ratio  9:1 
  Mean Age (range) 39 (19-71 yrs) 
 Race   Chinese  81    
     Malay  14  
    Indian  5    
  Disease duration (range) 11 (1-20 yrs) 
Non-Lupus (n=130) 
 Female: Male ratio  1.4:1 
  Mean Age (range) 52 (21-81 yrs) 
 Race   Chinese  91    
     Malay  10 
    Indian  29 
Control (n=102) 
 Female: Male ratio  2.7:1 
  Mean Age (range) 35 (21-41 yrs) 
 Race   Chinese  82    
     Malay  14 
    Indian  6 
---------------------------------------------------------------------------------------------------- 
Table 3.2. Demographic data of non-lupus patient cohort. 
---------------------------------------------------------------------------------------------------- 
RA (n=20)  Female: Male ratio  4:1 
    Mean Age (range) 54 (30-75 yrs) 
   Race   Chinese  16    
       Malay  1 
      Indian  3 
PA (n=20)  Female: Male ratio  1:1.5 
    Mean Age (range) 51 (21-70 yrs) 
 Race   Chinese  15    
       Malay  0 
      Indian  5 
OA (n=20)  Female: Male ratio  9:1 
    Mean Age (range) 62 (40-81 yrs) 
    Race   Chinese  14    
       Malay  1 
      Indian  5 
AS (n=20)  Female: Male ratio  1:9 
    Mean Age (range) 44 (27-60 yrs) 
   Race   Chinese  18    
       Malay  0 
      Indian  2 
APS (n=50)  Female: Male ratio  4:1 
 (Primary)  Mean Age (range) 50 (26-67 yrs) 
   Race   Chinese  28    
       Malay  8 
      Indian  14 
---------------------------------------------------------------------------------------------------- 
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Table 3.3. ACR criteria presentation of lupus patients at diagnosis (n=100)  
---------------------------------------------------------------------------------------------------- 
No ACR Criteria   No of Pts  (%) 
---------------------------------------------------------------------------------------------------- 
1 Antinuclear antibody  97  (97)  
2 Immunologic Disorder 95  (95)   
3 Hematologic Disorder  81  (81)   
4 Arthritis   77  (77)   
5 Renal Disorder  53  (53)   
6 Malar Rash   41  (41)  
7 Photosensitivity  31  (31)   
8 Oral Ulcers   29  (29)   
9 Serositis   16  (16)   
10 Neurologic Disorder  10  (10)   




Table 3.4. NP syndromes recorded in SLE cohort (n=100)  
------------------------------------------------------------------------------------------------------- 
NP syndromes        no of  patients (%) 
------------------------------------------------------------------------------------------------------- 
Total          27 (27)  
Acute Confusional State      0    - 
Acute Inflammatory Demyelinating Polyradiculoneuropathy 0    - 
Anxiety Disorder       0    - 
Aseptic Meningitis       2   (2)  
Autonomic Disorder       0    - 
Cerebrovascular Disease      2   (2)  
Cognitive Dysfunction      6   (6)    
Demyelinating Syndrome      0    - 
Headache        12 (12)  
Mononeuropathy (single/mutiplex)     0    - 
Mood Disorders       0    - 
Movement Disorder (Chorea)      0    - 
Myasthenia Gravis       0    - 
Myelopathy        0    - 
Neuropathy, Cranial       0    - 
Plexopathy        0    - 
Polyneuropathy       0    - 
Psychosis*        4    (4)   
Seizures and Seizure Disorders*     6    (6)  
------------------------------------------------------------------------------------------------------- 
Psychosis* and/or Seizures*      10  (10) 
------------------------------------------------------------------------------------------------------- 
(* Psychosis and Seizure were neurological disorder defined by 1997-updated 
ACR criteria for classification of SLE) 
 




Table 3.5. Renal involvement in SLE cohort (n=100)  
------------------------------------------------------------------------------------------------------- 
Renal involvement     no of patients (%) 
------------------------------------------------------------------------------------------------------- 
Total        53 (53)  
Persistent proteinuria*    46 (46)  
Cellular casts*      25 (25)  
Nephrotic syndrome     12 (12) 
Nephritic syndrome     6   (6)  
Rapidly Progressive GN    2   (2)  
------------------------------------------------------------------------------------------------------- 
Persistent proteinuria* and/or Cellular casts*  53 (53) 
------------------------------------------------------------------------------------------------------- 
(* Proteinuria and cellular casts were renal disorders defined by 1997-updated 
ACR criteria for classification of SLE) 
 





Table 3.6. Distribution of damage according to the organ system (n=100)  
---------------------------------------------------------------------------------------------------- 
Organ system or disease  no of patients with score ≥1  (%) 
 
Total       47   (47)     
NP and/or Renal   26   (26)     
Ocular     12   (12)    
NP      6   (6)      
Renal     22   (22)    
Pulmonary    0   - 
Cardiac    4   (4)   
Peripheral vascular   2   (2)   
Gastrointestinal   4   (4)   
Musculoskeletal   6   (6)   
Skin     2   (4)   
Premature gonadal failure  0   - 
Diabetes Mellitus   6   (6)   
Malignancy    0   - 
---------------------------------------------------------------------------------------------------- 
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of MBL exon 1 using DNA samples from our database and gifts of rare genotypes.  
 
Using Web Cutter (http://rna.lundberg.gu.se/cutter2/index.html), the expected 
different fragments of MBL Exon 1 PCR product (134-bp) were calculated for 
different restriction enzymes Mwo I, Ban I and Mbo II. The cleaved products were 
tabulated together with uncleaved PCR products, according to possible homozygous 
and heterozygous alleles at respective codons (Table 3.7.A). PCR product of MBL 
promoter (410-bp product) was also analysed using Web Cutter for double-digest with 
Btg I and Drd I enzymes. The expected and logical different haplotypes were 
presented (Table 3.7.B).  
  
All three polymorphic sites at exon 1 of MBL were tested successfully. Since we 
introduced an enzyme recognition site (Mwo I) at Codon 52 in the mismatched primer 
(MBL-E1-FOR), all Codon 52 wild type alleles were cleaved by restriction 
endonuclease Mwo I and seen clearly on gel electrophoresis. Codon 54 polymorphic 
alleles were also cleaved by restriction endonuclease Ban I, which has been described 
elsewhere. Although we did not expect to observe any mutant alleles of codon 57 
from our local control group, we used gift-samples with all different alleles in order to 
optimize the PCR-RFLP protocol (Figure 3.1.A).  PCR product containing L allele (-
550 bp site) will be cleaved by restriction endonuclease Drd I and PCR product 
containing Y allele (-221 bp site) will be cleaved by Btg I restriction endonuclease. 
Our results showed the presence of all possible haplotypes except HX/HX, HX/HY, 
HX/LY and HX/LX haplotypes (Figure 3.1.B). These four haplotypes were not 











Codon 52  109 bp 134 bp 109+134 bp 
Codon 54  95 bp 134 bp 95+134 bp 
Codon 57  134 bp 78 bp 78+134 bp 
 
  
Haplotypes 410 bp 389 bp 354 bp 333 bp
HX/HX +    
LX/LX  +   
HY/HY   +  
LY/LY    + 
HX/LX + +   
HX/HY +  +  
HX/LY +   + 
HY/LX  + +  
LX/LY  +  + 
HY/LY   + + 
 
Table 3.7. Expected fragments of PCR-RFLP genotyping for MBL gene 
A: Exon 1 polymorphism for respective codons 



























































































































































Fig 3.1: Observed fragments of RFLP in MBL genotyping; UC-PCR-E= uncut 
Exon 1 PCR product; UC-PCR-P= uncut promoter PCR product control.  












  95bp 




We have validated the novel PCR-RFLP method using various approaches and our 
PCR-RFLP method is found to be able to genotype codons 52, 54 and 57 of exon 1 




The sequencing results of the different genotypes and haplotypes of MBL gene 
showed concordance with that of PCR-RFLP (data not shown). 
 
Comparison with PCR-SSP  
 
The PCR-SSP was done according to conditions described (Steffensen et al., 2000). 
We found (in agreement with previous reports) that optimization of the PCR-SSP is 
not easy to perform. However it was observed that optimization of PCR-SSP for the 
promoter gene region was easier than that for PCR-SSP of exon 1. We have tested all 
possible genotypes and haplotypes using PCR-SSP methods. All results are in 
concordance with our PCR-RFLP results (Data not shown). 
 
Independent performance by volunteers 
 
The various genotyped and haplotyped DNAs were distributed among five volunteer 
laboratory personnels to analyze according to our PCR-RFLP protocol. The results 
were tabulated and found to be in concordance with our PCR-RFLP typing results, 
DNA sequencing results and PCR-SSP results (Data not shown). There was no 
discordant result among the 5 volunteers. 
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3.2.2.Genetic frequencies of control individuals  
 
We have genotyped the exon 1 and haplotyped the promoter gene of MBL in our local 
control group and compared our results with Chinese (Mainland) and Japanese gene 
polymorphisms obtained by PCR-based methods (Huang et al., 2003, Wang et al 
2001) (Table 3.8 and Table 3.9). The genetic variations at codon 54 are observed 
among three control groups. However haplotype frequencies of promoter regions for 
local controls (PCR-RFLP), Japanese (PCR-SSP) and China Chinese (PCR-UHG) are 
almost similar with minor variations in LY/LY, LX/LX, HY/HY, LX/LY. This has to 
be confirmed by more genotyping on different ethnic groups. 
 
3.2.3.Genetic frequencies of lupus patients 
 
We have carried out genotyping of structural polymorphism of exon 1 and 
haplotyping of promoter region of MBL gene in 100 lupus patients using our novel 
PCR-RFLP approach. The gene frequencies of these polymorphisms were presented 
in Table 3.10 and Table 3.11.  
 
3.2.4. Prevalence of MBL genetic variants in lupus patients  
 
The genetic frequencies of MBL gene (both exon 1 and promoter region) were 
compared in both control group and lupus patients. It was noted that mutant alleles at 
codon 52 were significantly increased in lupus patient (p < 0.0001) while other 
polymorphic sites at codons 54 and 57 did not show significant difference (Table 
3.10). It was also interesting to note the genetic frequencies of MBL high- and  
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Table 3.8. Genotype frequencies of MBL exon 1 (Singaporean Controls, 
Mainland Chinese Controls, Japanese controls) * Hung et al. 2003 ; + Wang et 
al. 2001 
------------------------------------------------------------------------------------------------------- 
Exon 1 MBL  Singaporean  Chinese (China)* Japanese + 
Genotypes  (n=102)  (n=111)  (n=143) 
------------------------------------------------------------------------------------------------------- 
Codon 52 
  WT/WT  102 (100)  ND   ND 
  WT/MU  0     (   0)  ND   ND 
  MU/MU  0     (   0)   ND   ND 
Codon 54 
  WT/WT  76   (74.5)    92 ( 82.9)   77 ( 53.8) 
  WT/MU  25   (24.5)   18 ( 16.2)  58 ( 40.6) 
  MU/MU  1     (  1.0)   1   (   0.9)    8 (   5.6) 
Codon 57 
  WT/WT 102 (100)   ND   ND  
  WT/MU 0     (   0)  ND   ND 
  MU/MU 0     (   0)  ND   ND 
------------------------------------------------------------------------------------------------------- 
Haplotypes frequencies were presented as absolute numbers with percentage in 
parenthesis; ND = Not done; PCR-RFLP = Singaporean controls, Japanese controls; 




Table 3.9. Haplotype frequencies of MBL promoter gene region  (Singaporean 
Controls, Mainland Chinese controls, Japanese controls) * Hung et al. 2003 ; + 
Wang et al. 2001 
------------------------------------------------------------------------------------------------------- 
MBL Promoter region  Singaporean  Chinese (China)* Japanese + 
Haplotypes    (n=102)   (n=111) (n=143) 
------------------------------------------------------------------------------------------------------- 
HX/HX   0   0    0 
LX/LX   8   (7.8)  1   (0.9)  2    (1.4) 
HY/HY   28 (27.5)  15 (13.5)  28  (19.6) 
LY/LY   15 (14.7)  30 (27.0)  39  (27.3) 
HX/LX   0   0   0 
HX/HY   0   0   0 
HX/LY   0   0   0 
HY/LX   1   (1.0)  9   (8.1)  10  (7.0) 
LX/LY   14 (13.7)  8   (7.2)  10  (7.0) 
HY/LY   36 (35.3)  48 (43.2)  54  (37.8) 
------------------------------------------------------------------------------------------------------- 
Haplotypes frequencies were presented as absolute numbers with percentage in 
parenthesis; PCR-RFLP = Chinese (Singaporean); PCR-SSP = Japanese; PCR-UHG 




Table 3.10. Genotypic frequencies of exon 1 of MBL in controls and lupus 
patients.  
------------------------------------------------------------------------------------------------------- 
Exon 1 MBL    Controls Lupus patients  Chi-square 
Genotypes    (n=102) (n=100)   p 
--------------------------------------------------------------- --------------------------------------- 
Codon 52 
  WT/WT   102 (100) 74 ( 74)  
  WT/MU   0     (   0) 26 ( 26)  <0.0001 
  MU/MU   0     (   0)  0   (   0)  
 
Codon 54 
  WT/WT   76   (74.5)  63 ( 63) 
  WT/MU   25   (24.5)  37 ( 37)  0.0764 
  MU/MU   1     (  1.0)  0   (   0) 
 
Codon 57 
  WT/WT  102 (100)  100 (100) 
  WT/MU  0     (   0) 0     (    0) 
  MU/MU  0     (   0) 0     (    0) 
------------------------------------------------------------------------------------------------------- 
Gene frequencies were presented as absolute numbers with percentage in parenthesis 





Table 3.11. Haplotype frequencies of MBL promoter gene region in controls and 
lupus patients 
------------------------------------------------------------------------------------------------------- 
MBL Promoter region  Controls Lupus patients  Chi-square 
Haplotypes    (n=102) (n=100)  p 
------------------------------------------------------------------------------------------------------- 
HX/HX   0   (  0)  0    (   0) 
LX/LX   8   (  7.8) 14  ( 14)  0.2386 
HY/HY   28 (27.5) 14  ( 14)  0.0291 
LY/LY   15 (14.7) 6    (   6)  0.0724 
HX/LX   0   (  0)  0    (   0) 
HX/HY   0   (  0)  0    (   0) 
HX/LY   0   (  0)  0    (   0) 
HY/LX   1   (  1.0) 0    (   0)  nd 
LX/LY   14 (13.7) 9    (   9)  0.4034 
HY/LY   36 (35.3) 57  ( 57)  0.0031 
------------------------------------------------------------------------------------------------------- 
Haplotypes frequencies were presented as absolute numbers with percentage in 
parenthesis; nd = not done 
------------------------------------------------------------------------------------------------------- 
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intermediate-producing promoter haplotypes (HY/HY and LY/LY) were lower. The 
LX/LX haplotype associated with low-production of MBL showed a higher frequency 




3.3.1.Expression and purification of nephrin protein fragments. 
 
The theoretical properties of expressed nephrin protein fragment were calculated from 
Proteomics and sequence analysis tools of ExPASy Proteomics Server 
(http://au.expasy.org/tools/pi_tool.html) (Figure. 3.2). 
 
Expression of protein was done using expression strain BL21 competent cells. The 
expected protein of 28.5 kD was seen in SDS-PAGE after inducing with 1mM IPTG 
for one hour (Figure. 3.3). The expressed fragment of mouse nephrin protein, 
separated on SDS-PAGE, was visualised using Coommaie blue stain and it was 
punched out from polyacrylamide gel. The punched gel was sent to Agenica Protein 
Services, Singapore, for peptide mass fingerprinting (PMF) using matrix-assisted 
laser desorption ionization- Time of Flight - Mass Spectrometry (MALDI-TOF-MS). 
 
The trypsin-cleaved peptide masses were analyzed in available protein databases 
(NCBI and Swissport) and it was reported as murine nephrin protein. The expressed 
protein is thus confirmed as nephrin protein of mouse origin, and this protein was 
used to raise polyclonal antibodies and monoclonal antibodies. It was also used as 










Theoretical pI   = 6.83 
Molecular weight = 28544 Daltons  
 
Fig 3.2: Physical properties of eexpressed protein with His-tag using web base 
software (http://au.expasy.org/tools/pi_tool.html) 
Fig 3.3: Induced and Uninduced E. Coli proteins electrophoresed on SDS-
PAGE and stained with Coomassie Blue stain; UN= uninduced; IND=induced 
The nephrin protein fragment (28.5 kD) was seen on IPTG-induced expression.  







UN       IND     UN      IND 
 100
3.3.2.Polyclonal antibodies against nephrin protein fragment  
 
The polyclonal antibodies were raised in Rabbits using purified nephrin protein 
fragment of mouse origin. During the production of polyclonal antibodies, we have 
noted that one of the rabbits died after one week of immunization, however no 
infection or abscess was seen at the site of immunization. The definitive cause of 
death was not known. The production of polyclonal antibodies was continued in 
remaining rabbit. The polyclonal antibodies were crudely purified using ammonium 
sulfate precipitation.  
 
3.3.3.Monoclonal antibodies against nephrin protein fragment  
 
The monoclonal antibodies were raised using myeloma cell line of murine BALB/c 
origin (P3X63Ag8.653) and splenic cells of BALB/c mice immunized with the aid of 
ClonaCellTM complete kit. The splenic cells were harvested upon observation of the 
increased titer of anti-nephrin antibodies in the immunized mice. The fusion steps 
were satisfactory and we have noted that supernatant of three wells (fused cells) were 
showing significantly increased anti-nephrin antibodies. These cells were further 
expanded, but unfortunately these cells did not survive in the expansion media. 
Therefore, we failed to obtain monoclonal antibodies against nephrin protein fragment 
in this study.  
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3.3.4.Characterization of nephrin protein fragment and its polyclonal antibodies  
 
The nephrin protein fragment of mouse origin expressed in E. Coli system was 
separated on SDS-PAGE and sent for peptide mass fingerprinting. The results had 
shown the protein expressed was nephrin of mouse origin (Figure. 3.4). 
 
Furthermore, the polyclonal antibodies that raised in rabbits were tested in frozen 
sections of mouse kidney using immunohistochemical approach (Figure. 3.5). It was 
noted that these antibodies bound to glomerulus of mouse kidney. We conclude that 
the proteins expressed were nephrin proteins and polyclonal antibodies raised were 
targeting against the nephrin protein. 
 
The nephrin protein was used in ELISA and Immunoblotting experiment to detect 
anti-nephrin antibodies in controls, lupus and non-lupus patients in our study. 
  
3.3.5.Detection of anti-nephrin antibodies  
 
The anti-nephrin antibodies in lupus mouse model (PL/JxNZW) F1xNZB) were 
detected by ELISA and 19 (95%) out of 20 lupus mouse models showed positive anti-
nephrin antibodies in their serum (Table 3.12). 
 
The 102 control individuals, 100 unselected lupus patients and 130 non-lupus patients 
were screened for presence of anti-nephrin antibodies (Table 3.13). The ELISA 
approach could not be optimized for human samples, hence an immunoblotting 
approach was used for human samples. We observed that the antibodies against 
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expressed fragments of nephrin protein were negative in all control samples (n=102) 
and non-lupus samples (n=130) while there were 14 lupus patients (14%) showed 
positive anti-nephrin antibodies (n=100) (Figure. 3.6). 
 
3.3.6. Prevalence of anti-nephrin antibodies in lupus nephritis  
 
The anti-nephrin antibodies were found in sera of lupus mouse models and human 
lupus patients. None of the BALB/c mice, controls and non-lupus patients showed 
positive anti-nephrin antibodies. This finding was significant for mice samples 
(p<0.0037) and human samples (p<0.0001) (Table 3.12 and Table 3.13). 
 
3.4.Brain reactive autoantibodies 
 
All membrane protein preparations were carried out according to protein solubility. 
 
3.4.1.Observation of BRAA in lupus patients by standard protocol 
 
W started immunoblotting assay using mouse neuronal membrane protein lysates in 
unselected lupus patients. Antibodies reactive with two brain antigens (between 24 kD 
and 35 kD) were detected and used for our study. These autoantibodies were 
collectively named as Brain Reactive AutoAntibodies (BRAA). The calculated 
molecular weights of these proteins were 27.5 kD and 29.5 kD.  
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Fig 3.4: purified nephrin proteins (M.W 28.5 kD) electrophoresed on SDS-
PAGE and stained with Coomassie Blue stain; the protein was punched and sent 
for protein finger-printing by MALDI-TOF-MS method. 
             








Fig 3.5: Immunohistochemically stained glomerulus of mouse kidney frozen 
section; using polyclonal antibodies against expressed nephrin protein and 
DAB stains. 
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Fig 3.6: Immunoblotting result of anti-nephrin antibodies in control, non-
lupus and lupus samples; 
Pos: Anti-nephrin positive serum; Neg: Anti-nephrin negative serum;  
1-4: representative control samples; 5-8: representative non-lupus sample;  
9-12: representative lupus samples               
 
NB: Sample 9 showed anti-nephrin positive results 
Pos  Neg   1      2      3     4      5       6      7      8      9      10    11   12     
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Table 3.12. Anti-nephrin antibodies in control and lupus mouse model (ELISA) 
------------------------------------------------------------------------------------------------------- 
       Positive Negative  
BALB/c mice  n = 10   -  10   
MRL/lpr mice  n =  5   4  1   
PL/J F1xNZB  n = 20   19*  1   
------------------------------------------------------------------------------------------------------- 
*p=0.0037; The cut-off point for both anti-nephrin was mean OD value of BALB/c 










Table 3.13. Anti-nephrin antibodies in controls, lupus and non-lupus groups  
------------------------------------------------------------------------------------------------------- 
      Positive   Negative  
Control group  n = 102 -   102 
Lupus patients  n = 100 14   86 
Non-lupus patients n = 130 -   130  
------------------------------------------------------------------------------------------------------- 




3.4.2.Detection of BRAAs in controls, non-lupus and lupus patients 
 
We found BRAAs present in 10 (10%) out of 100 unselected lupus patients and none 
(0%) of the 100 healthy individuals. One BRAA-positive serum (from unselected 
lupus patients) and one BRAA-negative serum (from healthy controls) were used as 
positive and negative samples in subsequent experiments (Figure. 3.7).   
 
To detect these antibodies in other rheumatic diseases, we further tested 130 non-
lupus rheumatic patients. Positive and negative controls were added in all 
immunoblotting experiments. The 130 non-lupus patients comprised of 20 RA, 20 
OA, 20 AS, 20 PsA and 50APS. They did not show presence of BRAAs. Thus 
BRAAs reacting with mice neuronal membrane proteins were found only in lupus 
patients, not in the healthy individuals and non-lupus rheumatic patients (p <0.0007) 
(Table 3.14). 
 
3.4.3.Tissue and Species specificity of BRAAs 
 
The immunoblotting experiment was carried out using membrane protein lysates from 
different mouse tissues (heart, liver, spleen and kidney). It was noted that BRAAs 
react with only membrane protein lysates from mouse brain tissue (Figure 3.8). 
 
The same experiment was carried out using neuronal membrane protein lysates of 
different animals. It is interesting to note that BRAAs target neuronal membrane 
protein lysates of mammalian origin and did not react with those of other species such 








































Table 3.14. BRAA in controls, lupus and non-lupus groups  
------------------------------------------------------------------------------------------------------- 
      Positive   Negative  
Control group  n = 102 -   102 
Lupus patients  n = 100 10   90 
Non-lupus patients n = 130 -   130  
------------------------------------------------------------------------------------------------------- 
p < 0.0007 
  
Fig. 3.7. Immunoblotting results of BRAAs in sera of lupus, non-
lupus and healthy controls; 1-3 Î non-lupus patients; 4-7Î lupus 
patients; 8-9Î controls lupus patients; P Î positive serum; N Î 
negative serum; this is the representative immunoblotting results of our 
study. The positive lupus sample (P) and negative controls sample (N) 
were selected to represent the positive and negative groups and used in 
subsequent immunoblotting experiments. All serum samples were tested 
at least twice in immunoblotting experiments,  










Fig.3.8. Immunoblotting results of BRAA against membrane proteins 
extracted from different mouse tissues; M Î protein marker; Br Î 
membrane proteins of mouse brain; Liv Î membrane proteins of mouse liver;  
Ht Î membrane proteins of mouse heart; Sp Î membrane proteins of mouse 
spleen; Kid Î membrane proteins of mouse kidney; Positive serumÎ serum 
representing positive samples; Negative serum Î serum representing negative 
samples.  
N.B: The immunoblotting experiment done using 12% SDS-PAGE was not able 
to differentiate proteins reacting with BRAA. Therefore, we repeated 
immunoblotting experiments using 20% SDS-PAGE and it was clearly observed 
the brain proteins reacted with the BRAA were not expressed in other tissues.  
 
NB: 20% SDS-PAGE was used in this experiment.  
 
Å            negative serum                   Æ Å               positive serum                    Æ 






Fig.3.9. Immunoblotting results of BRAA against brain membrane proteins 
extracted from different animal species;  
M-Br Î mouse brain membrane proteins; R-Br Î rat brain membrane proteins; 
P-Br Î pig brain membrane proteins; H-Br Î human brain membrane proteins; 
CH-Br Î chicken brain membrane proteins; D-Br Î duck brain membrane 
proteins; Q-Br Î quail brain membrane proteins; Fg-Br Î Frog brain membrane 
proteins; Fi-Br Î Fish brain membrane proteins.  
    
 
 
     M-Br          H-Br             R-Br           P-Br     
24 kD 
35 kD 




3.4.4. Peptide Mass Fingerprinting of brain antigens reacting with BRAA  
 
We used 2-D gel electrophoresis to separate the BRAAs. The protein spots of silver 
stained SDS-PAGE, matching with BRAAs result of immunoblotting results were 
sent for peptide mass fingerprinting using MALDI-TOF-MS analysis (Figure 3.10). 
The trypsin-cleaved peptides mass spectra were matched against public protein 
databases (NCBI and Swissport). It was noted that these membrane proteins did not 
match to any published protein sequences.  
 
3.4.5. Prevalence of BRAAs in lupus patients 
 
The prevalence of BRAAs was calculated in control, lupus and non-lupus patients. 
BRAAs were detected in 10 out of 100 lupus patients (10%) while none of healthy 
individuals (n=100) and non-lupus (n=130) present their presence in their sera 
(p=0.0035) (Table 3.14) 
 
3.5.Correlation of MBL genetic variants, anti-nephrin antibodies positivity and 
BRAAs positivity with clinical data and SLE Damage Index  
 
Based on the results we have, we focused on the mutant alleles of codon 52 and MBL 
low-producing haplotypes (LX/LX) of promoter region, we postulated that this 
combination will be associated with infections in lupus patients, hence leading to 
more severe disease in SLE. Table 3.15 shows the correlation between infections and 
MBL polymorphisms. Though the codon 52 variants and MBL (LX/LX) haplotypes 


















Fig.3.10. Immunoblotting results of BRAA against mouse brain 
membrane proteins separated by 2-D gel electrophoresis.  
This experiment was done for a pair of 2-D gel strips with a guide 
lane using mouse brain membrane proteins (M-Br) was used. One gel 
was processed to immunoblotting using BRAA positive serum. 
Another gel was visualised using silver plus stain.  The protein spots 
of silver-stained similar gel matching to A and B were punched, 





 Å        M-Br separated by iso-electric points        Æ  M-Br        
24 kD 
35 kD B. 
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Table 3.15. Correlation of infection with MBL polymorphism in lupus patients 
Correlation of MBL polymorphism with infections  
------------------------------------------------------------------------------------------------------- 
Lupus patients with infections (Bacterial and/or viral) 
 n =66   
  with mutant codon 52   20  (30%) 
  with wildtype codon 52  46 
Lupus patients without infections  
  n = 34 
 with mutant codon 52   6 (18%)  
  with wildtype codon 52  28 
------------------------------------------------------------------------------------------------------- 
p = ns 
 
Correlation of MBL promoters polymorphism with infections 
------------------------------------------------------------------------------------------------------- 
Lupus patients with infections (Bacterial and/or viral) 
 n =66   
  with LX/LX    10  (15%) 
  without LX/LX   56 
Lupus patients without infections  
  n = 34 
 with LX/LX     4 (12%)  
  without LX/LX   30 
------------------------------------------------------------------------------------------------------- 
p = ns 
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infections – codon 52 mutant variant (30% vs 18%) and LX/LX haplotype (15% vs 
12%) . 
  
To evaluate the relationship of MBL variants and infection under the influence of 
immunosuppressive drugs, the lupus patients were divided into four groups according 
to immunosuppressive drugs used and analyzed the infections together with MBL 
genetic variants (Table 3.16). The patients treated with corticosteroids and cytotoxic 
drugs did not differ between mutant codon 52 variant frequencies, but patients with 
LX/LX haplotypes were more prone to infections. For lupus patients on 
corticosteroids alone, mutant MBL variant may predispose to increased frequency of 
infections compared to those with normal MBL alleles.  The small numbers in the 
other group do not allow us to detect any trends.  
 
The lupus mouse models with positive anti-nephrin antibodies were found to be 
significantly associated with proteinuria (p<0.0001), however we did not detect an 
association in human lupus patients (Table 3.17 and Table 3.18). 
 
The BRAAs were found to be highly associated with psychoses and seizures.  6 
(60%) out of 10 BRAA-positive lupus patients had psychoses and/or seizures while 
only 4 (2%) of 90 BRAA-negative lupus patients had psychoses and/or seizures 
(p<0.0001) (Table 3.19). This strong association was still present when BRAA-
positive patients were analyzed with NP lupus syndromes as described by ACR Ad 





Table 3.16. MBL influence on infection in lupus patients under 
immunosuppressive drugs 
 
Correlation of MBL polymorphism with infection 
------------------------------------------------------------------------------------------------------- 
Lupus patients with steroid and cytotoxic drugs No Infection 
 n =50   
  with mutant codon 52    14 10 (71%)  
  with wildtype codon 52   36 26 (72%)  
Lupus patients with steroid  
 n = 46 
 with mutant codon 52    12 10 (83%)  
  with wildtype codon 52   34 19 (56%)  
Lupus patients with cytotoxic drugs only 
 n = 2 
 with mutant codon 52    0 
  with wildtype codon 52   2 0 (0%)  
Lupus patients without steroid and cytotoxic drugs 
 n = 2 
 with mutant codon 52    0 
  with wildtype codon 52   2 1 (50%)    
------------------------------------------------------------------------------------------------------- 
 
Correlation of MBL promoters polymorphism with infections  
------------------------------------------------------------------------------------------------------- 
Lupus patients with steroid and cytotoxic drugs No Infection 
 n =50   
  with LX/LX      8 8   (100%) 
  without LX/LX     42 28        (66%)  
Lupus patients with steroid  
 n = 46 
 with LX/LX      2 1  (50%)  
  without LX/LX     44        27       (61%)  
Lupus patients with cytotoxic drugs  
 n = 2 
 with LX/LX      2 1  (50%)  
  without LX/LX     0         - 
Lupus patients without steroid cytotoxic drugs 
 n = 2 
 with LX/LX      2 1  (50%)  




Table 3.17. Correlation of Anti-nephrin antibodies with renal involvement 
(proteinuria) in control and lupus mice model (ELISA) 
------------------------------------------------------------------------------------------------------- 
    Positive Negative Proteinuria anti-dsDNA 
BALB/c mice  
n = 10   -  10  ND  ND 
MRL/lpr mice  
n =  5   4  1  ND  ND 
PL/J F1xNZB  
n = 20   19*  1  17   16  
------------------------------------------------------------------------------------------------------- 
*p=0.0037; The cut-off point for both anti-nephrin and anti-dsDNA antibodies were 
mean OD value of BALB/c mice + 3 SD; Proteinuria was defined as > 100 mg/dL of 
protein in urine;  ND = not done 
 
 
Table 3.18. Correlation of Anti-nephrin antibodies with renal involvement 
(proteinuria/cellular cast) in controls, lupus and non-lupus groups 
(Immunoblotting method) 
------------------------------------------------------------------------------------------------------- 
       Proteinuria/cast    No proteinuria/cast 
Lupus patients + anti-nephrin abs n=14 6   (42%)  8     (58%) 




Table 3.19. Correlation of BRAA in lupus patients with Psychosis and Seizure 
------------------------------------------------------------------------------------------------------- 
      Psychosis/seizure No Psychosis/seizure 
Lupus patients + BRAA (n=10)  6 (60%)  4    (40%) 





Table 3.20. Correlation of BRAA in lupus patients with NP-lupus syndromes 
(ACR suggested guideline for NP-lupus) 
------------------------------------------------------------------------------------------------------- 
       NP lupus  No NP-lupus 
Lupus patients + BRAA (n=10)  6   (60%)  4    (40%) 




The SLE disease Damage Index was analyzed with regards to immunosuppressive 
drugs in lupus management. Not surprisingly, we noted that the patients treated with 
corticosteroids and cytotoxic drugs were found to be associated with the Disease 
Damage Index and combined NP and renal damage index (p<0.0001). The index was 
also associated with patients on corticosteroids alone (p <0.0001). The number was 
small for those with only cytotoxic and those without any of steroid or cytotoxic 
drugs, it was noted the association with disease Damage Index was low. 
 
The MBL genetic variants were also analyzed with the SLE Damage Index in order to 
find out the if they predispose or worsen the SLE disease.  First of all, the drugs used 
in lupus management were analyzed with SLE Damage Index. Disease damage was 
divided into two groups, i.e. NP and renal damage and overall damage based on the 
SLICC/ACR damage index. The lupus patients under both steroids and cytotoxic drug 
were found to have more damage compared to those with single drug therapy (Table 
3.21). For the influence of MBL genetic variant on SLE damage Index, both MBL 
codon 52 mutant alleles and LX/LX haplotypes were analyzed. It was found lupus 
patients with mutant codon 52 variant were more prone to have damage in NP and 
renal organ system damage and in overall SLE damage (Table 3.23). However we did 
not such finding in lupus patients with LX/LX alleles (Table 3.24). Therefore we 
decided to analyze this finding in lupus patients with mutant codon 52 variants with 
regards to drugs used in lupus management. It was interesting to know MBL codon 52 
variant was associated with NP and renal organ system damage and in overall SLE 
damage compared to those with wild-type alleles.   
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Table 3.21. Correlation of drug used in lupus management with SLICC/ACR 
damage index (NP and renal damage vs all systems)   
------------------------------------------------------------------------------------------------------- 
Lupus patients on corticosteroids and cytotoxic drugs  NP/Renal All 
 n = 50        22 (44%)1 36 (72%)2 
Lupus patients on corticosteroids alone  
  n = 46          4 (  9%)3 10 (22%)4 
Lupus patients on cytotoxic drugs alone       
  n = 2           0    2 (100%) 
Lupus patients not on corticosteroids and cytotoxic drugs  
 n = 2            0     0 
------------------------------------------------------------------------------------------------------- 
p = 0.0003 (1 vs.3); p < 0.0001 (2 vs.4); p = 0.0084 (1 vs.2); p = n.s (3 vs.4) 
 
 
Table 3.22. Correlation of MBL exon 1 polymorphism with SLICC/ACR damage 
index (NP and renal damage vs all systems)   
------------------------------------------------------------------------------------------------------- 
        NP/Renal All 
Lupus patients on corticosteroids and cytotoxic drugs  
 n =50  
 MBL 52 mutant  n = 14    8   (57%)* 10 (71%) 
  MBL 52 wildtype n = 36    14 (39%)  26 (72%) 
Lupus patients on corticosteroids alone  
  n = 46 
 MBL 52 mutant  n = 12    4 (33%)* 4 (33%) 
  MBL 52 wildtype n = 34    0 (0%)  6 (18%) 
Lupus patients on cytotoxic drugs alone        
  n = 2         
 MBL 52 mutant  n = 0    -     - 
  MBL 52 wildtype n = 2    0 (0%)      2 (100%) 
Lupus patients not on corticosteroids and cytotoxic drugs  
 n = 2                
 MBL 52 mutant  n = 0    -     - 
  MBL 52 wildtype n = 2    0 (0%)        0  
------------------------------------------------------------------------------------------------------- 
 
Table 3.23. Correlation of MBL exon 1 polymorphisms with SLICC/ACR 
damage index (NP and renal damage vs all systems)   
------------------------------------------------------------------------------------------------------- 
       NP/Renal  All 
Lupus patients with MBL 52 mutant  
 n =26       12 (46%)1  14 (54%)2 
Lupus patients without MBL 52 mutant  
 n =74       14 (19%)3  34 (46%)4 
------------------------------------------------------------------------------------------------------- 





Table 3.24. Correlation of MBL promoters polymorphism with SLICC/ACR 
damage index (NP and renal damage vs all systems)   
------------------------------------------------------------------------------------------------------- 
       NP/Renal  All 
Lupus patients with LX/LX  
 n = 14       2 (14%)1     8 (57%)2 
Lupus patients without LX/LX  
 n = 86       24 (28%)3  40 (47%)4 
------------------------------------------------------------------------------------------------------- 




Table 3.25.Correlation of anti-nephrin autoantibodies with renal damage score 
------------------------------------------------------------------------------------------------------- 
       Renal D-Score >0 Renal D-Score =0 
Lupus patients + anti-nephrin antibodies n=14 2   (14%)  10 (86%)  






Table 3.26. Correlation of BRAA in lupus patients with NP damage score 
------------------------------------------------------------------------------------------------------- 
      NP D-Score >0 NP D-Score =0 
Lupus patients + BRAA (n=10)  0 (0%)   10 





For anti-nephrin antibodies and BRAA, we could not find any significant association 




















4.1.Mannose Binding Lectin 
 
Mannose Binding Lectin (MBL) is an acute phase protein secreted by the hepatocytes 
into the blood circulation. MBL recognises, binds and enhances phagocytosis of 
mannose-rich microorganisms, i.e. bacteria, viruses, protozoas and yeasts without the 
need for specific antibodies. Thus MBL plays an important role in innate immunity.  
 
Low levels of MBL cause defective opsonization and phagocytosis, resulting in 
increased susceptibility to bacterial, viral and fungal infections in humans, especially 
in children. Patients with low plasma MBL are reported to have association with 
prolonged and recurrent infections. Significantly, immunosuppressed patients with 
low level of plasma MBL are more prone to having infections than those with normal 
plasma level.  
 
Affinity purified MBL from pooled fresh human plasma (pMBL) has been used to 
treat patients with frequent and chronic infections and initial results were encouraging 
(Valdimarsson et al, 2003). Now recombinant MBL (rMBL) have been used as 
replacement protein in patients with low level of plasma MBL in clinical trials. MBL 
replacement therapy is potentially available soon for patients with uncontrolled 
infections, pending the results of clinical trials. 
 
Currently, plasma levels of MBL are measured by ELISA methods. However, serum 
MBL level may not represent actual normal levels because it is an acute phase 
protein. Circulating MBL in human varies from <0.01 to >5μg/ml and MBL 
concentration in the umbilical cord blood was reported to be lower than that in the 
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systemic circulation (Thiel et al.,1995). Furthermore, MBL being an acute phase 
protein, its concentration can show an increase of up to three-fold following infections 
or surgical trauma (Thiel et al., 1992). Dysfunctional proteins resulting from mutant 
structural MBL gene can give normal levels of serum MBL, but poor functionality.  
 
Its gene is assigned at chromosome 10q11.2-q21 (Sastry et al 1989). Genetic 
polymorphisms of MBL gene have been recorded in the promoter region as well as in 
part of exon 1. Although the frequency of the different genotypes varies among 
different population groups, mutant genotypes of exon 1 and different haplotypes of 
MBL are associated with low levels of plasma MBL. Thus patient with mutant 
allotypes are more prone to having infections, especially in immunocompramised 
state.   
 
Since low-MBL producing mutant alleles and haplotypes has been identified, 
genotyping of MBL gene will be able to provide an alternative way of predicting 
serum MBL level. Two studies have shown association of infections with different 
MBL alleles and haplotypes in children. Summerfield et al. (1997) reported a 
retrospective study of children attending a pediatric hospital and concluded that 
mutations in the MBL gene are an important risk factor for infections in children. In a 
prospective population-based study on young children, Koch et al. (2001) suggested 
that MBL insufficiency play an important role in host defense, particularly during 
childhood from age 6 through 17 months, when the adaptive immune system is 
immature. These two findings suggest that the MBL pathway is important in defense 
against infection during the interval between the loss of passively acquired maternal 
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antibodies and beginning of a mature immunologic repertoire.  
 
Current methods for assessing MBL gene polymorphisms include PCR-SSP, PCR-
SSO, PCR-RFLP (partially) and multiplex PCR using UHG. The disadvantage of the 
PCR-SSP method is the need for many PCR cycles, which requires many primers. 
Difficulties with optimization compound this problem. In the case of MBL gene 
polymorphisms, at least 10 PCRs using sequence specific primers will be needed 
(Steffensen et al., 2000). In other words, more genomic DNA, more reagents and 
longer processing time will be required. Furthermore, Steffensen et al. (2000) 
highlighted that difficulties in optimization of PCR-SSP may require re-optimization 
whenever a new set of reagents or a new PCR machine is used. These difficulties have 
been confirmed in our experience with optimization of PCR-SSP for detection of 
MBL gene polymorphisms. 
 
PCR-SSO needs an experienced operator to perform, longer time to complete and 
stringent conditions for clear and good results. Two PCRs and 10 hybridization steps 
were necessary in the radioactive detections of MBL gene polymorphisms. (Madsen 
et al., 1994, 1995) The PCR-SSO method is more complex and more costly than 
PCR-SSP and PCR-RFLP to perform.  
 
The genotyping method based on the generation of DNA heteroduplexes using a 
PCR-amplifiable synthesized DNA (Universal Heteroduplexes Generator – UHG) has 
been successfully employed to detect all three mutant alleles in exon 1 of MBL gene 
(Jack et al., 1997). However, the nature of the test requires an experienced person to 
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perform, use of more resources, time and at increased cost as compared to other 
methods.  
 
Steffensen et al. (2003) reported rapid genotyping of MBL gene polymorphism by 
using real-time PCR with fluorescent hybridization probes. The genotyping was done 
in a relatively short time. However, the costs of real-time PCR machine and 
fluorescent hybridization probes are significant.  
 
The PCR-RFLP method is simple, easy to perform, does not require special training 
and gives unambiguous results. PCR-RFLP approach is available mainly for Codons 
54 and 57 at exon 1 and for X/Y polymorphic site at promoter gene region. No 
enzyme-recognition sites are readily available at Codon 52 and H/L polymorphic 
sites. Since there are only partial PCR-RFLP methods (Lipscombe et al., 1992 and 
Roelofs et al., 2003) available for genotyping of MBL gene polymorphisms, we, 
therefore, decided to design mismatched primers to introduce enzyme-recognition 
sites in the PCR product. 
 
The ideal method to detect genetic polymorphisms should be simple, inexpensive, 
reproducible, reliable, with a rapid turnaround time, and should be able to be 
performed in laboratories with basic facilities. Though the focus of our study is not to 
design new molecular biological techniques, we felt the need to do so for our study as 
well as the benefits that arise from it when the technique is published. We have 
demonstrated a simple and reproducible PCR-RFLP method to genotype the MBL 
gene polymorphisms using manually-designed mismatched primers which possess 
recognition sites for restriction endonucleases. We have optimized the conditions with 
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regards to simplicity and reproducibility. Our method is suitable for population 
studies targeting large sample numbers. Our method can be used in routine diagnostic 
laboratories where limited manpower is available and rapid turn-around time is 
required.  
 
In our PCR-RFLP, only 2 PCR reactions (one for exon 1 and one for promoter gene) 
will be required for subsequent cleavage by the respective restriction endonucleases. 
We need to do only one PCR for genotyping of MBL exon 1 which is followed by a 
one-hour digestion with respective restriction endonucleases. We therefore can 
genotype all three polymorphisms at exon 1 within a day. We tested different 
incubation times for enzyme cleavage and it was noted total cleavage by enzymes 
occurs after as short a period of time as 30 minutes. The amount of restriction 
endonucleaes required for RFLP was optimized (2 units, 1unit, 0.5unit, 0.25unit and 
0.13unit of corresponding enzymes tested for over night incubation). Based on the 
minimum amount of enzymes required for overnight digestion, the time required for 
enzyme cleavage were also tested (one hour, two hours, four hours and over-night 
incubation). We found that Mwo I (0.13 unit) and Ban I (0.13 unit) for 4μl of exon 1 
MBL PCR product and Mbo II (1 unit) for 1 μg of plasmid DNA are sufficient for 
complete cleavage at their respective optimum temperature with one hour incubation. 
 
For promoter gene region polymorphisms, only one PCR product will be required for 
double-digestions by Drd  I and  Btg I with overnight incubation at 37°C. We also 
optimized for time and amount of enzymes required for double digestions. However 
we settled on the double digest with Drd  I (0.13 unit) and  Btg I (0.5 unit) overnight 
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because we wanted to use minimum enzyme amount in double digestion and 
overnight incubation showed clearer results.  
 
One of the advantages of our PCR-RFLP is the use of routine gel electrophoresis to 
visualize the PCR-RFLP products. We do not require polyacrylamide gel to visualize 
the cleaved fragment, as agarose gel electrophoresis is sufficient to separate the 
fragments after enzyme cleavages. We successfully showed that these PCR products 
are accurately cleaved by appropriate restriction endonucleases to easily identifiable 
fragments. Furthermore, one agarose gel will be enough for visualization of the three 
different exon 1 enzyme-digests because the fragments will not overlap in the gel 
electrophoresis. In our laboratory, one enzyme-digest is loaded every 30 minutes so 
that the time required for separation and the cost of agarose gel are significantly 
reduced.  
 
Since we have introduced an enzyme recognition site at Codon 52 in the mismatched 
primer, all Codon 52 wild type alleles were cleaved by restriction endonuclease Mwo 
I and seen clearly on gel electrophoresis. The heterozygous sample was also seen in 
our control group. These samples (both wild type homozygous and heterozygous 
samples) were sent for sequencing to validate our PCR-RFLP method. For Codon 54, 
mutant alleles were cleaved by restriction endonuclease Ban I, which has been 
described elsewhere. We did not find any mutant allele at Codon 57 where restriction 
endonuclease Mbo II would cleave, however we managed to receive such DNA 




We have successfully genotyped the exon 1 and haplotyped the promoter gene of 
MBL in our local healthy controls using novel PCR-RFLP method. We have 
presented those gene frequencies of our control group (Table 3.8 and Table 3.9). We 
also compared our results with those of Chinese (Mainland) and Japanese gene 
polymorphisms obtained by PCR-based methods (Huang et al., 2003, Wang et al 
2001). It is understandable to note that they did not report codons 52 and 57 results in 
their local population because firstly there are no PCR-RFLP methods available at 
that time and secondly mutant alleles of codon 57 are not expected in Oriental 
population. The comparison of codon 54 polymorphisms at MBL exon 1 results was 
carried out and the frequencies of codon 54 are comparable between our cohort and 
their populations. PCR-RFLP method was used for our local and Japanese populations 
while PCR-UHG approach was employed for Chinese (China). The frequencies of 
promoter gene haplotypes among local population (PCR-RFLP), Japanese (PCR-SSP) 
and China Chinese (PCR-UHG) are almost similar with minor variations in LY/LY, 
LX/LX, HY/HY, LX/LY. This has to be confirmed by more genotyping on different 
ethnic groups. 
 
We genotyped the lupus patients using our novel PCR-RFLP protocol and gene 
frequencies results were presented (Table 3.10). We found no mutant alleles in codon 
57 in both control and lupus groups. Similar polymorphic patterns were observed 
between codons 54 and 57 of control and lupus patients groups. However the mutant 
allele of codon 52 is significantly increased in lupus patients group compared to 
control group. For promoter regions, the gene frequencies of control and lupus 
patients groups were presented (Table 3.11).  It is widely accepted that HX 
haplotypes of MBL gene are not reported so far and their association with MBL 
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production is as follow; HY as high-promoting haplotype, LY as medium-promoting 
haplotype and LX as low-promoting haplotype. We did not find any of HX 
haplotypes, which is in accordance with other reports. There were decreased high-
promoting haplotypes (HY/HY), decreased medium-promoting haplotypes and 
increased low-promoting haplotypes in lupus patients compared to control group. And 
it was noted that lupus patients had decreased LX/LY haplotypes and increased 
HY/LY haplotypes. This finding will provide important information on the MBL gene 
as a disease predisposing factor in pathogenesis or aggravating factor in SLE, 
especially for those under immunosuppressive drugs. Low-promoting haplotypes 
(LX) will cause “MBL Insufficiency State” which eventually lead to an inefficient 
MBL complement system compared to those with high-promoting haplotypes (HY) 
and medium-promoting haplotypes (LY). Complement system plays an active role in 
innate immunity and disposal of immune complexes. Hence, genetic variation (codon 
52 mutant alleles or low-promoting haplotypes) may confer disease susceptibility and 
severity predisposing factor in lupus patients. The severity state may be the result of 
predisposition to recurrent infections. We further explore if these genetic variants are 
associated with infections while treated with immunosuppressive agents in lupus 
patients. 
 
Among 100 unselected lupus patients, 98 patients were treated with 
immunosuppressive agents (50 with corticosteroids and cytotoxic agents; 46 with 
corticosteroids alone; 2 with cytotoxic agents alone). Only 2 patients did not have 
corticosteroids or cytotoxic agents. We found that 66 lupus patients (66%) had 
significant infections during their disease course. 20 (30%) of 66 lupus patients with 
infections had codon 52 mutant alleles while 6 (18%) of 34 lupus patients without 
 129
infections. 10 (15%) of 66 patients presented with low-promoting LX/LX haplotypes 
and 4 (12%) of 34 lupus patients without infection also had low-promoting LX/LX 
haplotypes. However we did not find anyone having codon 52 mutant alleles and low-
promoting LX/LX haplotypes. 
 
The importance of MBL variants with MBL insufficiency with regards to infection 
was studied in lupus patients with different immunosuppressive drugs used. It is 
interesting to note that a higher percentage of lupus patients with codon 52 mutant 
allele (71%) or low-promoting haplotype (100%) presented with infections while 
being treated by immunosuppressive drugs. However this needs to be studied further 
if this is because of MBL variant or due to extensive use immunosuppressive drug. It 
is noted that those without codon 52 mutant alleles (72%) and those without LX/LX 
haplotypes (66%) do also have infections too. However those with codon 52 mutant 
alleles (83%) presented with more infections compared to those without codon 52 
mutant alleles (56%) when corticosteroid is used.  
 
The relationship of SLE Damage Index with drugs used in lupus treatment was 
significant in those treated with steroids and immunosuppressive drugs in both overall 
damage score and NP and renal damage scores. The damage score was reduced in 
those with steroids alone or cytoxic drugs. This finding support that survival rate of 
lupus patients are increasing with effective lupus management with steroid and 
cytotoxic drug, lupus patients are presenting with organ damage. In such situation, 
MBL, complement protein, may have a role in predisposing or worsening the 
situation. We found that lupus patients with MBL 52 mutant and LX/LX haplotypes 
did not show any significant effect on overall SLE disease damage. However lupus 
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The kidney is one of the most commonly affected organ systems in SLE. With the use 
of sensitive light, electron, and immunofluorescence microscopy, at least one 
abnormality is seen in kidney biopsy specimens from almost all patients with lupus. 
Approximately 75% of renal biopsy specimens reported in several series have been 
classified as focal proliferative, diffuse, or membranous glomerulonephritis (Golbus 
and McCune., 1994). In unselected group of lupus patients, abnormalities in urine or 
renal functions occur in about 25%-50% early in the course of the disease (Cameron., 
1999). In the study of Vlachoyiannopoulos et al (1993), renal diseases manifested as 
proteinuria, microscopic hemuturia, decreased clearance of creatinine, increased 
serum creatinine level or the presence of casts was found in about 50% of lupus cases. 
In other studies, using similar definitions, the prevalence of renal diseases ranged 
from 29% to 75% (Wallace et al., 1980; Cervera et al., 1993). 
 
Proteinuria is considered a hallmark of renal involvement in lupus and it was reported 
to occur in 100% of lupus patients, sometime during the course of their disease 
(Golbus and McCune., 1994).  Proteinuria in SLE is due to deposition of immune- 
complexes in the filtration unit, the glomerulus. The glomerular filtration barrier to 
proteinuria composed of: -(1) innermost endothelial cells, (2) middle glomerular 
basement membrane and (3) outermost slit diaphragm (Tryggvason and Wartiovaara. 
2001). The plasma filtrate first passes through the vascular endothelium, where the 
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blood cells were retained. The glomerular basement membrane then serves as a pre-
filter of larger plasma proteins and finally the slit diaphragm is thought to function as 
the decisive ultrafilter that prevents proteins larger than albumin from leaving the 
blood circulation (Tryggvason K and Wartiovaara. 2001). Of the three components of 
glomerular filtration barrier, the crucial barriers for plasma proteins larger than 70 
kDa are the glomerular basement membrane (GBM) and the glomerular slit 
diaphragm (Farquhar et al., 1999; Schneeberger., 1974; Rodewald and Karnovsky.,  
1974). Thus, Karnovsky and Ainsworth (1972) proposed that the glomerulus 
functions as two molecular filters acting in series:- the GBM (the coarse filter) and the 
slit diaphragm (the ultimate fine filter).  
 
Slit diaphragm, the ultimate molecular size filter, is a specialized cell adhesion 
structure between the interdigitating glomerular podocyte foot processes. Based on 
the electron microscopic studies on mouse and rat kidney tissues, Rodewald and 
Karnovsky (1974) proposed that the slit diaphragm is an orderly isoporous filter. 
According to them, the slit diaphragm is a three dimensional protein structure with 
highly ordered periodic cross bridges forming zipper-like appearance. While the 
filtration barrier is freely permeable by water and small solutes, the slit diaphragms of 
podocytes will decide the permeability of molecules at larger extent. Several proteins 
have been shown to localize in the slit diaphragm, however, it may require more 
studies to understand how they interact or how they contribute to maintain the 
functional integrity of the slit diaphragm. Within a recent few years, several 
molecules such as, ZO-1 (Schnabel et al. 1990), nephrin (Ruotsalainen et al. 1999), 
CD2AP (Shih et al.1999), FAT (Inoue et al. 2001) and P-Cadherin (Reiser et al. 2000) 
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have been shown to be expressed with in slit diaphragm. This suggests that some/all 
of these proteins may play a major role in maintaining integrity of slit diaphragm. 
 
Nephrin is a member of an immunoglobulin superfamily (IgCAM) and 
transmembrane protein expressed in podocytes and suggested to play an important 
role in maintaining selective permeability in slit diaphragm. Extracellular domain has 
eight IgG motifs and one type III-fibronectin domain. Topham et al. (1999) reported 
the relationship between the antigen recognized by mAb 5-1-6 and nephrin. In their 
study, rat glomeruli were incubated in vitro with mAb 5-1-6, then cross-linked the 
antibody to its antigen with chemical cross-linker, solubilised glomeruli, extracted the 
immune complexes, separated the immunoglobulin (IgG) and antigen on a gel by 
electrophoresis, and then identified the isolated antigen by mass spectrometry. The 
antigen that was recognized by mAb 5-1-6 turned out to be part of the extracellular 
domain of nephrin.   
 
Currently pathogenesis of proteinuria in SLE is not a well-understood process. Some 
proposed the circulating immune complexes composed of antibodies are 
inappropriately deposited in the kidney of lupus patients, which in turn cause altered 
permeability for serum protein by damaging the glomerular basement membranes 
(Mavragani and Moutsopoulos., 2003). Autoantibodies may have a role in 
pathogenensis of renal involvement in SLE (Termaat RM et al., 1993). 
Autoantibodies, which are characteristics of SLE, may play a role in pathogenesis of 
renal involvement and proteinuria. Glomerulonephritis mediated by antibodies to 
glomerular basement membrane (GBM) is the prototype of human glomerular disease 
produced by pathogenic antibodies to intrinsic glomerular components. Anti-
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glomerular basement membrane (anti-GBM) antibody disease is a rare autoimmune 
disorder in which circulating antibodies are directed against an antigen normally 
present in the GBM and alveolar basement membrane. The target antigen is the α-3 
type IV collagen and the resultant clinical syndrome due to antiGBM antibodies 
provides a spectrum from mild renal involvement to a rapidly progressive 
glomerulonephritis.  
 
The disease is more common in whites than in African Americans. The disease can 
manifest in persons of any age with equal distribution on both sexes. In adults, anti-
GBM disease is responsible for approximately 5% of glomerulonephritis and is 
diagnosed in 1-2% of renal biopsy specimens. Anti-GBM glomerulonephritis 
accounts for 10-20% of rapidly progressive glomerulonephritis in both adults and 
children. In untreated patients, the disease usually progresses to renal failure or death. 
Treated patients have a significant risk of morbidity and mortality from renal failure, 
pulmonary hemorrhage, and complications of treatment.  
 
The combination of glomerulonephritis and pulmonary hemorrhage has been 
commonly referred to as Goodpasture syndrome. Pulmonary and/or renal 
manifestations can be encountered in a variety of conditions such as antineutrophilic 
cytoplasmic antibody (ANCA)– positive vasculitis and other autoimmune disorders. 
Consequently, the identification of anti-GBM antibodies in the patient's serum or 
tissues is of paramount importance in the diagnosis of Goodpasture disease. Anti-
GBM antibodies are uncommon in lupus patients. The prevalence of renal 
involvement is high in local Chinese lupus patients (Fong et al. 1997). Consequently 
anti-nephrin antibodies may explain proteinuria in lupus patients and their presence 
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may represent a novel severity factor in SLE. Thus we decided to express the most 
homologous area of extra-cellular domain among mouse and human nephrin proteins.  
 
We have expressed this fragment of nephrin protein using His-Tag expression vector 
(pET-16b) in E.Coli expression system. The expressed protein was confirmed as 
“nephrin” protein fragment by protein fingerprinting (MALDI-TOF-MS) after 
identifying the trypsin-cleaved fragments in available protein databases. We raised the 
monoclonal antibodies and polyclonal antibodies against expressed protein, however 
the monoclonal antibody production was unsuccessful because of technical problems. 
The purified polyclonal antibodies were found to be reacting with glomeruli of frozen 
section of mouse kidney. 
 
An ELISA was set up to detect antibodies against nephrin protein in both human and 
mice sera. It was noted the antibodies against nephrin protein were raised in 19 (95%) 
out of 20 lupus mouse models (PL/J F1xNZB) and 4 (80%) out of 5 MPR/lpr mice 
and none (0%) of 10 BALB/c mice. These anti-nephrin antibodies were associated 
with proteinuria (89%) and anti-dsDNA antibodies (84%) in these lupus mouse 
models.    
 
However, optimization of ELISA for use with human sera was unsuccessful despite 
repeated attempts using different blocking reagents. Among gelatin, fetal bovine sera, 
bovine sera albumin, nonfat dry milk, casein, human albumin, none worked well 
enough to yeild clear and consistent results. We therefore switched to immunoblotting 
to detect anti-nephrin antibodies in human sera for both controls and patients.  
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The 102 control individuals, 100 unselected lupus patients and 130 non-lupus patients 
were screened for presence of anti-nephrin antibodies. The results were presented in 
Table 3.13. Briefly, we observed that the antibodies against expressed fragments of 
nephrin protein were not seen in all control samples and non-lupus samples.  14 
(14%) out of 100 unselected lupus patients have shown positive results against anti-
nephrin antibodies.  
 
These antibodies were further correlated with proteinuria and renal organ-system 
Damage score of unselected lupus group. Even though we have significant association 
of anti-nephrin antibodies in lupus patients, we did not find any significant association 
of these antibodies with proteinuria or renal damage in lupus patients. Firstly it was 
shown that resultant clinical syndrome due to antiGBM antibodies which are found to 
be associated with Goodpasture disease, provides a spectrum from mild or no renal 
involvement to a rapidly progressive glomerulonephritis. Secondly, autoantibodies 
can predate the clinical presentation in autoimmune disease. Arbuckle et al. presented 
a retrospective study on development of autoantibodies before clinical onset of SLE in 
2003. They found that at least one SLE autoantibodies (anti-nuclear antibodies, anti 
ds-DNA antibodies, anti-phospholipid antibodies, anti-Ro antibodies, anti-La 
antibodies and anti nuclear ribonucleoprotein antibodies) was present in 88 percentage 
of lupus patients before the clinical diagnosis of SLE (the mean duration is 3.3 year 
with 0- 9.4 year range). Therefore, those with positive anti-nephrin antibodies may 
not present with proteinuria or renal damage yet, but may present in the later course of 
disease. This phenomenon can be seen in myasthenia gravis where anti-acetylcholine 
receptor antibody can be detected several weeks before clinical presentation. This 
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would explain the nature of autoantibodies where they can be detected without a 
symptom.  
 
The pathogenesis of renal involvement is rather diverse with many possible 
explanations at the moment. Although proteinuria and cellular cast are presented in 
about half of lupus patients, biopsy studies demonstrate some degree of renal 
involvement in almost all patients. It may not be able to conclude a single pathogenic 
mechanism for all renal involvements. We may need to recruit more lupus patients in 
the study to be able to correlate anti-nephrin antibodies with renal involvement. It will 
be better if sera from same cohort of lupus patients are serially collected and analyzed 
together with renal involvement. 
 
Furthermore, expressed nephrin protein was from mouse origin, which may not 
antigenic to human nephrin. Thus we will plan to express complete extracellular 
domain of nephrin protein so that it will be able to match most antigenic epitopes in 
lupus patients. The expressed nephrin protein will be used in determination of anti-
nephrin antibodies in sera serial collected from larger cohort of lupus patients. 
 
4.3.Brain Reactive Autoantibodies (BRAAs) 
 
It was reported that 31%-70% of SLE patients has significant neuro-psychiatric (NP) 
manifestations in both retrospective and prospective studies (West et al., 1995; Kaell 
et al., 1986; Futrell et al., 1992; Sibley et al., 1992; Rood et al., 1999). The spectrum 
of NP manifestation in SLE includes both neurologic and psychiatric features, many 
of which may be subjective in nature. They vary from overt neurologic dysfunctions 
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due to psychoses, seizures, to subtle abnormalities in neurocognitive functions such as 
memory, intellect etc. (Hanly and Hong., 1993). They are not easily identifiable 
because lupus itself or drugs used in lupus management or other associated 
pathological condition may contribute to pathogenesis of NP-lupus.  
 
The unclear pathogenesis of NP-lupus contributes to difficulties in diagnosis and 
management. Clinicians depend on exclusion of other causes to diagnose NP-lupus 
(Hanson et al., 1992). The pathogenic roles of many autoantibodies are not well 
defined in autoimmune disorders and also in SLE, especially in NP-lupus. Prevalence 
of brain reactive autoantibodies reacting against different neuronal proteins was 
reported. They were detected in sera and cerebrospinal fluid (CSF) in both human and 
animal studies (Hanson et al., 1992; Bluestein and Zvaifler 1976; Wilson et al., 1979; 
Toh and Mackay 1981; Hoffman et al., 1987; Zameer and Hoffman 2001; Moore PM; 
1992). However, not all brain reactive autoantibodies are responsible for NP-lupus, 
i.e, they are not necessarily of pathogenic importance (Khin and Hoffman., 1993). Of 
these autoantibodies, some pathogenic autoantibodies might also attack neuronal 
tissue and lead to NP manifestations. These autoantibodies can bind to neuronal 
surface membranes (Koren et al., 1992) and cause injury via a direct toxic effect, or 
alternatively it disrupts physiological function of neuronal tissue when bound, but 
without causing cell death.  
 
In our immunoblotting experiments using neuronal membrane proteins extracted from 
the mouse brains to detect any antibodies in unselected-lupus patients, we found, not 
surprisingly, that many lupus antibodies were reactive with mouse neuronal 
membrane proteins. Among them, two lupus antibodies reacting against mouse brain 
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membrane proteins between 24 and 35 kD molecular weights were particularly 
prominent. We found their presence in 10 (10%) out of 100 unselected lupus patients 
and in none (0%) of the 100 healthy individuals. Calculated molecular weights of the 
membrane proteins are 27.5 and 29.5 kD and we used the term “Brain Reactive 
Autoantibodies” as both seem to be present in concordance. We tested whether these 
antibodies are specific to lupus sera, we immunoblotted the sera of 130 non-lupus 
rheumatic patients comprising 20 RA, 20 OA, 20AS, 20 PsA and 50 APS patients. 
We were particularly interested in the primary APS patients with history of CNS 
manifestation e.g. stroke. Hence we are confident that the BRAAs represent 
independent factors that are associated with NP-lupus and not due to antiphospholipid 
antibodies. However these antibodies (BRAAs) were not found in rheumatic patients 
with non-lupus disease. 
 
The membrane proteins extracted from different mouse tissues (liver, heart, spleen 
and kidney) were used as antigen source in immunoblotting experiments and no 
similar bands were seen. BRAAs were specifically reacting with membrane proteins 
of mouse brain neuronal cells and they did not cross react with membrane proteins 
from other cells. 
 
To explore if similar brain membrane proteins extracted from the different species 
react with lupus antibodies, immunoblotting experiment was set up using brain 
membrane proteins extracted from rat, pig, chicken, duck, quail, frog and fish. The 
results showed the lupus antibodies still react with similar membrane proteins 
extracted from mammalian brains such as rat and pig. However lupus antibodies 
failed to show binding with such proteins from neuronal membrane proteins of other 
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species such as avian, amphibian and fish species. Our main interest is whether these 
BRAAs react with human neuronal membrane proteins. Immunoblots using human 
neuronal lysate produce the 2 bands as predicted. We therefore conclude that these 
BRAAs react with human and mammalian neuronal membrane proteins. 
 
With 2-dimensional gel approach, we attempt to identify the autoantigens by peptide 
mass fingerprinting using MALDI-TOF-MS analysis. Matching the results against 
public protein databases, NCBI and Swissport, it was noted that they may be 
previously undescribed proteins. We did not attempt to expand further time and effort 
in further identifications at present as this is not the focus of our current project. 
 
We concluded that these two membrane antigens of mammalian brain origin are 
reacting with antibodies present in the sera of lupus patients. We found these BRAAs  
in 10 out of 100 lupus patients (10%) while none of the healthy individuals (n=102) 
and non-lupus (n=130) patients had these antibodies. We then proceeded to determine 
the association of these antibodies with neuro-psychiatric manifestations (psychosis 
and seizure) and whether they represent a disease severity factor in SLE. According to 
chart review, of the 10 patients with positive BRAAs, 6 patients presented with NP 
manifestations (3 with psychosis and 3 with seizures) according to 1997-updated 
ACR criteria. However, only 4 patients out of 90 lupus patients without BRAAs had 
NP-lupus (seizures). This association is statistically significant (p<0.001). We 
extended our analysis to include the NP-lupus syndromes, which is more diverse. The 
significant association of BRAA with NP lupus is still present. The pathogenesis of 
NP lupus is yet unclear. There are probably many sub-sets of NP-lupus in existence. 
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BRAAs could be antibodies that are associated with the sub-set presenting with 
psychosis or seizure in NP-lupus.  
 
NP manifestations may be related to targets of autoantibodies. Khin and Hoffman 
(1993) reported that monoclonal antibody prepared against brain membrane proteins 
was seen not binding to membranes of all neuronal cells. Thus autoantibodies may 
selectively bind to different area of brain (perhaps different expression of protein in 
different anatomical location) and NP-manifestations may differ from one patient to 
another depending on anatomical locations. Sakic et al., (1998) reported that cognitive 
deficits are associated with hippocampal lesions in the mice. The BRAAs target area 
in mouse brain will need further studies to be defined.  
 
Presence of different autoantibodies is hallmark of lupus disease, antibodies alone will 
not be significant. It is important to correlate presence of autoantibodies with clinical 
manifestations. We have identified the BRAA, which are highly associated with 
psychosis and/or seizure. We hypothesized that over-expressed BRAA which can 
cross the blood-brain-barrier in certain clinical conditions, bind membrane proteins of 
brain and alter physiological functions causing psychosis and/or seizure in lupus 
patients. We plan to identify and characterize the membrane proteins reacting with 




















1. We have successfully optimized the PCR-RFLP approach to genotype the Exon 1 
and haplotype promoter region of MBL gene and applied this method to genotype 
and haplotype the MBL gene in controls and lupus patients. We found that codon 
52 mutant alleles are highly associated with lupus patients and they can be 
considered as predisposing factor in pathogenesis of SLE as a result of impaired 
immune-complex clearing function by the MBL protein. More MBL low-
producing haplotypes are seen in lupus patients. They may also worsen the disease 
severity by failing to protect against invading pathogenic microorganism when 
intensive immunosuppressive lupus treatment is being carried out. 
 
2. We have identified anti-nephrin antibodies, which are highly associated with 
proteinuria in lupus mouse models. However, we did not find this association with 
proteinuria in human samples. Firstly, the difference in origin of proteins might be 
an important factor to determine the specificity between mouse and human. 
Secondly the different epitopes may play an important role in their antigen-
antibody reaction. Moreover its action on mouse models indicates a potential role 
in disease severity. 
 
3. We have identified BRAAs in lupus patients, which are highly associated with 
psychosis, or seizure in NP-lupus. These BRAAs are highly tissue, disease and 
species-specific and do not correlate with other NP syndromes in lupus patients.  
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4. Among these three findings, codon 52 mutant MBL alleles confer increased 
disease severity by increasing disease Damage Index (SLICC/ACR score) both in 




1. MBL gene has three mutation sites at exon 1 and two polymorphic sites at 
promoter. We plan to design a method to haplotype the all these polymorphic site 
so that we can further study its functional correlation. We also plan to administer 
purified MBL into the lupus mouse model to study whether it attenuates severity 
of lupus manifestation. 
 
2. The nephrin protein will be expressed in full length or nephrin protein of human 
origin will be expressed, and further studied as to their relationship with renal 
involvement in lupus patients. 
 
3. Brain autoantigens reacting with BRAA will be isolated and identified so that an 
ELISA method will be employed to detect BRAA in lupus patients prospectively 
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“Patients Data Entry Form” 
 
Code    __________________ 
Sex    _______________________ 
Ethnic Group   _______________________ 
Date of Birth   _______________________ 





Tick Y or N 




Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds. 
  
ACR2 Discoid rash 




Skin rash as a result of unusual reaction to sunlight, documented by patient history or physician observation. 
  
ACR4 Oral ulcers 
Oral or nasopharyneal ulceration, usually painless, observed by a physician. 
  
ACR5 Arthritis   
Nonerosive arthritis involving two or more peripheral joints characterized by tenderness, swelling, or effusion 
  
ACR6 Serositis   
a)  Pleuritis - convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion OR  
b) Pericarditis – documented by ECG or rub or evidence of pericardical effusion. 
  
ACR7 Renal disorder   
a) Persistent proteinuria greater than 0.5 grams per day or greater than 3+ if quantitation not performed  OR 
b) Cellular casts – may be red cell, hemoglobin, grandular, tubular, or mixed 
  
ACR8 Neurologic disorder   
a) Seizures – in the absence of offending drugs or known metabolic derangements, eg uremia, ketoacidosis, or 
electrolyte imbalance  OR   
b) Psychosis – in the absence of offending drugs or known metabolic derangements, eg uremia, ketoacidosis, or 
electrolyte imbalance 
  
ACR9 Hematological disorder:   
a) Hemolytic anemia – with reticulocytosis OR  
b) Leukopenia – less than 4,000/mm3 total on two or more occasions  OR 
c) Lymphopenia – less than 1,500/mm3 on two or more occasions OR 
d) Thrombocytopenia – less than 100,000/mm3 in the absence of offending drugs.  
  
ACR10 Immunological disorder:   
a) Anti-DNA antibody to native DNA in abnormal titer OR  
b) Anti-Sm: presence of antibody to Sm nuclear antigen OR 
c) Positive finding of antiphospholipid antibodies based on  
i) an abnormal serum level of IgG or IgM anticardiolipin antibodies, OR 
ii) a positive test result for lupus anticoagulant using a standard method, OR 
iii) a false-positive serologic tests for syphilis known to be positive for at least 6 months and confirmed by 
Treponema pallidum immobilization or fluorescent treponemal antibody absorption test.   
  
ACR11 Antinuclear antibody   
An abnormal titer of antinuclear by immunofluorescence or an equivalent assay at any point in time and in the 




MODIFEID RENAL INVOLVEMENT 
 
Enter Y or N 
Y             N 
R 1 Persistent Proteinuria:  
proteinuria > 0.5 gm/day or > 3+ on lab-stix on > 1 occasion 
  
R 2 Cellular Casts:  
presence of red cell, hemoglobin, granular, tubular, mixed casts. 
  
R 3 Nephrotic Syndrome:  
proteinuria > 3.0 gm/day with peripheral edema and serum Albumin < 30 gm/dL. 
  
R 4  Nephritic Syndrome:  





Rapidly Progressive Glomerulonephritis:  






NEUROPSYCHIATRIC SYNDROMES   
 
Enter Y or N 
Y             N 
NP 1 Acute Confusional State   
NP 2 Acute Inflammatory DemyelinatingPolyradiculoneuropathy (Guillain-Barre Syndrome)    
NP 3 Anxiety Disorder   
NP 4 Aseptic Meningitis   
NP 5 Autonomic Disorder   
NP 6 Cerebrovascular Disease   
NP 7 Cognitive Dysfunction   
NP 8 Demyelinating Syndrome   
NP 9 Headache   
NP 10 Mononeuropathy (single / multiplex)   
NP 11 Mood Disorders   
NP 12 Movement Disorder (Chorea   
NP 13 Myasthenia Gravis     
NP 14 Myelopathy     
NP 15 Neuropathy, Cranial    
NP 16 Plexopathy   
NP 17 Polyneuropathy    
NP 18 Psychosis   





MBL, anti-nephrin antibodies and BRAA result   
 
 
Enter appropriate result.. 
1 MBL  
 MBL Codon 52 polymorphism (wildtype homo=0; mutant homp=1; hetro=2)  
 MBL Codon 52 polymorphism (wildtype homo=0; mutant homp=1; hetro=2)  
 MBL Codon 52 polymorphism (wildtype homo=0; mutant homp=1; hetro=2)  
 MBL promoter (Refer to PCR-RFLP chart of MBL promoter)  
2 Anti-nephrin antibodies (Y or N)  
3 BRAA (Y or N)  
 xxiii
THERAPEUTIC MODALITIES  
Indicate yes if patient has at any time been on the modality since the last entry:  
Enter Y or N 
Y            N 
DRG1  Prednisolone   
DRG2  Anti-malarial   
DRG3 Azathioprine    
DRG4 Methotrexate   
DRG5 Cyclophosphamide (p.o.)   
DRG6 Cyclophosphamide (i.v.)   
DRG7 Methylprednisolone   
DRG8 Vincritstine (i.v.)   
DRG9 Immunoglobulin (i.v.)   
DRG10 NSAIDS   
DRG11 Danazol   
DRG12 Plasmapheresis   
DRG13 Warfarin/Heparin    
DRG14 Aspirin    
DRG 15 Alternative medication: Traditional medication (Chinese, Malay and Indian) or herbal 




 DEFINITIONS FOR INFECTIONS   
Enter Y or N 
Y    N 
Bacterial 
INF1 Pneumonia Îair space shadowing on X-rays.    
INF2 Urinary Î Pyuria (> 10 WBC/high power field) and/or positive urine cultures   
INF3 CNS Îcerebrospinal fluid results or imaging suggestive of a cerebral infection or 
EEG/CSF features suggestive of a viral encephalitis.  
  
INF4 Hepatobiliary Î serum alkaline phosphatase more than 2 times normal range with 
suggestive imaging (thickened gall bladder, biliary sludge, cholelithiasis demonstrated). 
  
INF5 BacteraemiaÎ organism isolated on blood cultures with no source identified.   
INF6 SkinÎ cellulitis, necrotising fascitis, etc   
INF7 JointsÎ purulent joint aspirate or positive joint fluid cultures or suggestive operative 
findings 
  
INF8 OthersÎ infections at other sites and confirmed by positive cultures or histology   
Viral 
INF9 Herpes ZosterÎ grouped vesicles as on an erythematous base in a dermatomal 
distribution involving 1 dermatome. 
  
INF10 Disseminated Varicella Î grouped vesicles as on an erythematous base involving > 1 
dermatome.  
  
INF11 Disseminated Herpes Simplex Î grouped vesicles as on an erythematous base 
distributed extensively (may not be possible to distinguish this clinically from 
disseminated varicella). 
  
INF12 CytomegalovirusÎ any of the following: (a) 4 fold rise in antibody titres in 2 weeks (b) 
strongly positive CMV IgM assay (c) cytopathic effect on histological specimen. 
  
Fungal 
INF13 Cryptoccocal Meningitis Î infection involving the meninges and has any of the 
following: (a) positive cryptococcal antigen assay (b) torula seen on fungal smears or 
isolated on cultures 
  
INF14 Other Cryptoccocal Infections Î infection involving sites other than the meninges and 
has any of the following: (a) positive cryptococcal antigen assay (b) torula seen on 
histology or isolated on cultures. 
  








Systemic Lupus International Collaborating Clinics / American Collegue of Rheumatology (SLICC / 
ACR) Damage InNdex for Systemic Lupus Erythematosus*  
(* Damage: nonreversible change not related to active inflammation occurring since onset of lupus, ascertained by clinical 
assessment and present for at least 6 months unless otherwise stated. Repeat episodes must occur at least 6 months apart 
to score 2. The same lesion cannot be scored twice.)       
     
Enter appropriate score 
Organ 
system 
Descriptions Score Guide Score 
1 Ocular (either eye, by clinical assessment)   
O1 Any cataract ever 1  
O2 Retinal change or optic atrophy 1  
2 Neuropsychiatric 1  
N1 Cognitive impairment (eg. Memory deficit, difficulty with calculation, Poor 
concentration, difficulty in spoken or written language, impaired performance level) 
or major psychosis 
1  
N2 Seizures requiring therapy for 6 months 1  
N3 Cerebrovascular accident ever Score 2 if > 1  
N4 Cranial or peripheral neuropathy (excluding optic) 1  
N5 Transverse myelitis 1  
3 Renal   
R1 Estimated or measured glomerular filtration rate < 50% 1  
R2 Proteinuria >= 3.5 gm/24 hours 1  
R3 End-stage renal disease (regardless of dialysis or transplantation)  3  
4 Pulmonary 1  
P1 Pulmonary hypertension (right ventricular prominence, or loud P2) 1  
P2 Pulmonary fibrosis (physical and radiograph) 1  
P3 Shrinking lung (radiograph) 1  
P4 Pleural fibrosis (radiograph)  1  
P5 Pulmonary infarction (radiograph)  1  
5 Cardiovascular   
CV1 Angina or coronary artery bypass    1  
CV2 Myocardial infarction ever  score 2 if >1  
CV3 Cardiomyopathy (ventricular dysfunction 1  
CV4 Valvular disease (diastolic, murmur, or systolic murmur > 3/6)  1  
CV5 Pericarditis for 6 months, or pericardiectomy 1  
6 Peripheral vascular   
PV1 Claudication for 6 months  1  
PV2 Minor tissue loss (pulp space) 1  
PV3 Significant tissue loss ever (eg loss of digit or limb 1  
PV4 Venous thrombosis with swelling, ulceration, or venous stasis Score 2 if >1site  
7 Gastrointestinal   
GI1 Infarction or resection of bowel below duodenum, spleen, liver, or gall bladder ever, 
for cause any 
Score 2 if >1 site   
GI2 Mesenteric insufficiency  1  
GI3 Chronic peritonitis 1  
GI4 Stricture or upper gastrointestinal tract surgery ever 1  
8 Musculoskeletal   
MS1 Muscle atrophy or weakness 1  
MS2 Deforming or erosive arthritis (including reducible deformities, excluding avascular 
necrosis)   
1  
MS3 Osteoporosis with fracture or vertebral collapse (excluding avascular necrosis 1  
MS4 Avascular necrosis Score 2 if >1   
MS5 Osteomyelitis 1  
9 Skin   
SK1 Scarring chronic alopecia 1  
SK2 Extensive scarring or panniculum other than scalp and pulp space 1  
SK3 Skin ulceration (excluding thrombosis) for > 6 months 1  
10 Premature gonadal failure 1  
11 Diabetes (regarding of treatment) 1  
12 Malignancy (exclude dysplasia) Score 2 if >1 site  





DNA and RNA protocols 
 
A. Genomic DNA extraction from peripheral blood (salting-out method) 
 
• 5 ml of peripheral blood was withdrawn in Na2EDTA tube. 
• Centrifuge the anti-coagulated blood at 2400 rpm for 15 minutes at RT. 
• Remove the plasma and carefully transfer the white cells (buffer coat) to 15ml tube. 
• Add Red Cell Lysis Buffer (RCLB; 0.144M NH4Cl, 10mM NaHCO3) to brim of plain 
tube and incubate about 5-10 minutes at RT to allow complete lysis of red blood cells. 
Centrifuge at 2400 rpm for 15 minutes at RT. 
• Remove the supernatant and wash the white cell pallet gently once with RCLB. 
• Add 3 ml of Nuclei Lysis Buffer (NLB; 10mM Tris-HCl pH 8.2, 0.4M NaCl, 2mM 
Na2EDTA), 100 μl of Proteinase K 10mg/ml (dissolved in PK Buffer; 2mM 
Na2EDTA, 1% w/v SDS) and 100 μl of 10% SDS. Vortex and incubate for 3 
hours/overnight at 56°C. 
• Add 1 ml of 5M NaCl and vortex vigorously for 15 seconds. 
• Centrifuge at 3000 rpm for 30 minutes at RT. Transfer the supernatant into clean 15-
ml centrifuge tube without disturbing the pallet. 
• Add 2 volumes of ice-cold absolute ethanol and mix well by gentle inversion. 
• Thread-like DNA strands will be removed and re-suspended in 200 μl of TE buffer 




NB: Standard PCR will require 1μl of diluted DNA as template. No spectrometry will be 
needed for standard PCR. 
 
B. Total RNA extraction 
 
• 50-100mg tissue was crushed on liquid nitrogen. Add approximately 1ml Trizol and 
used syringe and needle to further homogenize. Incubate the homogenized samples for 
5 minutes at room temperature to permit the complete dissociation of nucleoprotein 
complexes. 
• Add 0.2 ml of Chloroform per 1 ml of Trizol reagent used. And shake vigorously by 
hand for 15 seconds. 
• Incubate again for 3 minutes at room temperature. 
• Centrifuge the samples at 12,000xg for 15 minutes at 4°C. 
• Transfer the aqueous layer into fresh tube. Add 0.5 ml of isoamyl alcohol per 1 ml of 
Trizol reagent used. 
• Incubate again for 10 minutes at room temperature. 
• Centrifuge the samples at 12,000xg for 10 minutes at 4°C. 
• Remove the supernatant and wash the RNA pallet once with 75% ethanol (1 ml of 
75% ethanol per 1 ml of Trizol reagents used). Mix the sample by vortexing and 
centrifuge at 7,500xg for 5 minutes at 4°C. 
• Remove the supernatant and briefly dry the RNA pallet. Dissolve the RNA pallet in 20 
μl RNAse-free water. 
• Measure the amount of RNA by spectrophotometer, 
NB:  1.0 OD260nm contains 40ng/μl RNA 
 Clean RNA has ratio of OD260nm/OD260nm about 1.8-2.0. 
 xxvii
C. Polymerase Chain Reaction (PCR) 
 
• All PCRs are performed as following standard protocol and optimization are done as 
and when necessary.  
• PCR composition 
 
   Working [C] Final [C]  Volume [μl] 
H20 - -  15.7 
10x Buffer 10x 1x    2.0  
dNTP 2.5mM .1mM    0.8 
Forward primer 20μM .2μM    0.2 
Reversed primer 20μM .2μM    0.2 
DNA polymerase 2units/μl .2 unit    0.1 
DNA diluted      1.0 
    20.0 
 
• PCR conditions 
  Initial Denaturing  1 cycle  at 95°C for 5 minutes    
  Three-step amplification  35 cycles  at 95°C for 10 seconds 
            60°C for 30 seconds 
            72°C for 30 minutes 
  Final extension   1 cycle  at 72°C for 10 minutes  
 
  
D. Reverse transcription and PCR (RT-PCR) 
 
• Reversed transcription-polymerase chain reaction (RT-PCR) was done using QIAGEN 
OneStep RT-PCR kit.   
 xxviii
• RT-PCR composition 
   Working [C] Final [C]  Volume [μl] 
RNase-free water - -  Variable 
5x RT-PCR Buffer 5x 1x    10.0  
DNTP 10mM 1.6mM      2.0 
5x Q-solution 5x 1x    10.0 
Forward primer 20μM .2μM      1.5 
Reversed primer 20μM .2μM      1.5 
RT-PCR enzyme mix - -      2.0 
RNA template (1pg-2μg) - -    Variable 
     50.0 
   
• RT-PCR conditions 
 Reverse transcription  1 cycle  at 50°C for 30 minutes 
 Initial Denaturing  1 cycle  at 95°C for 15 minutes 
 Three-step amplification  35 cycles  at 95°C for 30 seconds 
           60°C for 30 seconds 
           72°C for 60 seconds 
 Final extension   1 cycle  at 72°C for 10 minutes   
 
• Thaw all reagents and keep them on ice. 
• Prepare the reaction-mix according to RT-PCR composition 
• Add template RNA not more than 2 μg per reaction was added 
• Start the RT-PCR while keeping reaction tube on ice. 
• Place the reaction tube in thermocycler only when it has reached 50°C.     
 
NB: Generally RNase inhibitor is not necessary. RNase-free environment was maintained 






Molecular Cloning Protocol 
 
A. Preparation of chemically competent cells 
 
• Grow E.Coli of interest overnight in LB agar plate without antibiotics 
• Pick one colony and grow in 5 ml of LB without antibiotics for 2-3 hours 
• Transfer to 50 ml of LB without antibiotics and grow until OD600 becomes ≈ 5.0 
• Centrifuge at 5000 rpm for 15 minutes at 4°C. 
• Discard the supernatant and resuspend the cells in 10 ml (0.2 x original volume) of ice-
cold 0.1M MgCl2. 
• Centrifuge at 5000 rpm for 15 minutes at 4°C. 
• Discard the supernatant and resuspend the cells in 2.5 ml (0.05 x original volume) of 
ice-cold 0.1M MgCl2 containing 75% of Glycerol. 
• Incubate on ice for exactly one hour.  
• Keep away from any disturbance to increase transformability. 
• Freeze the cells in 50 μl of aliquots at -70°C. 
 
B. Plasmid DNA extraction by Alkaline Prep. 
 
• Streak a ice flake of stock bacteria (empty vector or vector with insert) on LB agar-
plate with appropriate selection antibiotics and incubate the agar-plate in 37°C 
incubator. 
 xxx
• Pickup single colony and grow in 1.5 ml LB/antibiotic on shaker for four hours at 
37°C. 
• Collect the supernatant by quick spinning for 30 seconds and discard the supernatant. 
• Resuspend pellet in 100 μl lysis solution  
• Add 200 μl alkaline-SDS solution. Vortex well and incubate for 5 min on ice  
• Add 150 μl high salt solution. Vortex well and incubate for 10 min on ice  
• Separate the supernatant by quick spinning for 10 min  
• Remove 400 μl supernatant and transfer to new tube prefilled with 400 ml 
isopropanole. Vortex well and incubate tube on ice for 10 min  
• Remove the supernatant by quick spinning for 10 minutes  
• Wash pellet with 70% ethanol. 
• Vacuum dry pellet for 5 min and suspend in 100 μl 1xTE with 20 mg/ml RNAse A. 
NB:- Usually 1-2 μl is enough for digest (high-copy plasmid). keep DNA frozen at -20°C. 
Lysis solution:(freshly prepared) Alkaline SDS solution:(stable for 1 week) 
 7.55 ml H2O    7.6  ml H2O 
 2    ml 50% glucose   2    ml 5% SDS 
 0.2  ml 0.5 M EDTA   0.4  ml 5 N NaOH 
 0.25 ml 1 M Tris-HCl pH 8  ------ 
10    ml total    10 ml total 
 
C. Dephosphorylation of expression vector. 
 
Dephosphorylation was normally performed prior to ligation process to prevent the self-
ligation of expression vector. It was commonly done immediately after the enzymatic 
cleavage of plasmid vector. 
 
• 20 pmoles of expression vector (pET-16) was cleaved by Nde I enzyme 
 xxxi
• The status of plasmid DNA cleavage by enzyme was monitored by 0.8% agarose gel 
electrophoresis. 
• The Nde I enzyme was heat inactivated at incubation for 20 minutes at 60°C. 
• 1 unit of the calf intestine alkaline phosphatase (Fermentus) was added 
• The reaction was continued incubating for 30 minutes at 37°C. 
• Stop the reaction by heating for 15 minutes at 85°C 
• Precipitate the dephosphorylated expression vector by ethanol precipitation method. 
 
D. Ligation of dephosphorylated vector and gene of interest. 
 
Ligation was performed to insert “gene of interest” or “gene fragment of interest” into the 
cloning vector. Promega T4 DNA ligase was used to ligate the gene fragment of interest in 
our study. Even though molar ratio of vector:insert varies from 1:3 to 3:1 when cloning the 
fragment into a plasmid vector, we used molar ratio of vector:insert 1:3 in our experiment. 
 
Calculation of amount of vector and insert  
pET-16 size  Î 5.711 kb 
insert size Î .732 kb 
ng of insert  = (ng of vector x kb size of insert)/ kb size of vector 
   = (200x.732)/5.711 
   = 25 ng 
Composition of ligation reaction  
• Set up the following reaction in a sterile microfuge. 
 
  Vector DNA     -  200ng 
 xxxii
  Insert DNA     -    25ng 
10x Ligase buffer    -      1μl 
T4 DNA ligase (weiss units)   -      1 unit 
Nuclease free water to final volume of       10 μl  
 
Condition of ligation reaction  
Incubate the reaction at room temperature for 3 hours or overnight at 4°C. 
 
 
E.  Heat-shock transformation and selection of correct clone by PCR. 
 
• Thaw E. Coli competent cells prepared chemically by CaCl2 method on ice.  
• Add 20 ng of pDNA into the competent cells, and mix with gentle flicking and 
swirling. 
• Incubate on ice for 30 minutes.  Heat shock at 42°C for exactly 90 seconds.  Incubate 
on ice again for two minutes. 
• Add 1 ml of room-temperatured LB without antibiotics.  Incubate at 37°C, shaking at 
250 rpm for one hour.   
• Place two LB agar plates with ampicillin at 37°C. 
• Spin at 13,000 rpm for 90 seconds in table-top microfuge.  Pour off supernatant and 
add 100 μl room-temperatured LB, and resuspend pellet with glass rod. 
• Plate 90 μl of the resuspended cells on LB/Ampicillin plate pre-incubated at 37°C, and 
the remaining resuspended cells (10μl) on another plate. 
• Incubate the plates overnight at 37°C. 
 xxxiii
• Pick single colony and grow in 1.5 ml microcentrifuge tube containing 1 ml of 
LB/ampicillin. (grow for as many as possible) 
• Incubate at 37°C, shaking at 250 rpm for 4 hours. 
• Transfer 100 μl each of bacteria into 8 wells 200μl PCR strip and centrifuge at 2400 
rpm for 10 minutes at room temperature.  
• Discard the supernatant and add 50 μl of sterile water to each well and mixed well by 
vortexing. 
• Incubate the resuspended bacteria at 100°C for 15 minutes. 
• Proceed standard PCR using these bacterial lysates for checking of correct expression 
vector.  
NB:- LB/Ampicillin plates will have 1:1000 Ampicillin at 100 mg/ml. 
  Normally 2μl of baterial lysate is enough for PCR amplification. 
 
F. Expression and purification of expressed protein. 
 
Small-scale expression is normally carried out to test if expressed proteins are soluble. If 
expressed proteins are not soluble, purification under denatured condition will be applied 
for purification. Large-scale, about one-liter culture, is carried out for more protein, and 
purification process is done in column type instead of batch approach.  
 
• Two 15 ml centrifuge-tubes are used to grow 1:200 dilution of E. Coli with expression 
vector in LB media where appropriate antibiotics are added.   
• Incubate at 37°C, shaking at 250 rpm for four hours. 
• Read the OD600 of the cultures every 30 minutes after four hours.  
• When the OD600 reaches 0.5 – 0.6, one of tubes will be induced with 0.1mM IPTG. 
 xxxiv
• The induction will be carried out for another two hours. 
• The pallet collected after centrifugation will be lysed without using Urea or 
Guanidine-HCl ( Lysis buffer;50mM Na2HPO4 pH 8.0, 0.3M NaCl, 1mM PMSF; or 
mechanically or freeze-thaw cycles) 
• The resultant supernatant and pallet of induced and uninduced pallets will be analyzed 
on SDS-PAGE.  
 
In this experiment, we found that the expressed protein is in insoluble form so that strong 
denaturant (8M Urea) was used to denature the expressed protein and Ni-NTA purification 
will proceed. 
 
• Resuspend pellet of 10ml bacterial culture in 1ml lysis buffer (8M Urea, 50mM 
Na2HPO4 pH 8.0, 0.3M NaCl, 1mM PMSF) 
• Sonicate the resuspended pallet on ice 3 x 20 seconds and centrifuge at maximum 
speed for 15 minutes at 4°C. 
• Transfer supernatant into clean tube containing 50µl Ni-NTA beads (QIAGENS) 
which was equilibrated with equilibration buffer (8M Urea, 50mM Na2HPO4 pH 8.0, 
0.5M NaCl) 
• Add the crude extract to the beads and incubate for 1 hour at 4°C while shaking 
• Centrifuge at 3500 rpm for 3min and remove unbound material.  
• Wash thrice with wash buffer (8M Urea, 50mM Na2HPO4 pH 8.0, 0.5M NaCl ) 
• Wash thrice with wash buffer containing 10mM Imidazole.  
• Elute thrice 100µl of elution buffer ( 8M Urea, 20mM Tris pH 7.5, 100mM NaCl , 
250mM Imidazole)  






A. Protein extraction from tissues 
 
The membrane proteins are extracted using the simple concept of water-insolubility. This 
concept is used for extraction of membrane proteins from different tissues of mouse and 
brains of different species. 
 
• The frozen tissue is cut into small pieces by scalpel. 
• Homogenization is carried out by using “motor and pastel method” followed by 
syringe and needle (started from 19G and gradually reduced in different bore sizes 
until 27G). 
• Homogenized tissues are resuspended in 1xPBS containing a cocktail of proteinase 
inhibitors (5μg/ml leupeptin, 5μg/ml approtinin and 1mM PMSF). 
• The water-insoluble pallet was separated by centrifugation at 12,000xg for 10 minutes 
at 4°C.  
• Repeated washings with 1x PBS containing cocktail of protein inhibitors were done 
until proteins were not detected in wash buffer using BioRad protein assay. 
• The water-insoluble protein was dissolved in 1xPBS containing 6M urea together with 
1 mM PMSF and incubated on shaker for 15 minutes at room temperature. 
• The urea-soluble protein was separated using centrifugation at 12,000xg for 30 
minutes at room temperature.  
 xxxvi
• The protein concentration was measured using BioRad protein assay and aliquoted 
proteins were kept in -80°C freezer for future use.     
 
B. Denatured Protein Gel Electrophoresis (SDS-PAGE) 
 
• SDS-PAGEs (denature protein gel electrophoresis) were used to separate protein 
according to protein molecular weights. It was widely used in protein separation, 
immunoblotting and 2-dimentional gel electrophoresis. Laemmli’s method was applied 
in SDS-PAGE experiment.   
• Gel composition. 
 SEPARATING GEL STACKING GEL 
 10% 12% 15% 20% 4% 
H20 4.845 4.345 3.595 2.345 2.278 
1.5M Tris 8.8 2.500 2.500 2.500 2.500 - 
0.5M Tris pH6.8 - - - - 0.375 
40%acrylamide 2.500 3.000 3.750 5.000 0.300 
10%SDS 0.100 0.100 0.100 0.100 0.030 
10% APS 0.050 0.050 0.050 0.050 0.015 
TEMED 0.005 0.005 0.005 0.005 0.002 
 10 ml 10 ml 10 ml 10 ml 3 ml 
 
• BioRad Proteon III was used for SDS-PAGE casting. Except for SDS-PAGE gel in 2-
dimensional gel electrophoresis with separating gel polymerized overnight, all other 
SDS-PAGEs were polymerized in three hours. 
• Gel electrophoresis was run at constant current (30mA for single gel ad 45mA for 
double gels). 
• Gels were proceeded for comassie staining, silver staining, immunoblotting 









Both mice and rabbit bleeding were carried out under sterile conditions. 
 
• For mice bleeding 
¾ Mice were warmed using electric light bulbs for 1 hour before bleeds.  
¾ Put the mouse in strainer, rub with ethanol swab at tail where a small slit at tail 
vein was done. 
¾ The blood was collected in 1.5 ml centrifuge tubes immediately after blood is 
oozing out from the slit. Collect about  0.1 ml of blood for pre-bleed, 0.3 ml for 
subsequent bleeds. 
¾ Apply pressure to the wound. When the bleeding has stopped (~10 seconds), 
sterilize the slit with ethanol.  
¾ Remove the mouse from the restrainer and place it in its cage.  
¾ Leave the collected blood at RT for 2 hours.  
¾ Centrifuge at 4°C 10,000g for 10 minutes. Remove the serum, label accordingly 
and keep in -20°C for future uses. 
 
• Rabbit bleeding 
 
¾  Rabbit was given a mixture of Ketamine 50 mg/kg and Xylazine 10mg/kg 
intramuscularly and wait for 10 minutes. 
¾  Rub with ethanol on the top middle of the ear where the large vein can be seen. 
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¾ Insert the butterfly needle in the vein and collect the about 5 ml of blood for pre-
bleed, 20 ml for subsequent bleed and 40 ml for final bleed. 
¾ Remove the needle and apply pressure to the wound. When the bleeding has 
stopped (~10 seconds), sterilize the ear with ethanol. 
¾ Leave the collected blood at RT for 2 hours.  
¾ Centrifuge at 4°C 10,000g for 10 minutes.Remove the serum, label accordingly 





Both mice and rabbit immunizations were carried out under standard sterile conditions. 
 
• For mice immunization 
¾ Rub the abdominal wall with ethanol and pre-prepared antigen preparation 
(Complete Freund's Adjuvant) was given to mouse intraperitoneally. 
¾  Sterilize again with ethanol.  
¾ The subsequent immunizations were done with antigens prepared with Imcomplete 
Freund's Adjuvant and given at  2-week intervals 
 
 
• Rabbit immunization 
 
¾  Rabbit was given a mixture of Ketamine 50 mg/kg and Xylazine 10mg/kg 
intramuscularly and wait for 10 minutes. 
¾  Rub with ethanol on both sides of thigh muscles and pre-prepared antigen 
preparation (Complete Freund's Adjuvant) was given intramuscularly on both 
sides. 
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¾ The injection sites were sterilized again with ethanol. 
¾ The subsequent immunizations were done with antigens prepared with Imcomplete 









Immunological Protocols  
 
A. Enzyme Linked Immunosorbent Assay (ELISA)  
 
The indirect ELISA is used primarily to determine the strength and/or amount of antibody 
response in a sample, whether it is from the serum of an immunized animal or the cell 
supernatant from growing hybridoma clones or patients’ sera. 
 
• Prepare the antigen solution at 2μg/ml using PBS.  
• Add 50μl (0.1μg) in each well of a 96-well ELISA plate, cover with parafilm and 
incubate overnight at 4°C. 
• Remove antigen solution and wash thrice with PBS-T 
• Add 100 µl of blocking buffer (1% BSA in PBS-T). Incubate for 1 hour at RT. 
• Remove the blocking buffer.  
• Add 100 μl of test samples prepared in 1:100 dilution using blocking buffer and 
incubate for 1 hour at room temperature (RT).  
• Remove the first antibody solution and wash 3 times with PBS-T.  
• Add 100 µl/well of HRP-conjugated antibodies directed against first species prepared 
in PBS-T.  Incubate for 1 hour at RT. 
• Remove the antibody enzyme conjugate and wash 3 times as before.  
• Add 100 µl/well of chromogenic peroxidase substrate OPD (o-Phenylenediamine) and 
incubate for 15 minutes at RT. 
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• Add 100 µl/well stop solution (2N H2SO4) and read absorbance at 490 nm in an 
ELISA reader. 
 
NB: Positive, negative and blank controls were used in every ELISA procedure.  Checker 
board titration for first antibodies and second antibody conjugate were done in initial 
optimization. If the OD of test samples were beyond the range of 0.2-1.5, repeat the 
ELISA with necessary dilutions.   
 
 
B. Immunoblotting protocol 
 
• The proteins separated by SDS-PAGE gel were transferred onto Nitrocellulose 
(Amercham) using BioRad Transfer Unit at constant 100 Volts for one hour in cold 
room. 
• The nitrocellulose membranes with transferred proteins are blocked by blocking buffer 
(3% BSA in TBS-T) for 1 hour at RT with constant shaking. 
• Remove the blocking solution, add the primary antibodies diluted in blocking solution 
(3%BSA in TBS-T), incubate overnight in 4°C with constant shaking.   
• Remove the first antibodies and wash thrice with TBS-T 
• Add second antibodies conjugated with Alkaline Phosphatase diluted in TBS-T, 
incubate for 1 hour at RT with constant shaking. 
• Remove the second antibodies and wash thrice with TBS-T. 
• Add pre-prepared NBT/BCIP (ZyMed Laboratories Inc) and incubate for 30 minutes at 
RT with constant shaking. 
• The reaction was stopped by washing the Nitrocellulose membrane in sterile water 
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C.  Immunohistochemistry 
 
• The frozen mouse kidney was prepared and 5 μm-thick section were cut using 
Cryostat. Fix the slides with cold acetone for 2 minutes, air dry at RT and proceed for 
immunostaining. 
• Rinse slides 3x in PBS, to remove the tissue-freezing matrix.  
• Block endogenous peroxidase activity by incubating the slides in 0.3% H2O2 solution 
in PBS for 10 minutes.  
• Rinse slides 3x in PBS, 2 minutes each time.  
• Block non-specific binding by incubating with blocking buffer (3% BSA in PBS) for 1 
hour at RT in a humidified chamber.  
• Dilute the polyclonal antibodies in blocking buffer and apply the diluted antibody to 
the tissue sections on the slide. Incubate for 1 hour at RT in a humidified chamber.  
• Rinse slides 3x in PBS, 2 minutes each time. 
• Dilute the Horseradish Peroxidase-conjugated second antibody and apply to the tissue 
sections on the slide and incubate for 30 minutes at RT in a humidified chamber.  
• Rinse slides 3x in PBS, 2 minutes each time. 
• Prepare DAB substrate solution by adding 1 drop of DAB chromagen to every 1 ml of 
DAB buffer. 
• Drain PBS from slides and apply the DAB substrate solution. Allow slides to incubate 
for 5 minutes or until the desired color intensity is reached.  
• Wash 3X in water, 2 minutes each time. 
• Counterstain slides: (Dip twice in Hematoxylin; Rinse thoroughly in water; Dip twice 
in Bluing Reagent or dilute ammonia water; Rinse thoroughly in water.) 
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• Dehydrate through 4 changes of alcohol (95%, 95%, 100% and 100%). Clear in 3 
changes of xylene and coverslip.  
